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RÉSUMÉ 
 Le glaucome est la deuxième cause de cécité irréversible dans le monde. La perte 
de vision qui  se produit lors du glaucome s’explique par une dégénérescence du nerf 
optique et une mort progressive et sélective des cellules ganglionnaires de la rétine 
(CRG). L'hypertension oculaire est un facteur de risque majeur dans le glaucome, mais 
des défauts du champ visuel continuent à se développer chez un contingent de patients 
malgré l'administration de médicaments qui abaissent la pression intraoculaire (PIO). Par 
conséquent, bien que la PIO représente le seul facteur de risque modifiable dans le 
développement du glaucome, son contrôle ne suffit pas à protéger les CRGs et préserver 
la fonction visuelle chez de nombreux patients. Dans ce contexte, j'ai avancé l'hypothèse 
centrale voulant que les stratégies de traitement du glaucome visant à promouvoir la 
protection structurale et fonctionnelle des CRGs doivent agir sur les mécanismes 
moléculaires qui conduisent à la mort des ces neurones.  
 Dans la première partie de ma thèse, j'ai caractérisé l'effet neuroprotecteur de la 
galantamine, un inhibiteur de l'acétylcholinestérase qui est utilisé cliniquement dans le 
traitement de la maladie d'Alzheimer. Cette étude s’est basée sur l'hypothèse que la 
galantamine, en modulant l'activité du récepteur de l'acétylcholine, puisse améliorer la 
survie des CRGs lors du glaucome. Nous avons utilisé un modèle expérimental bien 
caractérisé d'hypertension oculaire induite par l’administration d'une solution saline 
hypertonique dans une veine épisclérale de rats Brown Norway. Les résultats de cette 
étude (Almasieh et al. Cell Death and Disease, 2010) ont démontré que l'administration 
quotidienne de galantamine améliore de manière significative la survie des corps 
cellulaires et des axones CRGs. La protection structurelle des CRGs s’accompagne d’une 
préservation remarquable de la fonction visuelle, évaluée par l'enregistrement des 
potentiels évoqués visuels (PEV) dans le collicule supérieur, la cible principale des CRGs 
chez le rongeur. Une autre constatation intéressante de cette étude est la perte 
substantielle de capillaires rétiniens et la réduction du débit sanguin associé à la perte des 
CRGs dans le glaucome expérimental. Il est très intéressant que la galantamine ait 
également favorisé la protection de la microvascularisation et amélioré le débit sanguin 
rétinien des animaux glaucomateux (Almasieh et al. en préparation). J'ai notamment 
démontré que les neuro-et vasoprotections médiées par la galantamine se produisent par 
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l'activation des récepteurs muscariniques de l'acétylcholine.  
  Dans la deuxième partie de ma thèse, j'ai étudié le rôle du stress oxydatif ainsi que 
l'utilisation de composés réducteurs pour tester l'hypothèse que le blocage d'une 
augmentation de superoxyde puisse retarder la mort des CRG lors du glaucome 
expérimental. J'ai profité d'un composé novateur, un  antioxydant  à base de phosphine-
borane (PB1), pour tester sur son effet neuroprotecteur et examiner son mécanisme 
d'action dans le glaucome expérimental. Les données démontrent que l'administration 
intraoculaire de PB1 entraîne une protection significative des corps cellulaire et axones 
des CRGs. Les voies moléculaires conduisant à la survie neuronale médiée par PB1 ont 
été explorées en déterminant la cascade de signalisation apoptotique en cause. Les 
résultats démontrent que la survie des CRGs médiée par PB1 ne dépend pas d’une 
inhibition de signalisation de protéines kinases activées par le stress, y compris ASK1, 
JNK ou p38. Par contre, PB1 induit une augmentation marquée des niveaux rétiniens de 
BDNF et une activation en aval de la voie de survie des ERK1 / 2 (Almasieh et al. 
Journal of Neurochemistry, 2011).  
 En conclusion, les résultats présentés dans cette thèse contribuent à une meilleure 
compréhension des mécanismes pathologiques qui conduisent à la perte de CRGs dans le 
glaucome et pourraient fournir des pistes pour la conception de nouvelles stratégies 
neuroprotectrices et vasoprotectrices pour le traitement et la gestion de cette maladie.  
 
Mots-clés: glaucome, cellule ganglionnaire de la rétine, neuroprotection, inhibiteur de 
l'acétylcholinestérase, muscarinique, superoxyde, facteur neurotrophique dérivé du 
cerveau, kinases 1 et 2 régulées par des signaux extracellulaires, microvascularisation 
rétinienne, débit sanguin rétinien. 
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SUMMARY 
Glaucoma is the second cause of irreversible blindness worldwide. Loss of vision 
in glaucoma is accompanied by progressive optic nerve degeneration and selective loss of 
retinal ganglion cells (RGCs). Ocular hypertension is a major risk factor in glaucoma, but 
visual field defects continue to progress in a large group of patients despite the use of 
drugs that lower intraocular pressure (IOP). Therefore, although IOP is the sole 
modifiable risk factor in the development of glaucoma, its regulation is not sufficient to 
protect RGCs and preserve visual function in many affected patients. To address this 
issue, I put forward the central hypothesis that effective therapeutic strategies for 
glaucoma must interfere with molecular mechanisms that lead to RGC death to 
successfully promote structural and functional protection of these neurons.  
In the first part of my thesis, I characterized the neuroprotective effect of 
galantamine, an acetylcholinesterase inhibitor that is clinically used for the treatment of 
Alzheimer’s disease. The specific hypothesis of this study was that galantamine, by 
modulating acetylcholine receptor activity, can improve the survival of injured RGCs in 
glaucoma. A well characterized experimental model of ocular hypertension induced by 
administration of a hypertonic saline into an episcleral vein of Brown Norway rats was 
used. The results of this study (Almasieh et al. Cell Death and Disease, 2010) 
demonstrated that daily administration of galantamine significantly improved the survival 
of RGC soma and axons in this model. Structural protection of RGCs correlated with 
substantial preservation of visual function, assessed by recording visual evoked potentials 
(VEPs) from the superior colliculus, the primary target of RGCs in the rodent brain. An 
interesting finding during the course of my thesis was that there is a substantial loss of 
retinal capillaries and a reduction in retinal blood that correlates with RGC loss in 
experimental glaucoma. Interestingly, galantamine also promoted the protection of the 
microvasculature and improved retinal blood flow in ocular hypertensive animals 
(Almasieh et al. in preparation). Importantly, I demonstrated that galantamine-mediated 
neuro- and vasoprotection occur through activation of muscarinic acetylcholine receptors.   
 In the second part of my thesis, I investigated the role of oxidative stress and the 
use of reducing compounds to test the hypothesis that blockade of a superoxide burst may 
delay RGC death in experimental glaucoma. I took advantage of a novel phosphine-
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borane based antioxidant compound available to us (PB1) to investigate its 
neuroprotective effect and mechanism of action in experimental glaucoma. The data 
demonstrate that intraocular administration of PB1 resulted in significant protection of 
RGC soma and axons. I also explored the molecular pathways leading to PB1-mediated 
neuronal survival by analyzing the components of survival and apoptotic signaling 
pathways involved in this response. My results show that PB1-mediated RGC survival 
did not correlate with inhibition of stress-activated protein kinase signaling, including 
ASK1, JNK or p38. Instead, PB1 led to a striking increase in retinal BDNF levels and 
downstream activation of the pro-survival ERK1/2 pathway (Almasieh et al. Journal of 
Neurochemistry, 2011).  
In conclusion, the findings presented in this thesis contribute to a better 
understanding of the pathological mechanisms underlying RGC loss in glaucoma and 
might provide insights into the design of novel neuroprotective and vasoprotective 
strategies for the treatment and management of this disease.  
Key words: glaucoma, retinal ganglion cell, neuroprotection, acetylcholinesterase 
inhibitor, muscarinic, superoxide, brain-derived neurotrophic factor, extracellular signal-
regulated kinase 1/2, retinal microvasculature, retinal blood flow. 
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I.1. GLAUCOMA: DEFINITION, PREVALENCE AND RISK FACTORS 
Glaucoma is a group of chronic optic neuropathies characterized by progressive 
visual field defects and optic disc damage which ultimately leads to irreversible blindness 
due to the loss of retinal ganglion cells (RGCs). It is estimated that more than 60 million 
people suffer from glaucoma worldwide (Quigley and Broman, 2006) and according to a 
report from the World Health Organization, glaucoma is the second cause of blindness 
globally accounting for 12.3% of total cases (Resnikoff et al., 2004).  
There are a number of risk factors that increase the incidence of glaucoma. 
Demographic factors including age and ethnic background are among the most 
recognized risk factors for glaucoma. For example people over the age of 60 have a much 
higher risk of developing glaucoma (Coleman and Miglior, 2008). Also, the rate of 
glaucoma progression is faster in individuals diagnosed with glaucoma within certain 
population subgroups (Sommer et al., 1991; Varma et al., 2004). Moreover, belonging to 
a certain ethnic background significantly lowers the age at which those individuals are at 
risk of developing glaucoma. For instance, individuals of African-descent 40 years and 
older are at higher risk of developing glaucoma and have the highest rate of blindness due 
to glaucoma (Congdon et al., 2004; Leske, 2007). Family history is another recognized 
risk factor for developing glaucoma as individuals with a family member with glaucoma 
have a four times higher risk of developing this disease (Wiggs, 2007).  
Elevated intraocular pressure (IOP) is an important risk factor for developing 
glaucoma. Considering that the normal value of IOP for adult individuals is usually 
around 15 mmHg, people with an IOP over 21 mmHg are known as ocular hypertensive 
(Quigley et al., 1994). Interestingly, there is a correlation between systemic blood 
pressure and IOP levels as an increase or a reduction of systemic blood pressure results in 
higher or lower IOP, respectively (Klein et al., 2005; McLeod et al., 1990). Indeed, high 
systemic blood pressure is considered a risk factor in glaucoma (Deokule and Weinreb, 
2008). Although IOP is regarded as an important risk factor, it is not an accurate 
predictor of glaucoma since more than 30% of the glaucoma patients have an IOP in the 
normal range (Nemesure et al., 2007).  
Corneal thickness is also considered another risk factor and thinner central 
corneas have been correlated with visual field loss in glaucoma (Medeiros et al., 2003). 
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High myopia is another risk factor correlating with glaucoma occurrence (Loyo-Berros 
and Blustein, 2007; Mastropasqua et al., 1992). An association between diabetes and 
glaucoma has also been suggested (Bonovas et al., 2004). Some cases of diabetes also 
have higher IOP levels compared to control individuals (Klein et al., 1984; Tielsch et al., 
1995). 
 
I.2. PATHOLOGICAL AND CLINICAL FEATURES OF GLAUCOMA 
I.2.1. Loss of RGCs, optic disc cupping and axonal damage  
Glaucoma is characterized by damage to the neural components of the visual 
pathway including the retina, the optic tract and the brain. The visual information in the 
retina travels vertically through photoreceptors, bipolar cells and finally RGCs. RGCs 
play an essential role in vision because they are the only neurons responsible for relaying 
the visual signal from the eye to the higher centers in the brain (Figure 1). One of the 
highlights of glaucoma pathology is the selective loss of RGCs, which is characteristic of 
all glaucoma patients (Kendell et al., 1995; Quigley, 1999).  
RGCs axons extend from their cell bodies over the inner surface of retina to reach 
the optic disc. They join to form axon bundles at the retinal nerve fiber layer supported 
by both the processes of Müller cells and astrocytes (Radius and Anderson, 1979). The 
optic disc or optic nerve head (ONH) is the region where RGC axons exit the eye to form 
the optic nerve. The ONH includes a prelaminar area formed by loose trabecular glial 
tissue and bundles of unmyelinated nerve fibers. The laminar area of the ONH is called 
the lamina cribrosa; it is composed of parallel collagen laminas located in a canal in the 
posterior part of the sclera (Jonas et al., 1991). The lamina cribrosa forms a sieve-like 
network and axons of RGCs exit the retina through its pores; it also allows passage of the 
central retinal vessels (Hernandez et al., 1986). 
The area of the ONH that contains the nerve fibers, called the neuroretinal rim, 
surrounds the central and slightly depressed part called the cup (Jonas et al., 1988). 
Increased depth of the optic cup is a well known clinical feature of glaucoma (Jonas et 
al., 1999). ONH cupping is one of the first detectable signs of glaucoma and often 
precedes  the loss of  visual  field (Pederson and Anderson, 1980). The optic disc cupping  
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Figure 1. A schematic diagram of the retina demonstrating the principal cell types 
involved in retinal signaling. The photoreceptor cells (rods and cones) are the outermost 
neuronal layer of the retina. Photoreceptors are light-sensitive and transduce light stimuli 
into electrical signals. The signal is subsequently transferred from the photoreceptors to 
bipolar cells. The outer plexiform layer (OPL) contains the synaptic connections between 
photoreceptors to bipolar cells and horizontal cells. Bipolar cells make synaptic 
connections with RGCs in the inner plexiform layer (IPL). RGC axons travel toward the 
optic disc in the nerve fiber layer and exit the eye forming the optic nerve. Cellular 
components of the retina are supported by Müller cells and the interconnections provided 
by horizontal cells and amacrine cells participate in retinal processing and modifications 
of visual signal. Source of image: Mohammadali Almasieh. 
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correlates with changes in the organization of connective tissue bundles and thinning of 
laminar beams in the lamina cribrosa in experimental and human glaucoma (Fukuchi et 
al., 1992; Miller and Quigley, 1987; Morrison et al., 1990). ONH changes also include 
abnormal deposition of extracellular matrix components such as collagen, laminin and 
elastin (Hernandez et al., 1990; Johnson et al., 1996; Morrison et al., 1990).  ONH tissue 
remodeling occurs partly due to activation of resident glial cells since abnormal 
deposition of extracellular material correlates with increased expression of elastin mRNA 
in local astrocytes (Pena et al., 2001). Activated and proliferating astrocytes, 
characterized by hypertrophic soma and expression of glial fibrillary acidic protein 
(GFAP), are found in human and experimental glaucoma (Hernandez et al., 2008; 
Johnson et al., 2007a). Tissue remodeling can also result in biomechanical alterations at 
the ONH leading to stress-induced damage of RGC axons at this location (Burgoyne, 
2010).  
I.2.2. Loss of visual field 
Glaucoma is not the only optic neuropathy accompanied by visual loss; however, 
based on the characteristic changes of the optic disc and the typical patterns of visual 
field loss, glaucomatous visual defects can be distinguished from other optic 
neuropathies. Because damage to RGC axons happens mostly at the superior and inferior 
parts of the ONH and considering that nerve fibers make a superior or inferior arc around 
the horizontal raphe before entering the optic disc, typical arcuate scotomas are the 
characteristic visual field loss pattern in the glaucoma (Figure 2) (Hood and Kardon, 
2007; Spector, 1990). It is typical for glaucomatous vision loss to be peripherally located 
as occurrences of scotomas are usually paracentral; central vision will remain intact until 
very late in the course of the disease. Several methods are currently used for diagnosis of 
glaucomatous visual field abnormalities including standard achromatic automated 
perimetry (SAP) or selective perimetry (Sakata et al., 2007; Sample et al., 2000; Sharma 
et al., 2008). Due to considerable overlap in the receptive fields of different RGC types, 
SAP does not allow detection of visual defects unless 40-50% of RGCs are already lost. 
However, short-wavelength (blue-yellow color sensitive) automated perimetry (SWAP) 
that targets the small bistratified RGCs, enables physicians to detect functional  loss years 
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FIGURE 2. 
 
Figure 2. Grey scale plot of visual field derived from short-wavelength automated 
perimetry showing large arcuate scotoma in the superior visual field. Three panels 
indicate progressive loss of visual field. Different gray spectra show the level of visual 
loss and black indicates the blind spots. Source of image: adapted from Clement et, al., 
Br J Ophthalmol. 2009.  
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earlier because it is selective for a particular ganglion cell type (Johnson et al., 1993; Sit 
et al., 2004).   
Pathological changes in glaucoma are also detected in visual centers in the brain 
and could account for visual defects. The lateral geniculate nucleus (LGN), a major 
central target of RGC axons in primates, shows significant atrophy and neuronal loss in 
primate experimental glaucoma (Ito et al., 2009; Yücel et al., 2001). Activated glial cells 
play important roles in the degenerative changes in the LGN as astrocytosis and 
microglial activation have been reported in the LGN and visual cortex in experimental 
glaucoma (Lam et al., 2009). 
 
I.3. GLAUCOMA CLASSIFICATION AND EXPERIMENTAL MODELS 
Glaucoma has been divided into two major categories: primary angle-closure 
glaucoma (PACG) and primary open-angle glaucoma (POAG). However, other sub-
categories have been added to accommodate for the diversity of pathologies. The 
production, circulation and drainage of the aqueous humour (the clear fluid that fills the 
anterior and posterior chambers of the eye) are determining factors for the IOP level of 
the eye. Therefore, the anatomical structures of the eye involved in the production and 
circulation of the aqueous humour will be reviewed briefly.   
The aqueous humour is produced by the ciliary epithelium of the ciliary body, 
provides nutrition for the lens and removes metabolic waste as it flows through the pupil 
into the anterior chamber of the eye (Krupin et al., 1986). The aqueous humour fills the 
anterior chamber providing nutrition to the cornea as well. There is an area in the anterior 
chamber where the cornea and iris join, the angle, where the drainage of aqueous humour 
takes place (Figure 3). Aqueous fluid flows toward the angle where it enters the 
trabecular meshwork (TM) (Tamm, 2009), a sieve-like structure that filters and directs 
the aqueous fluid into the Schlemm's canal (Johnstone, 2004). A portion of the aqueous 
humour leaves the anterior chamber through an alternative route called the uveo-scleral 
pathway (Gabelt and Kaufman, 2005; Goel et al., 2010). Several models of inducible and 
spontaneous glaucoma rely on blockade of the aqueous humour drainage and will be 
discussed in subsequent sections. 
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FIGURE 3. 
 
 
 
Figure 3. A schematic presentation of the structures in the angle of the eye and 
aqueous humour circulation. The aqueous humour is produced by the ciliary body and 
enters the anterior chamber via the pupil. The trabecular meshwork (TM) is located in the 
angle between the cornea and iris and provides a circumferential outlet for drainage of 
aqueous. In PACG, access to the TM is limited or severed due to physical closure of the 
anterior chamber angle; whereas in POAG, the TM is accessible, however ultrastructural 
changes in the TM itself result in reduction of outflow. Aqueous humour enters 
Schlemm's canal and after being collected in a circumferential venous plexus, joins the 
blood circulation via episcleral veins. Source of image: Kwon et. al., N. Engl. J. Med. 
2009. 
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I.3.1. Primary angle-closure glaucoma 
PACG is characterized by the blockade of the aqueous humour drainage and/or its 
circulation. This results in increased IOP and consequent damage to the retina and optic 
nerve. If the IOP increase is sudden and acute, it is often accompanied by pain and 
redness of the eye, blurry vision, headache and nausea (Sihota, 2011). The name “angle-
closure” was originally used after the observation that the aqueous humour drainage is 
blocked in the angle of the eye resulting in IOP build up. PACG is primarily caused by an 
abnormal contact between anterior segment structures of the eye, including the cornea, 
iris, TM, ciliary body, and the lens. This could happen due to abnormal dilation of the 
pupil causing congestion of the iris in the angle of the eye. There is also a condition 
called plateau iris, characterized by an abnormal position of ciliary processes that push 
and hold the iris forward placing it too close to the TM (Kumar et al., 2008). Some 
PACG cases also involve pupillary blockade of the aqueous fluid. Pupillary blockade 
happens when the back of the iris adheres to the lens and blocks the passage of the 
aqueous humour to the anterior chamber. This not only increases the pressure in the 
posterior chamber but also pushes the periphery of the iris forward resulting in angle 
closure (Tarongoy et al., 2009). The extent of pupillary blockade and angle closure 
determines the magnitude and time-course of IOP increase, therefore PACG has been 
divided into acute (with sudden and severe IOP increase) and chronic (with a more 
gradual IOP increase) subcategories. When angle-closure happens as a result of other 
ocular diseases, it is referred to as secondary angle-closure glaucoma. For instance, 
secondary angle-closure glaucoma could happen due to an anterior-shift of the lens after 
ocular trauma (Sankar et al., 2001).  
People of Asian descent and individuals with small axial eye length, have a 
greater risk of developing PACG. The common procedure for the treatment of acute 
PACG is to lower the IOP by medications (Hoh et al., 2002). Surgical techniques such as 
peripheral iridotomy, the generation of small holes in the peripheral iris using a laser, 
might also be required (Lam et al., 2007; Tarongoy et al., 2009). Analysis of the eyes 
with acute PACG revealed that although IOP was lowered immediately after diagnosis, 
there was still a significant reduction in the thickness of the retinal nerve fiber layer 
(RNFL) weeks after the acute episode (Aung et al., 2004).  
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I.3.1.1. Experimental models of primary angle-closure glaucoma 
 Several breeds of dogs are prone to develop glaucoma (Reinstein et al., 2009) and 
the high prevalence of glaucoma in some pure-bred dogs suggests a genetic basis for this 
disease (Gelatt and MacKay, 2004). For instance, a canine model (Basset Hounds) of 
hereditary PACG shows gradual narrowing and collapse of iridocorneal angles leading to 
complete angle-closure by 20 months of age; angle-closure in these dogs is accompanied 
by IOP build up, cupping of ONH and loss of RGCs (Grozdanic et al., 2010). However, 
the high cost of purchasing and housing dogs, their requirements for special care and the 
inherent problem of handling dogs in large experimental groups, results in limited use of 
this model.   
Laser photocoagulation has been adapted for mice to induce the closure of the 
anterior chamber angle (Aihara et al., 2003). A diode laser is focused on the corneal 
limbus to create burn spots that directly attach the iris root to the peripheral cornea; 
consequently, obstruction of the aqueous outflow results in elevation of IOP (Aihara et 
al., 2003). Despite the differences in the structure of ONH between mice and humans, 
such as the lack of lamina cribrosa (May and Lütjen-Drecoll, 2002), the elevation of IOP 
in this model is accompanied by significant loss of RGC axons (Mabuchi et al., 2003). 
However, the small size of the mice eye demands a high level of expertise by the 
experimenter in using the laser as excessive or misplace laser burns could result in abrupt 
IOP increase, inflammatory response and retinal damage.  
I.3.2. Primary open-angle glaucoma  
Primary open-angle glaucoma (POAG) is the most common form of the glaucoma 
worldwide. POAG is characterized by changes in the optic disc, damage to RGC axons in 
the optic nerve, loss of RGCs in the retina and gradual visual field defects (Quigley, 
2005). POAG is not necessarily associated with IOP elevation, however, high IOP is a 
major risk factor for developing POAG and a significant percentage of POAG cases show 
a gradual increase of IOP over the years (Leske et al., 2003). The increase in IOP is not 
necessarily accompanied with severe changes in anterior angle structures as previously 
described for PACG. Since resistance to the aqueous humour outflow is a major 
determinant of IOP levels, age-related or pathologic changes in the TM or Schlemm's 
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canal might lead to the gradual increase of the outflow resistance and IOP build up 
(Gabelt and Kaufman, 2005; Wordinger and Clark, 1999). Although morphological 
changes in optic disc vary little between PACG and POAG (Boland et al., 2008; Nouri 
Mahdavi et al., 2011), functional evaluation demonstrated that PACG patients have a 
more diffuse pattern of visual field loss compared to POAG patients (Boland et al., 2008; 
Rhee et al., 2001).  
I.3.2.1. Experimental models of primary open-angle glaucoma   
Our understanding about the mechanism of aqueous humour outflow and its 
importance in regulating IOP has been used to develop a number of experimental 
glaucoma models. Several animal species are suitable for induction of experimental 
ocular hypertension (OHT) and have provided useful functional and structural 
information about glaucoma onset and progression.    
I.3.2.1.a. Primate model of POAG 
In this model, Rhesus or Cynomolgus monkeys are subjected to laser 
photocoagulation, that by creating burn spots on the circumference of the TM, results in 
moderate IOP increase (Wang et al., 1998).  A disadvantage is that multiple sessions of 
laser treatment are required to induce OHT. IOP elevation in this model is accompanied 
with ONH cupping and thinning of RNFL (Gaasterland and Kupfer, 1974). Loss of RGCs 
and functional defects are well documented in this model, indicating a close similarity to 
human POAG (Hare et al., 2001b; Hood et al., 1999; Morgan et al., 2000). Pathological 
changes in the visual centers in the brain such as loss of neurons in the magno and 
parvocellular layers of LGN are also detected (Yücel et al., 2003; Yücel et al., 2000). The 
high cost of monkeys, their limited availability and difficulty to work with are major 
disadvantages particularly for studies on neuroprotection since they require large number 
of animals.   
I.3.2.1.b. Rodent models of POAG  
The laser photocoagulation technique has also been used for induction of OHT in 
rodents (Levkovitch-Verbin et al., 2002b; Schori et al., 2001; Ueda et al., 1998; Wijono 
et al., 1999; WoldeMussie and Feldman, 1997). A beam of diode laser is concentrated on 
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the circumference of the TM to create burn spots; the peak IOP reaches 35-49 mmHg and 
it is sustained for at least 3 weeks (Levkovitch-Verbin et al., 2002b). A similar technique 
has been adapted for induction of OHT in mice (Gross et al., 2003; Ji et al., 2005). 
  The aqueous humour flows through the TM into the Schlemm's canal and then 
via collector channels into the limbal venous plexus and finally drains through the 
episcleral veins. This pathway has been used for retrograde transfusion of solutions 
towards the TM (Moore et al., 1993; Morrison et al., 1995).  In the Morrison model of rat 
OHT, hypertonic saline solution is injected into an episcleral vein of Brown Norway rat 
eyes. Hypertonic saline causes sclerotic damage to the TM cells, disrupts the structure of 
the TM and gradually reduces the aqueous outflow, resulting in IOP elevation (Morrison 
et al., 1997). Another method of reducing the aqueous outflow is by cauterizing the 
episcleral veins (Shareef et al., 1995).  In this model, two to three veins are isolated and 
blocked using an ophthalmic cautery (Shareef et al., 1995).  
Obstruction of the TM and elevation of IOP can also be achieved by injection of 
sterile latex microspheres (Urcola et al., 2006; Weber and Zelenak, 2001) or microbeads 
into the anterior chamber of rodents (Chen et al., 2011; Sappington et al., 2010). Finally, 
a hereditary mutation in the DBA/2J mice leads to iris pigment dispersion and anterior 
synechia (adhesion of the iris to the cornea) that results in significant elevation of IOP by 
6 months of age (John et al., 1998).  
To select a suitable rodent glaucoma model for research, the objectives of the 
study and the advantages/disadvantages of each model should be considered carefully. 
For instance, rat models are generally more appropriate for ONH studies because unlike 
mouse, the rat ONH has a well-defined lamina cribrosa. The structure of the lamina is 
similar to that in primates regarding protein content, connective tissue components and 
blood vessels (Morrison et al., 1995). Elevation of IOP in rat models results in cupping of 
ONH, loss of axons in the optic nerve and RGCs death. Mouse glaucoma models in the 
other hand, confer the advantage of using transgenic animals to study the role of specific 
genes in the development of glaucoma (Whitehouse et al., 1982).  
The major disadvantage of laser photocoagulation technique is the necessity of 
multiple treatments to achieve a steady IOP elevation. In addition, retinal oedema and 
haemorrhage often occur in this model. The cauterization model has a slow rate of 
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progress with considerable variability in the pattern and number of RGC death (Danias et 
al., 2006); there is also the possibility of necrosis of the eye if several episcleral trunks 
are blocked (Ahmed et al., 2001; Laquis et al., 1998).  The DBA/2J mouse model shows 
great variability in the onset and progression of glaucoma between individual animals 
which dramatically increases the number of animals required for each experiment. The 
microbeads injection model is a relatively simple and promising model but there is high 
variability in the levels of IOP achieved following injection of microbeads (Chen et al., 
2011; Sappington et al., 2010). The Morrison model is also a simple, reliable and 
reproducible model of experimental glaucoma in Brown Norway rats. IOP elevation in 
this model results in ONH cupping and gradual loss of axons in the optic nerve (Johnson 
et al., 1996; Morrison et al., 1997). Progressive loss of RGC in this model is also well 
documented (Guo et al., 2005; Johnson et al., 2007b). General anaesthetics are often used 
in rodents to allow IOP measurements, however, anaesthetics result in a substantial 
decrease of IOP (Jia et al., 2000). An advantage of the Morrison model is that Brown 
Norway rats are extremely docile allowing IOP measurements in unanaesthetized 
animals, thus providing the most accurate documentation of IOP history. Due to its 
advantages, particularly in regard to neuroprotection studies, the Morrison model was 
selected and used throughout this thesis. 
I.3.3. Normal tension glaucoma 
Many glaucoma patients display typical glaucomatous visual defects and RGC 
loss while their IOP is within the normal range (CNTGSG, 1998). These cases are 
classified as normal tension glaucoma (NTG). The visual field loss in NTG patient 
progresses with a similar rate as POAG patients, therefore diagnosis and treatment of 
NTG demands particular attention (Ahrlich et al., 2010). The exact cause of NTG is 
unknown; however, several mechanisms have been proposed. Among these are the 
association of visual field loss and decreased blood flow in the optic disc of NTG patients 
(Ciancaglini et al., 2001; Nicolela et al., 1996; Sato et al., 2006) and the higher rate of the 
hemorrhages in the fundus (Ishida et al., 2000; Tezel et al., 1996); suggesting a 
correlation between ocular blood flow and vascular dysfunction in NTG. There is also 
evidence of an autoimmune response, highlighted by elevated levels of antibodies against 
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heat shock proteins (HSPs) (Wax et al., 1998). Since glaucoma is now considered a 
neurodegenerative disease, oxidative damage and excitotoxicity may play a role in the 
pathology of NTG.  
 
I.4. MECHANISMS OF NEURONAL DAMAGE IN GLAUCOMA 
I.4.1. The role of vascular dysfunction in the pathology of glaucoma 
An increasing body of evidence suggests that retinal and ONH blood flow are 
among the risk factors for the development of glaucoma (Flammer et al., 2002; Osborne 
et al., 2001). There is a significant reduction of blood flow in the ONH of PAOG patients 
(Piltz-seymour et al., 2001). Elevated IOP and compression of the vessels at the level of 
the lamina cribrosa has been proposed to be the cause of blood flow reduction (Downs et 
al., 2008; Feher et al., 2005). However, loss of visual field in NTG patients is also 
associated with decreased optic disc blood flow (Ciancaglini et al., 2001; Nicolela et al., 
1996; Sato et al., 2006) and the severity of neuronal damage in NTG and POAG patients 
correlates with a reduction in retinal blood flow (Bjärnhall et al., 2007; Sato et al., 2006). 
When the IOP of healthy volunteers was temporarily increased, it resulted in a clear 
vasodilatory response. However, the same level of temporary IOP increase in POAG 
patients resulted in a much smaller vasodilatory response (Nagel et al., 2001). These 
observations suggest an underlying vascular deficiency contributing to the pathology of 
glaucoma.  
I.4.1.1. The retinal circulation 
In terms of blood supply, the retina is divided into two regions: i) the outer retina, 
including photoreceptors, outer nuclear and outer plexiform layers, is supplied by the 
choroid capillaries originating from the posterior ciliary arteries (Saint Geniez and 
D'Amore, 2004); ii) the inner retina, including the nerve fiber layer, RGC layer, inner 
plexiform and inner nuclear layer, is supplied by the central retinal artery (Figure 4). The 
branches of the central retinal artery expand to form two inner capillary networks, one 
superficial, at the level of nerve fiber layer and one deeper, between the inner nuclear and 
outer plexiform layers (Pournaras et al., 2008). The capillaries of the inner retinal 
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networks are in close interaction with RGCs and other neuronal-glial elements of the 
retina to meet the metabolic demands of this tissue. 
 Retinal capillaries are composed of a single layer of endothelial cells enclosed in 
a basement membrane shared with surrounding pericytes (Kniesel and Wolburg, 2000; 
Russ et al., 1998). Pericytes are specialized mural cells found in the CNS that play an 
integral role in vascular tone (Bandopadhyay et al., 2001). Retinal capillaries are smaller 
in diameter with thinner walls compare to non-neuronal capillaries and are 
morphologically very similar to cerebral capillaries; however, their endothelial cells have 
a higher density of vesicles and higher permeability compare to their counterparts in the 
brain (Stewart and Tuor, 1994). Retinal capillaries are also accompanied by a 
considerable higher number of pericytes (up to 4.5-fold) compared to cerebral capillaries 
and their pericyte processes cover more than 85% of the circumference of the retinal 
endothelial tube (Frank et al., 1987; Stewart and Tuor, 1994). Pericytes together with the 
glial cell’s end-foot processes, strengthen the blood-retinal barrier and play important 
roles in compensating for more permeable endothelial cells compared to brain capillaries 
(Kim et al., 2006a; Stewart and Tuor, 1994). 
I.4.1.2. Regulatory mechanisms of retinal circulation  
The proper regulation of ocular blood flow is vital for normal retinal function. 
The ocular vessels respond to the increased neuronal activity by increasing the blood 
flow, a phenomena known as neurovascular coupling (Garhöfer et al., 2004; Riva et al., 
2005). The choroidal vascular bed is innervated by autonomic vasoactive nerves that 
control the choroidal blood flow (Schrder et al., 1994). Unlike the choroid, the central 
retinal artery has limited sympathetic innervation that ends at the level of lamina cribrosa 
(Laties, 1967). Therefore, local vasodilatory and vasoconstrictor mediators play 
important roles in regulating the retinal blood flow (Metea and Newman, 2007). The 
production and release of vasoactive compounds by endothelial cells contribute to the 
regulation of retinal vascular tone. Nitric oxide (NO) and endothelins (ET) are among the 
most important endothelium-derived vasoactive factors (Chakravarthy et al., 1995; 
Loscalzo and Welch, 1995; Takagi et al., 1996). 
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FIGURE 4. 
 
 
Figure 4. Sources of blood supply for the retina and optic nerve. The central retinal 
artery and the posterior ciliary arteries are branches of the ophthalmic artery. Branches of 
posterior ciliary arteries enter the eye to form the choroid. The central retinal artery enters 
the optic nerve at 8–12mm behind the globe and after supplying the optic nerve with a 
few small branches, it divides into two major trunks before leaving the optic disc. The 
branches of the central retinal artery expand to form two inner capillary networks, one 
superficial, at the level of nerve fiber layer and one deeper, between the inner nuclear and 
outer plexiform layers. Source of image: Mohammadali Almasieh. 
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I.4.1.2.a. Nitric oxide   
NO is a potent neurotransmitter that regulates a wide variety of cellular functions. 
Three different isoforms of nitric oxide synthase (NOS) are involved in NO production: 
neuronal (nNOS or NOS1), inducible (iNOS or NOS2) and endothelial (eNOS or NOS3) 
(Alderton et al., 2001). In the retina, nNOS is expressed by RGCs, photoreceptors and 
amacrine cells; while eNOS is expressed by endothelial cells (Neufeld et al., 2000; 
Shareef et al., 1999). iNOS is activated in response to inflammation or tissue damage and 
is thought to contribute to cytotoxic NO signaling (Calabrese et al., 2007; Chiou, 2001). 
In physiological concentrations, NO signals through activation of guanylyl cyclase 
receptors and production of cGMP (Garthwaite, 2008). NO plays an important 
vasodilatory role in the retina. Experimental inhibition of retinal NOS by intravitreal 
injection of its inhibitors N-monomethyl-L-arginine (L-NMMA) or (L-NAME) resulted 
in significant vasoconstriction of retinal arterioles and venules indicating that NO 
production is necessary for maintaining a basal level of vascular relaxation (Donati et al., 
1995; Dorner et al., 2003). Hyperemia is the activity-induced increase in blood flow in a 
tissue and can be easily induced in the retina by light flicker (Maelicke, 2000). Inhibition 
of NOS significantly reduces the retinal hyperemic response to light flicker, indicating 
that NO also participates in the activity dependent modulation of the retinal blood flow 
(Dorner et al., 2003). In normal subjects, systemic inhibition of NOS significantly 
reduces ONH blood flow (Luksch et al., 2000). Dysfunctional NO signaling in 
glaucomatous eyes became evident by a much smaller response of POAG patients to 
NOS inhibition (Polak et al., 2007). NO levels also effect production and drainage of the 
aqueous humour (Whitehouse et al., 1982). Reduction of NO levels and eNOS activity 
has been reported in ocular tissues of POAG patients including the TM (Nathanson and 
McKee, 1995).   
I.4.1.2.b. Endothelins   
Endothelins are a family of vasoconstrictor peptides. They are released by 
endothelial cells and interact with their G-protein-coupled, ETA and ETB receptors 
(Davenport, 2002; Yanagisawa et al., 1988). ETA receptors are mainly expressed by the 
smooth muscle cells of blood vessels and mediate vasoconstriction upon binding of 
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endothelin-1 (ET-1) (Pierre and Davenport, 1998). ETB receptors have a broader pattern 
of expression and can be found on neuronal and glial components of the retina 
(MacCumber and D'Anna, 1994; Stitt et al., 1996). It appears that ETA and ETB subtypes 
can mediate opposing actions in a complex manner. Blockade of the ETB receptors 
significantly increases peripheral vasoconstriction (Strachan et al., 1999). Activation of 
ETB receptors alone has a net constrictor effect but simultaneous activation of both 
subtypes is vasodilatory (Just et al., 2004; Mickley et al., 1997). Endothelial cells express 
ETB and its activity results in the release of relaxing factors such as nitric oxide and 
prostanoids from endothelial cells (Hirata et al., 1993; Just et al., 2005).  
The level of endothelins and the expression of their receptors change in 
experimental and human glaucoma. For instance, levels of ET-1 in serum and aqueous 
humour of POAG patients is higher than in control individuals (Emre et al., 2005; 
Nicolela et al., 2003; Noske et al., 1997; Sugiyama et al., 1995; Tezel et al., 1997). In 
addition, ET-1 levels in the ONH of animals subjected to experimental glaucoma 
increases significantly compare to control groups (Howell et al., 2011; Prasanna et al., 
2005). Receptor dysfunction has been proposed to play central role in blood flow 
irregularities in glaucomatous eyes. While treatment of normal subjects with an 
antagonist of ETA resulted in a significant vasodilatory response, a similar treatment had 
a lesser effect on the vascular tone of NTG patients (Henry et al., 2006; Henry et al., 
1999). Recently, ETA gene polymorphisms have been considered to be a potential risk 
factor for developing NTG (Ishikawa et al., 2005; Kim et al., 2006b). Endothelins might 
also be involved in the induction of a glial response in the glaucomatous ONH. Reactive 
astrocytes in the ONH of experimental and human glaucoma are characterized by the 
expression of ETA and ETB (Wang et al., 2006; Wang et al., 2009). Incubation of isolated 
ONH astrocytes with ET-1 results in their activation and induces marked proliferation 
(Murphy et al., 2010; Prasanna et al., 2002). ETA is also expressed in structures of the 
anterior segment such as the iris, ciliary body, trabecular cells and endothelial lining of 
the Schlemm's canal (Fernández-Durango et al., 2003). Therefore endothelin signaling 
can also participate in the production of aqueous humour and the control of its outflow. A 
treatment strategy based on endothelin antagonism has been proposed to control IOP 
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increase and to improve retinal blood flow (Fernández-Durango et al., 2003; Rosenthal 
and Fromm, 2011). 
I.4.1.3. Vascular degeneration 
In addition to vasomodulatory abnormalities, there is also evidence of structural 
changes in the vasculature of glaucomatous eyes. In some POAG patients, the central 
retinal artery is characterized by arteriosclerotic changes such as the thickening of the 
basement membrane, proliferation of muscle cells into the intimae, fragmentation of the 
inner elastic membrane and arteriosclerotic plaques in the intimae (Gottanka et al., 2005). 
Narrowing of the lumen of smaller arterioles in the optic nerve and deposits of 
amorphous material in the basement membrane of endothelium are the other pathological 
findings in the POAG (Feher et al., 2005; Gottanka et al., 2005). A significant decrease in 
the density of capillaries has been observed in the optic nerve laminar region of POAG 
patients and in rat experimental glaucoma (Daz et al., 2010; Gottanka et al., 2005). These 
observation are in agreement with initial reports by Quigley and colleagues indicating a 
considerable loss of disc tissue and its capillaries (Quigley et al., 1984). Fluorescein 
angiograms show a high rate of capillary non-perfusion in the optic disc of NTG and 
POAG patients (Plange et al., 2006). Pathological changes in the vasculature also play 
important roles in the progression of other neurodegenerative diseases such as 
Alzheimer's disease (Budinger, 2003). In fact, pathological vascular changes like 
acellular capillaries have been found in both glaucomatous retinas and in the brains of 
Alzheimer's patients (Brown, 2010b). 
I.4.1.4. Neurotrophic factors and vascular reactivity  
In addition to neurons, neurotrophic factors also regulate survival and function of 
non-neuronal cells. In fact production of neurotrophic factors like BDNF and NGF is not 
limited to neuronal tissues as several non-neuronal tissues including the elements of 
cardiovascular system also express neurotrophins and their receptors (Scarisbrick et al., 
1993; Yamamoto et al., 1996). Interaction of neurons and vasculature through 
neurotrophic factors is in particular complex and plays important role in development and 
physiological functions of both systems. 
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Neurotrophins are involved in regulation of angiogenesis, for instance, activation 
of neurons by BDNF and NGF increases production and secretion of VEGF by neurons 
which in turn results in endothelial cells proliferation (Nakamura et al., 2011). Brain-
derived endothelial cells themselves shown to synthesis BDNF and express TrkB and 
p75NTR receptors (Kim et al., 2004b). They also produce NGF and express its receptor 
TrkA (Moser et al., 2004). Direct activation of TrkA receptors of endothelial cells by 
exogenous NGF results in proliferation of these cells and also increases the secretion of 
NGF by endothelial cells (Moser et al., 2004). In addition, NGF improves survival of 
endothelial cells under oxygen-glucose deprivation conditions (Lecht et al., 2010). Local 
production and release of major neurotrophin family members like BDNF and NGF by 
endothelial cells and the interaction of these trophic factors with TrkA, TrkB and p75NTR 
receptors provides an autocrine/paracrine regulatory system for cell proliferation in the 
vasculature (Kim et al., 2004b; Tanaka et al., 2004).  
Recent studies show that neurotrophic factors produced by brain endothelial cells 
could be important for survival of neurons as they significantly extend the survival of 
isolated cortical neurons (Dugas et al., 2008). Endothelial source of BDNF also provides 
significant support for neurons in a number of situations like oxidative stress-hypoxia and 
neurotoxicity (Guo et al., 2008). In addition, secration of BDNF by endothelial cells 
provides important support for migrating neuroblasts that originate from sub-ventricular 
zone or sub-ependymal zone and helps to guide them towards their targets in the brain 
(Leventhal et al., 1999; Snapyan et al., 2009).  
Currently, our knowledge about the effects of neurotrophins on retinal blood flow 
is limited; however, neurotrophins like BDNF stimulate the endothelial cells to generate 
more NO and shown to have vasodilatory effects in other systems (Meuchel et al., 2011). 
It has also been shown that using the viral vectors to overexpress BDNF in cerebral 
vessels results in upregulation of prostacyclin (PGl2) that leads to vascular relaxation 
(Santhanam et al., 2010);  however, no significant change in the expression or activity of 
the eNOS has been detected in these experiments (Santhanam et al., 2010). It is important 
to mention that early in the development of brain, PGI2 is the primary mediator of 
endothelium-dependent relaxations in cerebral circulation; however, in the adult and 
aging brain, nitric oxide takes over as the primary vascular vasodilator (Charpie et al., 
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1994; Willis and Leffler, 2001). Interestingly, intraocular application of BDNF results in 
a higher expression of vasoactive intestinal polypeptide by amacrine cells that by relaxing 
smooth muscle cells leads to vasodilation (Cellerino et al., 2003). 
Intraocular application of BDNF significantly increases survival of RGCs in the 
traumatic optic nerve damage models and also increases NOS activity as it has been 
evaluated by NADPH-diaphorase reactivity (Klcker et al., 1998). However, it is 
suspected that BDNF also results in activation of iNOS that considered to be a limiting 
factor for the survival of RGCs due to promotion of nitrosative stress through formation 
of peroxynitrite (Klcker et al., 1998; Klcker et al., 1999). Further studies in line with 
development of new experimental protocols are needed to evaluate the role of 
neurotrophic factors in the improvement of retinal blood flow and protection of RGCs in 
pathological conditions. 
I.4.2. Oxidative stress 
Oxidative stress, caused by the imbalance between the production of reactive 
oxygen species (ROS) and their elimination by antioxidants, has been recognized as a 
central contributor to neuronal injury and death. ROS are continuously produced by 
mitochondria through the electron transport chain, but can also be generated by 
enzymatic degradation of neurotransmitters, neuroinflammatory mediators, and redox 
reactions (Halliwell, 2006). Increased levels of ROS like superoxide anion (O2•) and 
hydroxyl radical (OH•), a common feature of neurodegenerative diseases, can originate 
from mitochondrial dysfunction, abnormal protein folding, and defective ubiquitination 
and proteasome degradation systems (Andersen, 2004).  
There is evidence that oxidative damage occurs in experimental models of optic 
nerve injury and in human glaucoma. For example, the presence of DNA damage and 
accumulation of protein and lipid peroxidation products have been documented in the TM 
and retinas from experimental ocular hypertension models and POAG patients 
(Babizhayev and Bunin, 1989; Izzotti et al., 2003; Ko et al., 2005; Moreno et al., 2004; 
Sacc et al., 2005; Tezel et al., 2005). Furthermore, an intracellular ROS superoxide burst 
has been proposed to be a critical death signal triggered by axonal injury leading to RGC 
apoptosis (Geiger et al., 2002; Kanamori et al., 2010; Lieven et al., 2006; Nguyen et al., 
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2003; Swanson et al., 2005). During hypoxia, the generation of mitochondrial ROS is 
necessary for activation of the hypoxia-inducible factor-1 alpha (HIF-1α), a 
transcriptional regulator required for the induction of a variety of genes (Chandel et al., 
2000; Duranteau et al., 1998). Expression of HIF-1α and HIF-1α target genes, including 
erythropoietin, heat-shock protein 27 (Hsp-27) and vascular endothelial growth factor, 
increase in experimental rat glaucoma (Ergorul et al., 2010), and high levels of HIF-1α 
are found in the retina and optic nerve head of glaucoma patients (Tezel and Wax, 2004). 
I.4.2.1. Neuronal antioxidant systems 
Cells are naturally equipped with an arsenal of protective antioxidant systems 
such as superoxide dismutase (SOD), catalase, and glutathione peroxidase and 
glutathione reductase (Vendemiale et al., 1999). The SOD family of enzymes catalyze the 
dismutation of superoxide into molecular oxygen (O2) and H2O2, decreasing the chance 
of OH• formation (Fridovich, 1995). The byproduct of this process, H2O2, is toxic and 
therefore is converted to water by catalases and glutathione peroxidases. Logic follows 
that an insufficiency in ROS neutralizing mechanisms in RGCs might play a role in the 
progression of glaucoma and, in fact, circumstantial evidence exists in favor of this idea. 
SOD activity decreases in the trabecular meshwork of patients with glaucoma (Behndig 
et al., 1998; De La Paz and Epstein, 1996) and in the retina in experimental ocular 
hypertension (Moreno et al., 2004). RGCs are particularly vulnerable to the lack of the 
copper- and zinc-containing cytoplasmic form of SOD (SOD-1), as SOD1 knock-out 
mice are characterized by loss of RGC function, accumulation of superoxide in RGC 
soma and age-dependent RGC loss (Hashizume et al., 2008; Yuki et al., 2011). 
Exogenous supplementation or overexpression of SOD-1, however, have yielded 
conflicting results: while some studies showed neuroprotection of axotomized RGCs 
following SOD-1 administration (Kanamori et al., 2010; Schlieve et al., 2006), others 
reported accelerated RGC death in transgenic mice overexpressing SOD-1 (Levkovitch-
Verbin et al., 2000).  
The regulation of cellular redox status is provided by the glutathione and the 
thioredoxin (TRX) systems. Glutathione is a tripeptide molecule composed of glutamate, 
cysteine and glycine; in its reduced form, reduced glutathione (GSH) is a necessary 
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cofactor for the glutathione peroxidase family of enzymes (Sarma and Mugesh, 2008). In 
the retina, glutathione is produced mainly by Müller cells but also in smaller quantities by 
horizontal cells (Pow and Crook, 1995). Glutathione is then transferred from Müller cells 
to RGCs and other neurons in the retina (Schtte and Werner, 1998). The TRX system is a 
key endogenous defense mechanism against oxidative damage that includes TRX 
proteins, TRX-interacting protein (TXNIP), TRX reductase (TRXR) and NADPH (Lillig 
and Holmgren, 2007). The major TRX protein isoforms, the cytoplasmic TRX1 and the 
mitochondrial TRX2, act as antioxidants by maintaining a reduced environment within 
cells through their dithiol/disulphide reducing activity and by inhibiting the oxidative 
aggregation of toxic proteins (Collet and Messens, 2010). TRX2 plays an important 
antioxidant role against mitochondrial oxidative stress (Yoshida et al., 2003): 
heterozygous (Trx2+/−) transgenic mice display reduced mitochondrial function and ATP 
production as well as increased oxidative damage (Pérez et al., 2008).     
Neurons also respond to redox imbalance by upregulating endogenous antioxidant 
machinery. Upon oxidative insult, expression of several antioxidant enzymes, controlled 
by the antioxidant response element (ARE) promoter, are upregulated. (Dringen et al., 
2005; Hayes and McLellan, 1999; Nguyen et al., 2009). NF-E2-related factor-2 (Nrf2) 
transcription factor plays a major role in activation of ARE-controlled genes in response 
to oxidative stress (de Vries et al., 2008; Kensler et al., 2007; Kobayashi and Yamamoto, 
2006). Activation and nuclear translocation of Nrf2 itself is controlled by cellular redox 
state; under normal conditions Nrf2 is bound to an inhibitor protein, Keap1, which retains 
Nrf2 in the cytoplasm and targets it for ubiquitination (Furukawa and Xiong, 2005; Sun 
et al., 2007). However Keap1 is a redox sensitive protein and its oxidation results in Nrf2 
and Keap1 dissociation, leading to nuclear translocation of Nrf2, where it promotes 
transcription of ARE-controlled genes (Kensler et al., 2007). 
I.4.2.2. Oxidative stress and activation of apoptotic pathways 
TRX proteins also regulate cell death by redox modification of pro-apoptotic 
kinases. The mitogen-activated protein kinases (MAPKs) are a large family of protein 
Ser/Thr kinases with central regulatory role in many cellular functions (Cargnello and 
Roux, 2011). Activation of pro-survival MAPKs like extracellular signal-regulated 
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kinases 1/2 (Erk1/2) promote RGCs survival (Zhou et al., 2005). In contrast, pro-
apoptotic MAPKs like p38 mitogen activated protein kinases and c-Jun N-terminal 
kinases (JNKs), also known as stress-activated protein kinases (SAPKs), are typically 
activated by a variety of stress signals and contribute to RGC death (Brecht et al., 2005; 
Cuadrado and Nebreda, 2010; Curran and Franza, 1988). 
Apoptosis signal regulating kinase 1 (ASK1), is a SAPK belonging to the 
mitogen-activated protein kinase kinase kinase (MAPKKK) family and plays key roles in 
human neurodegenerative diseases (Hattori et al., 2009); ASK1 activates JNK and p38 in 
response to diverse stress stimuli, particularly inflammatory cytokines and oxidative 
stress (Hatai et al., 2000; Ichijo et al., 1997; Min et al., 2008; Zhang et al., 2007a). 
Reduced TRX is normally bound to ASK1 thus preventing ASK1 autophosphorylation. 
Oxidation of cysteine thiols in TRX results in its dissociation from ASK1, triggering 
ASK1 autophosphorylation and downstream stimulation of JNK and p38 death signaling 
(Hatai et al., 2000; Ichijo et al., 1997; Saitoh et al., 1998). A significant decrease in 
TRX1 and TRX2 was reported in acute and chronic models of optic nerve damage, 
including ocular hypertension (Munemasa et al., 2008; Munemasa Y, 2009) while the 
levels of TXNIP, a negative regulator of TRX, increased (Caprioli et al., 2009). 
Furthermore, over-expression of TRX1 and TRX2 protected RGCs from 
pharmacologically-induced oxidative stress, optic nerve axotomy and ocular hypertension 
(Caprioli et al., 2009). 
A recent in vivo study using live imaging demonstrated that superoxide increases 
sharply in RGCs at the single-cell level, soon after optic nerve axotomy, and precedes 
RGC apoptosis (Kanamori et al., 2010). ROS can modulate protein function by altering 
redox states leading to cysteine sulfhydryl oxidation. Oxidative cross-linking creates new 
disulfide bonds causing protein conformational changes and subsequent activation of cell 
death signals (Carugo et al., 2003; Park and Raines, 2001). Consistent with this, RGC 
viability depends on the intracellular sulfhydryl redox state, with survival observed under 
mildly reducing conditions and increased death rates induced by sulfhydryl oxidation 
(Castagne and Clarke, 1996; Castagne et al., 1999; Geiger et al., 2002; Swanson et al., 
2005). An attractive hypothesis is that reduction of oxidized sulfhydryls on critical 
proteins might attenuate the activation of death pathways that influence the fate of RGCs 
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after injury. In this thesis, we will explore this hypothesis by using a reducing agent 
based on a borane-protected phosphine backbone. 
I.4.2.3. ROS and retinal vasculature  
Oxidative stress and ischemic retinopathies are often followed by activation of 
angiogenic cytokines leading to vascular inflammatory reactions and ocular 
neovascularization (Dong et al., 2009). It has been shown that exogenous ROS, in 
particular peroxynitrite, by nitrating the tyrosine residues of phosphatidylinositol 3-kinase 
results in inhibition of the Akt activity that blocks the pro-survival effect of VEGF on 
vasculature (El-Remessy et al., 2005). However, hypoxic conditions significantly 
increase the VEGF mRNA half-life; this post-transcriptional regulation is via 
modification of a 3′- region of the VEGF mRNA by ROS that results in the improved 
stability of the VEGF mRNA (Levy et al., 1996). Hypoxia also effects transcriptional 
regulation of an important gene encoding the VEGF receptor (Flt-1), resulting in 
upregulation in the expression of this receptor (Gerber et al., 1997). In addition, ROS like 
peroxynitrite, via activation of STAT3 pathway, increase expression of VEGF itself (Platt 
et al., 2005). Peroxynitrite also through a nitration-independent mechanism promotes 
angiogenesis as exogenous peroxynitrite was able to phosphorylate the VEGFR2 leading 
to endothelial cell growth and capillary formation (El Remessy et al., 2007). VEGF 
receptor activation is followed by intracellular generation of hydrogen peroxide that leads 
to activation of phosphatidylinositol 3-kinase and the small GTPase Rac-1and facilitates 
the angiogenesis, therefore, ROS could act as intracellular angiogenic mediators. 
(Colavitti et al., 2002). It is interesting to know that in the mice deficient for superoxide 
dismutase 1 (Sod1(-/-)), signs of oxidative stress are accompanied by severe ocular 
neovascularization, that is improved by antioxidants treatment (Dong et al., 2011). 
I.4.2.3.1. ROS and vascular tone 
ROS play important role in both physiologic and pathologic regulation of vascular 
tone. For instance, endothelium-dependent relaxation produced by vasodilator 
bradykinin, is mediated through hydroxyl radical (Rosenblum, 1987). Further studies 
showed that vasodilatory effects of bradykinin and arachidonic acid is mediated via SOD 
activity and is result of H2O2 production (Sobey et al., 1997). In the brain, exposure to 
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superoxide, hydrogen peroxide and peroxynitrite results in cerebral vasodilation (Wei et 
al., 1996). There are evidence that vascular regulatory systems are also under redox 
regulation, in particular, production of prostanoids is regulated by a nitric oxide-
superoxide system (Bachschmid et al., 2005; Schildknecht and Ullrich, 2009). Activity of 
vasoactive agent, ET-1, also has been linked to intracellular production of ROS as 
activation of ET(A) receptors in the retinal microvessles is followed by increased 
formation of superoxides anions (Matsuo et al., 2009).  
Hypoxic and ischemic conditions also result in release of ATP into the 
extracellular space that activates ATP-sensitive potassium channels of pericytes and leads 
to retinal vasodilation (Li and Puro, 2001). These ATP-sensitive potassium channels are 
predominantly located on capillaries of the retina (compare to arterioles) which boosts 
response of microvessels to hypoxic conditions (Jiang et al., 1998). ATP-sensitive 
potassium channels located on retinal microvasculature are redox sensitive and presence 
of ROS increases their activity (Ishizaki et al., 2009). Endothelial cells in this 
microvessels are also rich in polyamine-dependent potassium channels and their 
activation in hypoxic conditions is followed by endothelial cell death (Nakaizumi and 
Puro, 2011). 
I.4.3. Nitrosative stress 
 NO participates in the post-translational modification of proteins by nitrating 
specific cysteine amino acids, a process known as S-nitrosylation, which has a significant 
impact on the regulation of protein function (Choi et al., 2000; Jaffrey et al., 2001b). NO 
can also interact with other free radicals as it does with superoxide to form peroxynitrite, 
a potent oxidant and nitrating agent (Beckman and Koppenol, 1996). Unlike NO, which 
favors nitration of cysteine residues in proteins, peroxynitrite results in the nitration of 
tyrosine residues leading to the formation of nitrotyrosine which has been associated with 
neuronal damage (Beckman, 1996; Pacher et al., 2007). NO entry to the mitochondria can 
also increase superoxide production, therefore the risk of peroxynitrite formation 
increases in such cases (Brown, 1999). Several important cellular processes are regulated 
by S-nitrosylation including the transcriptional activity of NF-κB, CREB and HIF. S-
nitrosylation also modulates the Ca2+ influx through NMDAR and other Ca2+ channels 
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and nitrosylation of substrates such as caspase-3, TRX, Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and X-linked inhibitor of apoptosis protein (XIAP) critically 
effect the balance of cell survival and death (Chung, 2010). The wide range of roles and 
interactions attributed to NO might explain its contribution to both pro-survival and pro-
apoptotic pathways in neurons (Brown, 2010a; Fiscus, 2002; Kim et al., 1999; Nicotera et 
al., 1997). 
The initial evidence for the involvement of NO in the pathophysiology of 
glaucoma came from studies showing increased iNOS expression in the astrocytes 
isolated from the ONH of glaucoma patients (Liu and Neufeld, 2000; Neufeld et al., 
1997). Although increased expression of iNOS has also been reported in the retina and 
ONH astrocytes from rats with ocular hypertension (Shareef et al., 1999; Vidal et al., 
2006), other groups failed to detect changes in iNOS levels in both inducible and genetic 
models of glaucoma or ocular tissues from POAG patients (Libby et al., 2007; Pang et 
al., 2005). The non-specific NOS inhibitors N-nitro-L-arginine (NOLA) N-nitro-l-
arginine methyl ester (l-NAME) delayed RGC death after optic nerve axotomy (Koeberle 
and Ball, 1999). The iNOS inhibitor aminoguanidine was neuroprotective in an episcleral 
vein cauterization rat glaucoma model (Neufeld, 2004), but the same compound did not 
promote RGC survival in rats with ocular hypertension induced by episcleral injection of 
hypertonic saline (Pang et al., 2005). Furthermore, genetic deficiency of iNOS or 
aminoguanidine treatment did not attenuate optic nerve damage in DBA/2J mice (Libby 
et al., 2007).  
An alternative approach to evaluate the potential role of NO in glaucoma is to 
examine the generation of nitrotyrosine in target proteins, a hallmark of peroxynitrite 
production. The retinal expression of nitrotyrosine has been recently shown to increase in 
models of optic nerve crush injury (Thaler et al., 2010) and excitotoxic damage (Al-
Gayyar et al., 2010). In POAG patients, nitrotyrosine formation was detected in 
astrocytes, endothelial cells and smooth muscle cells located in the pre-laminar area of 
the ONH (Feilchenfeld et al., 2008). Nitrotyrosine expression was also detected in the 
TM of POAG subjects with a noticeable increase in iNOS and reduction of eNOS in this 
tissue (Fernndez-Durango et al., 2008). Of interest, increased nitrotyrosine 
immunoreactivity was detected in the LGN of primates with experimental glaucoma 
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(Luthra et al., 2005). Though circumstantial, these studies point to an abnormal 
accumulation of nitrosylation products that extends from the TM to the brain suggesting a 
possible role of NO pathology, acting in separate visual system compartments in 
glaucoma. The use of techniques with higher sensitivity and specificity, including 
proteomics, might improve the detection of nitrotyrosine-modified proteins in glaucoma 
as well as provide information about the identity of the target proteins involved (Bigelow 
and Qian, 2008). 
I.4.4. The role of neurotrophic factors 
I.4.4.1. The neurotrophin family and their receptors 
Neurotrophins are diffusible trophic molecules that exert a potent survival effect 
on adult CNS neurons. They are a family of small, secreted peptides that include nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) 
and neurotrophin-4/5 (NT-4/5) in mammals (Huang and Reichardt, 2001; Segal and 
Greenberg, 1996). In addition to cell survival, neurotrophins mediate several key cellular 
responses in the developing and mature CNS including proliferation, differentiation, axon 
growth, as well as dendrite and synapse formation. Among neurotrophins, BDNF has 
received particular attention because of its potent role on the survival of RGCs. The first 
evidence of the neuroprotective effect of BDNF emerged from studies showing that 
BDNF promoted the survival of developing, axotomized RGCs in culture (Johnson et al., 
1986). Since then, it has become clear that BDNF is a powerful neurotrophin for 
developing and adult RGCs following optic nerve injury (Ma et al., 1998; Mansour-
Robaey et al., 1994; Takano et al., 2002; Watanabe and Fukuda, 2002; Weibel et al., 
1995). Consistent with this, BDNF is strongly expressed in the superior colliculus (Hofer 
et al., 1990; Wetmore et al., 1990), the main target of RGCs in the rodent brain, and it is 
retrogradely transported by RGC axons to the retina (Herzog and von Bartheld, 1998; Ma 
et al., 1998). Within the retina, BDNF is produced by cells in the ganglion cell layer and 
inner nuclear layer (Cohen-Cory and Fraser, 1994; Pérez and Caminos, 1995; Vecino et 
al., 1998).  
The biological effects of neurotrophins are mediated by two classes of cell surface 
receptors: i) the tropomyosin related kinase (Trk) family of receptor tyrosine kinases 
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comprising TrkA, the receptor for NGF; TrkB, the receptor for BDNF and NT-4/5; and 
TrkC, the receptor for NT-3 (Kaplan et al., 1991; Klein et al., 1991; Lamballe et al., 
1991); and ii) the p75 receptor (p75NTR) which binds all neurotrophins with similar 
affinity (Huang and Reichardt, 2003; Teng and Hempstead, 2004). The Trk receptors 
share in common a large extracellular ligand binding domain, a single trans-membrane 
domain, and a cytoplasmic tyrosine kinase catalytic domain. Neurotrophins are 
homodimers, associated in a non-covalent fashion, that bind and dimerize Trk receptors 
thus triggering activation of the tyrosine kinase domain and intracellular signaling. Both 
Trk and p75NTR receptors can be present on the same cell population, however, activation 
of Trk receptors has been typically associated with cell survival, while p75NTR can 
stimulate both survival and apoptotic pathways (Chao, 1994; Miller and Kaplan, 2001).  
In the naïve retina, developing and adult RGCs have been shown to express high 
levels of TrkB (Jelsma et al., 1993; Pérez and Caminos, 1995; Rickman and Brecha, 
1995). The NGF receptor TrkA is also expressed by developing RGCs (Cui et al., 2002; 
Rickman and Brecha, 1995), but TrkA levels in adult RGCs are low (Lebrun-Julien et al., 
2009b; Rudzinski et al., 2004). The NT-3 receptor TrkC is expressed by RGCs during 
retinal development (Bovolenta et al., 1996; Das et al., 1997; Hallbook et al., 1996), and 
by a small population of adult RGCs (Cui et al., 2002; Lindqvist et al., 2002). 
Interestingly, although developing RGCs express p75NTR  (Frade et al., 1999; Frade et al., 
1996; Gonzalez-Hoyuela et al., 2001; Harada et al., 2006), this receptor is not expressed 
by adult RGCs (Hu et al., 1998; Hu et al., 1999; Lebrun-Julien et al., 2009b), and a 
structurally related receptor named TROY has been proposed to mediate some of the 
functions originally attributed to p75NTR (Park et al., 2005; Shao et al., 2005). Therefore, 
RGCs are endowed with the molecular machinery to differentially respond to 
neurotrophins depending on their developmental stage and on the injury modality as will 
be discussed in subsequent sections. 
I.4.4.2. The neurotrophic factor deprivation hypothesis  
The primary mechanism of RGC damage in glaucoma is not well understood, but 
there is evidence that neuronal loss in this disease occurs largely by apoptosis (Nickells, 
1999; Quigley, 1999). This self-destructive, genetically driven, death program can be 
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activated in all neurons. It is now widely accepted that neurotrophic factors promote 
neuronal survival by inhibiting default apoptotic pathways (Raff et al., 1993). During 
development of the nervous system, young neurons require trophic factors for their 
survival, differentiation and the establishment of synaptic connections. Neurotrophic 
factors are produced in limited amounts; therefore only neurons exposed to optimal levels 
of these molecules survive, whereas less fortunate neurons are eliminated by apoptosis 
(Lewin et al., 1998). In rodents, ~65% of RGCs die during retinal development (Crespo 
et al., 1985; Sefton and Lam, 1984; Tay et al., 1986). Excess RGCs are eliminated in two 
successive phases of cell death in the chick retina: the first phase peaks at embryonic day 
6 (E6), when RGCs differentiate; and the second phase coincides with the arrival of RGC 
axons to the brain, when these neurons become dependent on target-derived trophic 
support (Frade et al., 1997; Rager, 1980). RGC axon terminals uptake and retrogradely 
transport BDNF applied to the superior colliculus (Fournier et al., 1997; Herzog and von 
Bartheld, 1998). Moreover, intracollicular injection of BDNF in newborn hamsters 
reduces the rate of developmental RGC death (Ma et al., 1998) suggesting that target-
derived BDNF regulates the survival of developing RGCs (Figure 5A).  
The role of endogenous target-derived factors in the maintenance of adult RGCs 
is considerably less clear. Studies in which RGC target tissue was ablated in adult cats 
showed that RGC loss was not detected until six months after the lesion (Pearson and 
Stoffler, 1992; Pearson and Thompson, 1993). The observation that loss of target-derived 
neurotrophic factors does not affect RGC survival for several months is consistent with 
the protracted RGC death characteristic of glaucoma, which often occurs over several 
decades. It has been proposed that the retrograde transport of neurotrophins to the retina 
might initially be a redundant mechanism and that retina-derived neurotrophic factors 
may temporarily support the survival of RGCs that have been disconnected from their 
targets (Murphy and Clarke, 2006). Conversely, target-derived factors may act to 
compensate for deficits in local trophic support. Given that neurotrophic factors are 
produced locally in the retina and distally by target cells, it is logical to think that both 
sources are important for the survival and function of adult RGCs. At present, a full 
understanding of the contribution of target-derived neurotrophic factors for RGC survival 
in glaucoma is lacking. Target ablation experiments may result in terminal damage which 
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can potentially confound the interpretation of the results. Thus, experiments that 
selectively disrupt the production of neurotrophic factors by the target neurons using 
function blocking antibodies or genetic approaches that involve conditional deletion of 
neurotrophin genes might be useful in assessing the contribution of trophic factors 
derived from the target tissue in adult organisms. 
I.4.4.3. Axonal transport failure  
Although the requirement of target-derived neurotrophic factors in the survival of 
adult RGCs has been elusive, a current hypothesis is that blockade of axonal transport in 
glaucoma leads to deficits in the levels and availability of these factors and subsequent 
RGC death (Figure 5B). Evidence for this idea is provided by early observations that both 
anterograde and retrograde axonal transport in the optic nerve is blocked in experimental 
glaucoma in primates (Anderson and Hendrickson, 1974; Gaasterland et al., 1978; 
Hayreh et al., 1979; Minckler et al., 1977; Quigley and Anderson, 1976; Quigley and 
Addicks, 1980; Quigley and Anderson, 1977). More recently, deficits in retrograde 
axonal transport have been reported in rat and mouse glaucoma models (Kim et al., 
2004a; Salinas-Navarro et al., 2009; Salinas-Navarro et al., 2010) and in human high-
pressure secondary glaucoma (Knox et al., 2007). Moreover, retrograde transport of 
radiolabeled BDNF was impaired following intraocular pressure increase in rats, and 
accumulation of TrkB immunolabeling was found in the ONH in this model (Pease et al., 
2000; Quigley et al., 2000). Elevated  intraocular  pressure has  also been shown to 
correlate with the ONH and retinal accumulation of dynein, a motor protein required for 
axonal transport  (Martin et al., 2006). A recent study in DBA/2J mice, a strain that 
spontaneously develops glaucoma, demonstrated that axonal transport failure occurs early 
and progresses in a distal-to-proximal  pattern (Crish et al., 2010). Of interest, RGC  
axons  and  pre-synaptic terminals persisted in the superior colliculus well after axonal 
transport failed (Crish et al., 2010) suggesting that restoration of transport along RGC 
axons might be an early therapeutic target for glaucoma. Therefore, axonal transport 
blockade, whether it involves neurotrophic factor deprivation or insufficient levels of 
other essential molecules, continues to be an attractive posit for the loss of RGCs in 
glaucoma. 
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FIGURE 5. 
 
 
Figure 5. The neurotrophic factor deprivation hypothesis. Axonal transport failure 
leading to deficits in neurotrophic factor supply has been proposed to contribute to RGC 
death in glaucoma. (A) Neurons that successfully obtain optimal amounts of essential 
neurotrophic factors will survive. (B) Damaged RGCs that are disconnected from their 
targets and undergo obstruction of axonal transport will experience neurotrophic 
deprivation and die. Source of image: Almasieh et. al., Prog. Retin. Eye. Res., March 
2012. 
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I.4.4.4. Neurotrophin supplementation therapies 
Supplementation of neurotrophic factors has been extensively studied as a 
potential strategy to prevent the death of injured RGCs. Among neurotrophic factors, 
BDNF stands out because of its potent neuroprotective effect. Intraocular injection of 
exogenous BDNF protein or viral-mediated BDNF gene transfer using adenovirus or 
adeno-associated virus (AAV) promote robust RGC survival after optic nerve transection 
or crush (Chen and Weber, 2001; Di Polo et al., 1998; Klöcker et al., 2000; Leaver et al., 
2006; Mansour-Robaey et al., 1994; Mey and Thanos, 1993; Parrilla-Reverter et al., 
2009; Peinado-Ramon et al., 1996). For example, a single intraocular injection of 
recombinant BDNF confers 100% survival of axotomized RGCs at one week after lesion 
(compared to 50% in control eyes), and an average of 48% survival at two weeks post-
injury (compared to ~10% in control eyes), based on quantification of retrogradely 
labeled RGC soma (Berkelaar et al., 1994; Cheng et al., 2002; Mansour-Robaey et al., 
1994; Peinado-Ramon et al., 1996). The combination of BDNF gene transfer with 
additional therapies including free radical scavengers and cell-permeable cAMP further 
increase RGC neuroprotection (Hellström and Harvey, 2011; Isenmann et al., 1998). In 
experimental glaucoma induced by chronic eye pressure elevation, intraocular delivery of 
BDNF protein (Ko et al., 2001) or gene transfer using an AAV vector led to marked RGC 
neuroprotection (Martin et al., 2003). For example, at four weeks of ocular hypertension, 
68% of RGC survival was reported in eyes treated with AAV.BDNF compared to only 
48% in control eyes (20% protection) as assessed by  quantification of RGC axons 
(Martin et al., 2003). Therefore, exogenous BDNF confers RGC soma and axon 
protection in acute models of optic nerve injury and in experimental glaucoma. 
I.4.4.5. BDNF/TrkB signaling 
Several lines of evidence support a key role for BDNF/TrkB signaling on the 
survival of adult RGCs. Both exogenous BDNF administration and strategies that result 
in TrkB activation lead to enhanced RGC survival in acute and chronic models of optic 
nerve damage (Chen and Weber, 2001; Cheng et al., 2002; Di Polo et al., 1998; Hu et al., 
2010; Klöcker et al., 2000; Leaver et al., 2006; Mey and Thanos, 1993; Parrilla-Reverter 
et al., 2009). Paradoxically, the number of RGCs in BDNF or TrkB knockout mice have 
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been shown to be similar to those found in wild-type animals (Cellerino et al., 1997; 
Pollock et al., 2003; Rohrer et al., 2001), suggesting that other neurotrophic factors 
compensate for the lack of BDNF or that BDNF signaling through TrkB is not required 
for RGC survival during development. Of interest, however, RGCs from BDNF null mice 
displayed hypomyelinated axons (Cellerino et al., 1997) which correlated with marked 
functional deficits (Rothe et al., 1999), a phenotype that might increase the vulnerability 
of these neurons to die following glaucomatous optic nerve damage.  
Upon binding to the TrkB receptor, BDNF stimulates multiple signaling pathways in the retina, 
including the extracellular signal-regulated kinases 1/2 (Erk1/2) (Figure 6) and the 
phosphatidylinositol-3 kinase (PI3K)/Akt pathways. Erk1/2 and (PI3K)/Akt by activating 
transcription factors like cAMP response element binding protein (CREB) stimulate the 
transcription of pro-survival molecules such as Bcl-2 and Bcl-xL (Bonni et al., 1995; Du and 
Montminy, 1998; Finkbeiner et al., 1997; Wilson et al., 1996). Both the Erk1/2 and the PI3K 
pathways are stimulated in adult RGCs following TrkB activation in vivo (Cheng et al., 2002; Hu 
et al., 2010; Nakazawa et al., 2002). Furthermore, pharmacological inhibition of the obligate 
upstream activator of Erk1/2, the mitogen activated protein (MAP) kinase kinase 1 (MEK1), 
blocked the survival effect produced by AAV-mediated TrkB overexpression, while PI3K 
inhibition did not alter this neuroprotective  effect (Cheng et al., 2002). These  results  support  
the  hypothesis  that activation of the Erk1/2 pathway, but not the PI3K pathway, mediates TrkB-
induced RGC survival. Furthermore, in vivo stimulation of Erk1/2 by overexpression of a 
constitutively active MEK1 mutant potentiated RGC survival after optic nerve axotomy (Pernet et 
al., 2005)  and in a  rat model of ocular  hypertension (Zhou et al., 2005). These  data indicate 
that the Erk1/2 pathway plays a key role in the regulation of adult RGC survival after 
traumatic injury and in experimental glaucoma. 
I.4.4.6. Neurotrophins and neuronal redox homeostasis 
Under oxidative stress conditions, treatment with neurotrophins like NGF results 
in a rapid improvement in cell survival and reduction of ROS levels (Dugan et al., 1997). 
In the retina, BDNF application significantly increases survival of RGC in chemically 
induced hypoxia (Ikeda et al., 1999). Both BDNF and CNTF also demonstrat significant 
RGC protection in a model of NO-induced neuronal cell death in the retina (Takahata et 
al., 2003). Further study has shown that neurotrophins can alter the process of ROS 
synthesis  towards a less harmful  end-product,  for instance by  facilitating  production of 
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FIGURE 6. 
                                       
 
 
 
Figure 6. Activation of ERK1/2 survival pathway via BDNF and TrkB signaling. 
MAPK family members regulate the fate of injured RGCs and play anti- and pro-
apoptotic roles. BDNF-mediated activation of TrkB receptors stimulates the MEK1/2 and 
results in ERK1/2 activation leading to robust RGC survival after axotomy and in 
experimental glaucoma. Stress stimuli activate ASK1, and its downstream effectors JNK 
and p38, a pathway that contributes to RGC death and optic nerve degeneration. Source 
of image: Almasieh et. al., Prog. Retin. Eye. Res.,  March 2012. 
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H2O2 instead of superoxide anion (Satoh et al., 1999). Modulation in free radical 
formation mediated by neurotrophins has been linked to activation of MAPK pathway as 
application of PD98059, specific inhibitors of MEK, increases the ROS production 
(Dugan et al., 1997). However, in some conditions like mixed neuronal-glial culture, 
treatment with BDNF induces ROS production that is thought to be result of NADPH 
oxidase activation and leads to oxidative neuronal death (Kim et al., 2002). Other studies 
have suggested this ROS production could be result of increased activity of NADPH 
oxidase in glial cells (Abramov et al., 2005). 
Neurotrophins through activation of pathways like Ras/ERK, PI3K/Akt are 
involved in several important neuronal process like survival, growth and plasticity (Mayr 
and Montminy, 2001; Shaywitz and Greenberg, 1999). Many of downstream signaling 
pathways of neurotrophins lead to activation of CREB kinases that phosphorylate CREB. 
Interestingly, nNOS activity by regulating the redox homeostasis and protein S-
nitrosylation is also involved in neurotrophin control of transcriptional activity (Jaffrey et 
al., 2001a). It has been suggested that nuclear proteins that associate with CREB target 
genes are redox sensitive, BDNF by activation of nNOS initiates a NO-dependent 
signaling pathway that leads to S-nitrosylation of these proteins and therefore controls 
CREB-DNA binding and gene expression (Riccio et al., 2006). A recent study has shown 
that activity of nNOS is necessary for BDNF induced proteins synthesis and neuronal 
plasticity (Gallo and Iadecola, 2011). Similarly, inhibition of NOS by L-NAME abolishes 
S-nitrosylation of proteins associated with CRE sequences and although it does not affect 
BDNF stimulated CREB phosphorylation, however it blocks CREB-DNA binding and 
gene expression (Riccio et al., 2006). 
 I.4.5. Excitotoxic Damage 
Glutamate is the predominant excitatory amino acid in many regions of the CNS, 
including the retina. Glutamate-mediated neurotransmission plays a major role in the 
relay of visual information from photoreceptors to bipolar cells, then to RGCs and onto 
brain centers (Lukasiewicz, 2005). Retinal glutamate receptors are located in the outer 
plexiform layer where glutamatergic synapses connect photoreceptors to bipolar and 
horizontal cells; and also in the inner plexiform layer which contains the bulk of 
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glutamatergic synapses from bipolar cells to RGCs and amacrine cells (Gründer et al., 
2000; Lagrèze et al., 2000; Lukasiewicz, 2005; Peng et al., 1995). The central hypothesis 
of excitotoxic injury is that excess glutamate binds to cell surface ionotropic glutamate 
receptors, primarily N-Methyl-D-aspartic acid (NMDA) receptors (NMDAR), triggering 
massive Ca2+ influx and activation of pro-apoptotic signaling cascades in neurons. 
Elevation of endogenous glutamate and activation of glutamate receptors have been 
shown to contribute to a variety of acute and chronic neurological disorders, including 
stroke, trauma, seizures, and various forms of dementia and neurodegeneration (Kalia et 
al., 2008). In the retina, excess glutamate has been proposed to underlie common 
neurodegenerative disorders such as retinal artery occlusion and glaucoma (Casson, 
2006; Seki and Lipton, 2008). A number of studies have now demonstrated that adult 
RGCs are exquisitely sensitive to exogenously applied NMDA, which triggers rapid 
death of these neurons, and that inhibitors of NMDAR and/or downstream pathways are 
neuroprotective in experimental models of retinal ischemia and glaucoma (Hare et al., 
2004; Kido et al., 2000; Lam et al., 1999; Manabe and Lipton, 2003). 
I.4.5.1. Glutamate levels in glaucomatous retinas   
  Early reports indicated an increase in glutamate levels in the vitreous of dogs and 
monkeys with ocular hypertension and in glaucoma patients (Brooks et al., 1997; Dreyer 
et al., 1996). However, several studies thereafter were unable to reproduce these findings 
in vitreous humor samples from experimental animals with retinal ischemia or ocular 
hypertension, and in human glaucoma (Carter-Dawson et al., 2002; Honkanen et al., 
2003; Kwon et al., 2004; Levkovitch-Verbin et al., 2002a; Wamsley et al., 2005). 
Therefore, experimental data on this topic has been controversial and progress stalled 
after the field was marred by a major scientific fraud (Dalton, 2001). As a consequence, 
our understanding of the actual contribution of excitotoxic damage in glaucoma has 
advanced slowly. A misconception has been that, for excitotoxicity to occur, elevated 
glutamate levels must be detected in the retina/ocular fluids of experimental animals or 
humans with glaucoma (Lotery, 2005; Osborne et al., 2006). Massive glutamate release is 
a hallmark of acute brain injuries with fast and severe neural tissue damage (Choi and 
Rothman, 1990), but this is not necessarily characteristic of a slow, progressing 
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neurodegenerative disease like glaucoma. For instance, in retinal diseases with a clear 
ischemic component, such as retinal detachment, there is a detectable glutamate elevation 
in the vitreous and the subretinal space (Bertram et al., 2008; Diederen et al., 2006). 
However, the chronic, gradual nature of glaucoma defies any drastic elevation or 
accumulation of glutamate throughout the course of the disease. Glutamate increase is 
likely to occur only in localized areas of the retina or optic nerve at any one time during 
glaucomatous neurodegeneration and, together with glutamate clearance and diffusion 
mechanisms, is unlikely to result in a detectable increase in retinal or vitreal glutamate. 
On the other hand, small and consistent fluctuations in extracellular glutamate levels 
could play a role in glaucoma progression. For instance, the voltage-dependent activation 
of NMDAR is normally blocked by Mg2+ ions under resting membrane potential 
conditions (Mayer et al., 1984; Nowak et al., 1984). Glutamate-induced Ca2+ influx 
occurs through NMDAR activation in isolated post-natal RGCs, and extracellular Mg2+ 
inhibits the response of these neurons to glutamate (Hartwick et al., 2008). In principle, 
voltage-dependent Mg2+ blockade can be overcome when the neuronal membrane 
potential becomes more positive (depolarized) than the resting potential. This scenario 
may lead to NMDAR channel opening and excitotoxic damage even at physiological 
levels of glutamate. Of interest, motoneurons subjected to axonal injury displayed 
reduced voltage-dependent Mg2+ block of NMDAR currents in vivo which may increase 
neuronal susceptibility to excitotoxic damage (Furukawa et al., 2000). In summary, to 
rule out an excitotoxic component in RGC death in glaucoma based on the absence of 
glutamate accumulation in ocular tissues is far too simplistic. 
I.4.5.2. The role of glial cells: glutamate transporters 
A major limitation of the central tenet of excitotoxic injury is that it focuses only on the 
neuronal response, but growing evidence indicates that glial cells play critical roles in the 
regulation and response to glutamate. For example, Müller cells are responsible for the 
uptake of excess glutamate via glutamate/aspartate transporters (GLAST) or excitatory 
amino acid transporter 1 (EAAT1) (Derouiche and Rauen, 1995; Otori et al., 1994), 
which is essential to maintain physiological concentrations of glutamate. Even normal 
levels of glutamate in the retina can be potentially neurotoxic if this amino acid is not 
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removed in a timely manner. A number of other glutamate transporters are also expressed 
by both retinal glia and neurons including the glutamate transporter-1 (GLT-1 or 
EAAT2), the excitatory amino acid carrier 1 (EAAC1 in rats or EAAT3 in humans), 
EAAT4 and EAAT5 in rats (Danbolt, 2001; Kugler and Beyer, 2003). Most neuronal 
glutamate transporters in the retina are positioned at the synapse to rapidly remove the 
released glutamate and limit its spillover from the synaptic cleft (Diamond, 2001; 
Hasegawa et al., 2006; Scimemi et al., 2009). In contrast, glial glutamate transporters 
appear to remove the extrasynaptic portion of glutamate from the retina (Figure 7) 
(Rauen et al., 1998). Since most NMDAR on RGCs are believed to be distributed 
extrasynaptically (Chen and Diamond, 2002; Zhang and Diamond, 2006), the 
susceptibility of RGCs to glial glutamate transporter dysfunction is likely to contribute to 
excitotoxic damage. Consistent with this, decreased retinal GLAST and GLT-1 
expression has been correlated with optic nerve damage in experimental rat glaucoma 
(Martin et al., 2002)  and  in  DBA/2J  mice (Schuettauf et al., 2007).  Importantly, mice 
lacking the gene encoding GLAST displayed exacerbated loss of RGC soma and axons 
(Harada et al., 2007). However, the precise role of glutamate transporters in 
glaucomatous pathophysiology requires further evaluation. For instance, chronic and 
moderate elevation of intraocular pressure in rats did not disrupt retinal glutamate 
clearance mechanisms as shown by Ca2+ imaging experiments (Hartwick et al., 2005). 
Marked  increase  in the  GLAST (Woldemussie et al., 2004) and  GLT-1c  levels are also 
reported in experimental models and glaucoma patients (Sullivan et al., 2006). Since 
GLT-1c is not normally expressed by adult RGCs (Rauen et al., 2004), this finding 
suggests a compensatory response in neurons possibly triggered by dysregulation of 
glutamate clearance. Finally, single-nucleotide polymorphisms in the GLAST gene were 
not associated with the manifestation of normal tension glaucoma patients (Yasumura et 
al., 2011). Future work to establish the functional role of different subtypes of glutamate 
transporters after glaucomatous injury is warranted. 
I.4.5.3. The role of glial cells: cytokines 
Another mechanism by which glial cells may contribute to excitotoxic damage is 
the production of neurotoxic factors in response to excess glutamate. Along these lines, a 
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FIGURE 7. 
 
 
Figure 7. Neuronal and glial component of retina in the excitotoxicity. The classical 
model of excitotoxic damage is based on the premise that excess glutamate binds to 
ionotropic glutamate receptors (e.g. NMDA receptor) triggering calcium influx, organelle 
stress and activation of pro-apoptotic pathways. Excitotoxic damage overrides the pro-
survival effect of endogenous and exogenous neurotrophic factor supply. Glial cells are 
responsible for the uptake of excess glutamate via glutamate/aspartate transporters 
(GLAST) and deficits in transporter function have been shown to contribute to RGC 
damage. Source of image: Almasieh et. al., Prog. Retin. Eye. Res., March 2012. 
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recent study demonstrated that Müller cells are extraordinarily sensitive to NMDA and 
respond rapidly by upregulating NF-κB activity (Lebrun-Julien et al., 2009a). In this 
study, NF-κB activation induced by NMDA was detected in Müller cells, but not in 
retinal neurons. Furthermore, NMDA-dependent activation of NF-κB in Müller cells led 
to production of endogenous glia-derived TNFα which in turn rendered RGCs highly 
sensitive to excitotoxicity by increasing their surface levels of Ca2+-permeable type of 
AMPAR (Lebrun-Julien et al., 2009a). The observation that molecular events in Müller 
glia play a decisive role in RGC death shifts our understanding of excitotoxic damage and 
supports a novel model in which glial cells exacerbate RGC loss. A controversial study 
published in 2004 questioned the vulnerability of RGCs to excitotoxic damage because 
saturating concentrations of glutamate or NMDA did not promote RGC death in 
dissociated cultures or ex-vivo (Ullian et al., 2004). A simple explanation for this finding 
is that retinas were exposed to NMDA for 1 hr, which is a short time based on well-
controlled studies showing that RGC death only starts at 3-6 hrs after NMDA 
administration (Lebrun-Julien et al., 2009a; Manabe and Lipton, 2003; Pernet et al., 
2007). The slow onset of RGC death following excitotoxic damage was proposed to 
result from a loss of trophic support provided by amacrine cells which die rapidly in the 
presence of NMDA (Ullian et al., 2004). An alternative explanation is that NMDA affects 
Müller cells early, by a mechanism yet to be identified, and these glial cells then secrete 
neurotoxic TNFα that promotes RGC death (Lebrun-Julien et al., 2009a). In the case of 
chronic, neurodegenerative diseases where an excitotoxic component is thought to be 
involved, such as in glaucoma, blockade of glutamate receptors may not ameliorate 
disease progression unless other damaging factors (e.g. glia-derived TNFα) are also 
inhibited.  
I.4.5.4. AMPAR mediated excitotoxicity 
Another shortcoming of the traditional excitotoxicity model is that it focuses 
almost exclusively on the NMDAR. Antagonists of NMDAR have been intensely 
investigated as `agents that may confer neuroprotection, but these compounds have 
consistently failed to show neuroprotection in human clinical trials (Lipton, 2004; 
Osborne, 2008). Accumulating evidence supports that AMPA type of glutamate receptor, 
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are key contributors to neuronal injury. AMPAR mediate fast synaptic transmission and 
play crucial roles during development and synaptic plasticity (Dingledine et al., 1999). 
AMPAR channels are tetrameric complexes composed of various combinations of four 
subunits (GluR1-R4), each encoded by a different gene. The conductance of AMPAR 
varies depending on whether the GluR2 subunit is present and, if so, whether it has 
undergone mRNA editing. Editing of GluR2 mRNA changes the uncharged amino acid 
glutamine (Q) to positively-charged arginine (R) and, as a result, Ca2+ cannot be 
transported due to electrostatic repulsion by the arginine residues that line the AMPAR 
pore. Since most GluR2 subunits in the CNS are fully edited (e.g. GluR2(R) isoforms) it 
has been proposed that a role for this editing mechanism is to guard against excitotoxicity 
(Kim et al., 2001). Despite this, some cells express GluR2-lacking AMPARs and as a 
result are permeable to divalent ions in the external milieu such as Ca2+ and Zn2+ (Geiger 
et al., 1995; Hollmann et al., 1991; Verdoorn et al., 1991). Interestingly, the proportion of 
cells expressing Ca2+-permeable-AMPAR increases acutely during ischemia, 
excitotoxicity, epileptic seizures (Gorter et al., 1997; Grooms et al., 2000; Pellegrini-
Giampietro et al., 1992), and in neurodegenerative diseases such as Alzheimer’s disease 
and amyotrophic lateral sclerosis (Ikonomovic et al., 1997; Kawahara et al., 2004). 
Recent studies have demonstrated increased cell surface expression of Ca2+-permeable-
AMPAR in RGCs after excitotoxic damage (Lebrun-Julien et al., 2009a) and in 
experimental glaucoma (Cueva Vargas et al., 2011). An in-depth examination of non-
NMDA glutamate receptors is required to establish their role as mediators of RGC death 
in glaucoma. 
I.4.6. Common neurodegenerative pathways: glaucoma and Alzheimer’s disease 
It is increasingly being recognized that glaucoma shares a number of pathological 
features with other neurodegenerative diseases, most notably with Alzheimer’s disease 
(AD) (Jackson and Owsley, 2003; Kirby et al., 2010; McKinnon, 2003; Parisi, 2003). AD 
is the most common cognitive disorder worldwide (Sloane et al., 2002) and its progress is 
characterized by appearance of senile plaques and neurofibrillary tangles in brain tissues. 
Senile plaques are composed of amyloid beta (Aß) peptides whereas neurofibrillary 
tangles are composed of insoluble aggregated tau, a microtubule-associated protein 
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normally enriched in the axon (Lee et al., 2001; Mandell and Banker, 1996). AD patients 
are affected by visual deficits including difficulty reading, abnormal depth perception, 
color recognition and spatial contrast sensitivity (Cronin Golomb, 1995; Cronin Golomb 
et al., 1991; Gilmore and Whitehouse, 1995; Guo et al., 2010; Hinton et al., 1986; 
Jackson and Owsley, 2003; Katz and Rimmer, 1989; Lee and Martin, 2004; Mendez et 
al., 1996). A preferential loss of large diameter RGCs and axons has been documented in 
AD (Hinton et al., 1986), which may account for the impaired contrast sensitivity and 
motion perception in AD patients (Hinton et al., 1986; Jackson and Owsley, 2003; Katz 
and Rimmer, 1989; Lee and Martin, 2004). Likewise, there is a high occurrence of 
glaucoma amongst AD patients, and glaucoma shares a number of pathological and 
clinical features with AD such as the presence of retinal Aß and hyperphosphorylated tau 
(Guo et al., 2010; Gupta et al., 2008; Yoneda et al., 2005). Cognitive impairment, 
depression and anxiety have also been reported among glaucoma patients (Yochim et al., 
2011). AD and glaucoma are both age-related diseases, characterized by the loss of 
selective neuronal populations, mitochondrial dysfunction, and dendritic changes leading 
to loss of synaptic connectivity (Kong et al., 2009; Liu et al., 2011). 
Although several studies have suggested a clinical correlation between glaucoma 
and AD (Sugiyama et al., 2006; Tamura et al., 2006; Wostyn, 2006; Wostyn et al., 2009), 
a clear causal link between these two diseases has not been unequivocally established. 
Nonetheless, compelling evidence from laboratory work supports the idea that neuronal 
loss in AD and glaucoma share common neurodegenerative mechanisms. For example, 
abnormal processing of amyloid precursor protein (APP), a hallmark of AD, has been 
documented in an ocular hypertension rat glaucoma model (McKinnon et al., 2002). In 
this model, caspase-3 was activated in RGCs leading to cleavage of APP and neurotoxic 
accumulation of Aß (McKinnon, 2003). Intraocular injection of Aß, a major culprit in 
AD, has been shown to induce RGC apoptosis (Cordeiro et al., 2006). Furthermore, Aß 
deposition was associated with RGC apoptosis in experimental glaucoma, and blockade 
of the Aß pathway reduced glaucomatous RGC loss (Guo et al., 2007). A recent study 
demonstrated that curcumin, a biologically safe fluorochrome, can be used to visualize 
Aß plaques in the retina of a transgenic AD mouse model (Koronyo-Hamaoui et al., 
2011). These lesions appeared first in the retina and later in the brain, indicating that 
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early pathological changes in the retina could be used to predict onset and monitor 
progression of AD.  
I.4.6.1. Drug based neuroprotective strategies for treatment of glaucoma 
The observation that AD and glaucoma share common neurodegenerative 
pathways have raised the provocative idea that drugs currently used for the treatment of 
AD may also be used to treat glaucoma. An example of this is memantine, an NMDAR 
channel blocker (Parsons et al., 1999) approved by regulatory agencies for the treatment 
of AD (Reisberg et al., 2003). Several studies in rat and monkey OHT models 
demonstrated the efficacy of memantine to block RGC death (Hare et al., 2001a; Hare et 
al., 2004; Lagrèze et al., 1998). Subsequently, memantine was advanced for clinical 
testing in glaucoma but failed to meet its primary endpoint in Phase III trials 
(http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=290764). Although a 
neuroprotective strategy based entirely on the principle of blocking NMDAR function 
has intrinsic limitations (Danesh-Meyer and Levin, 2009; Osborne, 2008), nevertheless, 
the information stemming from this trial should serve as a baseline for the effective study 
design of future clinical testing for neuroprotection in glaucoma (Danesh-Meyer and 
Levin, 2009).  
Other drugs currently approved for the treatment of AD are acetylcholinesterase 
AChE inhibitors. AChE is the enzyme responsible for ACh breakdown, and its inhibition 
was introduced for AD treatment following the cholinergic hypothesis of AD. The 
cholinergic hypothesis argues that cognitive deficits in AD are partly due to the loss of 
cholinergic neurons and reduction of cholinergic transmission in the areas of the brain 
associated with learning, memory, and higher cognitive functions (Razay and Wilcock, 
2008; Whitehouse et al., 1982). Consequently, AChE inhibitors such as galantamine, 
donepezil and rivastigmine have been prescribed to boost the cholinergic signaling and 
provided modest cognitive improvements for the AD patients (Birks, 2006; Jann et al., 
2002). 
 Among the AChE inhibitors, galantamine conveys unique effects beyond those of 
AChE inhibition alone, since it is also an allosteric modulator of nicotinic ACh receptors 
(nAChRs) enhancing their sensitivity to ACh (Schrattenholz et al., 1996). An allosteric 
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potentiating ligand (APL) of nAChRs binds to a site on the receptor that differs from the 
agonist binding site (Schrder et al., 1994). APL binding to the postsynaptic nAChR 
results in conformational changes that amplifies the action of ACh, thereby increasing 
ionic conductance and neurotransmission (Maelicke, 2000). Binding of galantamine to 
nAChR also directly activates the PI3K and leads to phosphorylation of Akt; application 
of a specific antibody against the allosteric binding site on nAChR blocks the 
galantamine mediated PI3K activation (Kihara et al., 2004). In vitro, galantamine protects 
the cortical neurons from ß-amyloid toxicity and improves survival of the motoneurons in 
glutamate excitotoxicity (Kihara et al., 2004; Melo et al., 2009; Shimohama and Kihara, 
2001). In vivo, galantamine significantly improves the survival of hippocampal neurons 
in an ischemic model and also protects dopaminergic neurons against the neurotoxins 
(Lorrio et al., 2007; Yanagida et al., 2008). Pharmacological antagonists of nAChR have 
been shown to partially reduce the neuroprotective effect of galantamine against ß-
amyloid toxicity in culture (Arias et al., 2004; Kihara et al., 2004). These observations 
suggest that galantamine is a promising drug with potential for treatment of other 
neurodegenerative diseases. 
 
I.4.6.2. Retinal cholinergic system and glaucoma 
In the immature vertebrate retinas, cholinergic transmission is essential for the early 
development of retina. Inputs from the cholinergic amacrine cells produce synchronized 
bursts of action potentials in RGCs, known as retinal waves (Feller et al., 1996). These 
propagating waves driven by cholinergic transmission, together with other inputs to 
RGCs, define the pattern of connections between axonal terminals of RGCs and their 
central visual targets (Hahm et al., 1999; Wong, 1999). In the adult retina, inputs from the 
AChRs located on the RGCs no longer generate action potentials because glutamate-
mediated signaling pathway forms the major excitatory input for activation of RGCs 
(Lukasiewicz, 2005; Wong et al., 2000). However, RGCs continue to express both 
nicotinic and muscarinic AChRs and inputs from these receptors play important 
modulatory role on functional properties of the adult RGCs and the processing of the 
visual information (Baldridge, 1996; Beelke and Sannita, 2002; Fischer et al., 1998; 
Sastry, 1985a; Schmidt et al., 1987). Recent studies suggested a cholinergic dysfunction 
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might also contribute in the pathology of glaucoma. In DBA/2J mice, progression of 
glaucoma is accompanied by a significant reduction in the immunoreactivity of amacrine 
cells for choline acetyltransferase (ChAT), gamma-aminobutyric acid (GABA) and 
Protein kinase C (PKC) (Gunn et al., 2011; Hernandez et al., 2009; Moon et al., 2005). 
ChAT is the enzyme involved in the synthesis of ACh and it is mostly localized in the 
processes of the cholinergic amacrine cells in the inner plexiform layer (Ross et al., 
1985). These observations support the idea of a reduced cholinergic transmission in the 
glaucomatous retinas.  
I.4.6.3. AChRs and neuroprotection 
Nicotinic AChRs are a family of ligand-gated Na+ and Ca2+ permeable cation channels 
(Sargent, 1993). Nicotinic nAChRs receptors are pentameric and in the nervous system 
they are composed of different combinations of alpha (α2- α10) and beta (β2- β4) 
subunits (Gotti et al., 1997). Among the nAChRs subunits, the neuroprotective properties 
of the α4, α7 and β2 subunits have been well studied (Jonnala and Buccafusco, 2001; 
Thompson et al., 2006). Adult RGCs express several nAChRs subunits including the α7 
(Cox et al., 2008; Gilbert et al., 2009). The binding site for the APLs thought to be 
located on the α7 subunit (Schrattenholz et al., 1993). Activation of nAChRs promotes 
neuronal survival via stimulation of different pro-survival pathways (Figure 8) (Arias et 
al., 2004; Kihara et al., 2004). Signaling  through nAChRs also  modulates  the activity of 
the  pro-apoptotic pathways, as seen in a glutamate excitotoxicity model where nicotinic 
signaling protected neurons by reducing phospho-p38 MAPK levels (Asomugha et al., 
2010). p38 MAPK belongs to a major pro-apoptotic pathway and its activation leads to 
RGC death (Cuadrado and Nebreda, 2010; Kikuchi et al., 2000). Recently, it has been 
suggested that heteromeric nAChRs, such as α4 β2, have an anti-inflammatory effect. 
Non-receptor tyrosine kinases like janus kinase 2 (JAK2) suppress inflammation via 
down regulation of NF-kB at transcriptional level (Hosur and Loring, 2011). This anti-
inflammatory signaling pathway appears to be activated independently of calcium or 
cAMP (Hosur and Loring, 2011). 
Muscarinic AChRs (m AChRs) are G-protein coupled receptors consisting of five 
(M1-M5) subtypes (Caulfield and Birdsall, 1998). Signaling through mAChRs has been 
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FIGURE 8. 
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Figure 8. Activation of survival pathways via nAChRs signaling. Upon binding of 
ligands to the homomeric α7 and heteromeric nAChRs their channels are opened and 
allow Ca2+ entry. An increase in the intracellular concentration of Ca2+ promotes 
activation of protein kinase C (PKC) and Ras that in turn lead to phosphorylation of Raf 
and activation of MAPKs family. PI3K also is activated by increased Ca2+ levels and 
promotes phosphorylation of Akt and cell survival. cAMP-dependent activation of 
protein kinase A (PKA) results in activation of the transcription factor CREB and 
promotes cell survival. Activity of the low Ca2+ permeable heteromeric nAChRs also by 
inhibiting activation of NF-kB has an anti-inflammatory effect. Source of image: 
Mohammadali Almasieh. 
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linked to key transduction pathways including cell survival (Felder, 1995; Migeon and 
Nathanson, 1994). For example, M1/M3 subtypes mediate activation of the pro-survival 
ERK pathway (Berkeley et al., 2001) whereas M2/M4 subtypes via Gβγ enhance the 
activity of the PI3K/Akt pathway and neuronal viability (Wu and Wong, 2006). 
Intracellular Ca+2 homeostasis is another important example of the modulatory role of 
mAChRs. The interaction of M1/M3/M5 mAChRs with Gq/G11 complex stimulates 
phospholipase C (PLC) leading to the release of Ca+2 from intracellular stores (Felder, 
1995). Adenylate cyclase activity and intracellular levels of cAMP are also regulated by 
M2/M4 mAChRs through their interaction with Gi/o proteins (Felder, 1995; Migeon and 
Nathanson, 1994). The correlation of nicotinic and muscarinic AChRs activity with 
neuronal survival pathways provides a promising insight into novel neuroprotective 
strategies based on the modulation of these receptors for rescuing RGCs in glaucoma.  
 
I.5. OBJECTIVES OF THE THESIS, HYPOTHESES AND EXPERIMENTAL 
APPROACHES  
Problem and objectives: Glaucoma, a group of diseases characterized by 
progressive optic nerve degeneration, is the leading cause of irreversible blindness 
worldwide. Several risk factors have been proposed to contribute to glaucoma 
progression including elevated intraocular pressure, genetic background and age. The 
existence of any of these factors might determine an individual’s risk to develop 
glaucoma, but they are not necessarily the cause of this condition. For example, although 
high intraocular pressure is common among open-angle glaucoma patients, only a limited 
subset of individuals with ocular hypertension will develop this disease. Moreover, a 
significant number of patients presenting with glaucoma continue to lose vision despite 
responding well to therapies that lower eye pressure. Therefore, strategies that delay or 
halt RGC loss have been recognized as potentially beneficial to preserve vision in 
glaucoma. The success of these approaches, however, depends on an in-depth 
understanding of the mechanisms that lead to RGC dysfunction and death. The primary 
objectives of this thesis were: i) to test novel neuroprotective strategies for injured RGCs, 
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and ii) to elucidate the molecular pathways leading to neuronal survival using in vivo 
models of optic nerve injury. 
Hypotheses:  The central hypothesis of this thesis is that effective therapeutic 
strategies for glaucoma must take into account mechanisms that lead to RGC death to 
successfully promote structural and functional protection of these neurons. To test this, I 
used two different approaches that target distinct molecular pathways proposed to 
contribute to RGC death. First, I took advantage of an existing drug currently approved 
for the treatment of Alzheimer’s disease, the acetylcholinesterase inhibitor galantamine, 
to assess its neuro- and vasoprotective effects in experimental glaucoma and to elucidate 
its mechanism of action. The specific hypothesis for this project was that galantamine, by 
modulating acetylcholine receptor activity, can provide RGC and vascular protection in 
glaucoma. Second, I used a novel cell-permeable phosphine-borane compound (PB1) to 
investigate its effect on the survival of injured RGCs and to assess the role of reactive 
oxygen species superoxide in experimental glaucoma. The specific hypothesis for this 
project was that PB1 can promote RGC survival via inhibition of the negative effects of 
oxidative damage caused by axonal injury. 
  Experimental Approaches: I used a variety of experimental approaches to 
achieve our research objectives during my Ph.D. work including: 1) a rat model of 
experimental glaucoma in Brown Norway rats in which ocular hypertension is induced by 
injection of a hypertonic saline solution into an episcleral vein (Morrison model), 2) an 
acute paradigm of optic nerve injury in Sprague-Dawley rats based on complete 
transection (axotomy) of the optic nerve, 3) retrograde labeling of RGCs by application 
of fluorescent tracers to the superior colliculus, the main target region of these neurons in 
the brain, 4) intraocular and/or intraperitoneal administration of drugs, 5) quantification 
of RGC survival by counting fluorescently-labeled neurons in flat-mounted retinas, 6) 
western blot analysis of signaling components of survival and apoptotic intracellular 
pathways, 7) visual evoked potentials recorded from the superficial layers of the superior 
colliculus to assess the functional status of RGCs, and 8) quantification of retinal 
capillary density using isolectin staining and measurements of regional ocular blood flow 
assessed by quantitative autoradiography. 
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II.1. ABSTRACT   
Glaucoma is the leading cause of irreversible blindness worldwide. Loss of vision 
in glaucoma is caused by the selective death of retinal ganglion cells. Treatments for 
glaucoma, limited to drugs or surgery to lower intraocular pressure, are insufficient. 
Therefore, a pressing medical need exists for more effective therapies to prevent vision 
loss in glaucoma. In this in vivo study, we demonstrate that systemic administration of 
galantamine, an acetylcholinesterase inhibitor, promotes protection of retinal ganglion 
cell somata and axons in a rat glaucoma model. Functional deficits caused by high 
intraocular pressure, assessed by recording visual evoked potentials from the superior 
colliculus, were improved by galantamine. These effects were not related to a reduction 
in ocular pressure because galantamine did not change the pressure in glaucomatous eyes 
and it promoted neuronal survival after optic nerve axotomy, a pressure-independent 
model of retinal ganglion cell death. Importantly, we demonstrate that galantamine-
induced ganglion cell survival occurred via activation of types M1 and M4 muscarinic 
acetylcholine receptors, while nicotinic receptors were not involved. These data provide 
the first evidence of the clinical potential of galantamine as neuroprotectant for glaucoma 
and other optic neuropathies, and identify muscarinic receptors as potential therapeutic 
targets for preventing vision loss in these blinding diseases. 
Keywords: retinal ganglion cell, glaucoma, acetylcholinesterase, muscarinic. 
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II.2. INTRODUCTION   
Glaucoma is the leading cause of irreversible blindness worldwide. It has been 
estimated that >50 million people around the world are affected by this disease, with >7 
million presenting bilateral blindness (Quigley, 2005). Loss of vision in glaucoma is 
caused by the selective death of retinal ganglion cells (RGCs), the output neurons that 
relay visual information from the retina to the brain via their axons in the optic nerve. 
Although the precise cause of RGC death in glaucoma is unknown, high intraocular 
pressure (IOP) is a major risk factor for developing this disease. Current treatments for 
glaucoma are limited to lowering IOP by medication or surgery, but a significant number 
of patients continue to experience visual loss despite responding well to pressure 
lowering therapies (Georgopoulos et al., 1997). Moreover, >50% of patients have normal 
tension glaucoma characterized by optic nerve degeneration in the absence of high IOP 
(Anderson, 2003; Shields, 2008). Therefore, current therapies for glaucoma are 
insufficient and novel strategies to save RGCs and prevent vision loss would be valuable. 
Galantamine is a small molecule acetylcholinesterase (AChE) inhibitor and 
allosteric ligand of nicotinic ACh receptors (nAChR) currently used for the symptomatic 
treatment of Alzheimer’s disease (Razay and Wilcock, 2008). Galantamine was initially 
thought to ameliorate cognitive deficits in Alzheimer’s disease patients only due to its 
cholinergic boosting activity, but recent studies have demonstrated that it also has 
neuroprotective effects. In vitro, galantamine protects cortical neurons from ß-amyloid 
toxicity and motor neurons from excess glutamate (Kihara et al., 2004; Melo et al., 2009; 
Shimohama and Kihara, 2001). In vivo, galantamine improves the survival of 
hippocampal neurons following transient global ischemia and of dopamine neurons 
damaged by 6-OHDA (Lorrio et al., 2007; Yanagida et al., 2008). Pharmacological 
antagonists of nAChR have been shown to partially reduce the neuroprotective effect of 
galantamine against ß-amyloid toxicity in culture (Arias et al., 2004; Kihara et al., 2004), 
suggesting that nAChR may be involved in galantamine-induced cell survival. However, 
the precise mechanisms underlying neuroprotection mediated by galantamine in vivo 
remain poorly defined. 
In this study, we examined the role of galantamine in the visual system and asked 
whether it stimulates RGC survival in a rat glaucoma model. Our data demonstrate that 
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galantamine leads to structural protection of RGCs from ocular hypertension damage. We 
show that the profound functional impairments caused by high IOP are markedly 
attenuated in galantamine-treated eyes. Intriguingly, galantamine-induced RGC 
neuroprotection is mediated through activation of muscarinic ACh receptors (mAChR), 
and is independent of nAChR. Our study provides the first evidence of the therapeutic 
potential of galantamine in glaucoma and reveals mAChR as a potential clinical target for 
this neurodegenerative disease. 
 
II.3. MATERIALS AND METHODS 
II.3.1. Experimental animals 
 All procedures were carried out in accordance with the guidelines of the Society 
for Neuroscience, the Association for Research in Vision and Ophthalmology, and the 
Canadian Council on Animal Care for the use of experimental animals. Ocular 
hypertension (OHT) surgery was performed in aging, male Brown Norway rats (Charles 
River Canada), retired breeders between 10-12 months of age (300-400 g). Brown 
Norway rats were used because they have a larger eye suitable for the OHT surgical 
procedure, and this glaucoma model has been well characterized in these animals 
(Morrison et al., 1997). The optic nerve axotomy model, which is independent of OHT 
damage, was used as an acute paradigm of RGC death and was carried out in adult 
Sprague-Dawley rats (Charles River, 180-200 g). The number of animals used in each 
experiment is indicated above the bar in the corresponding graph. 
II.3.2. Retrograde labeling of RGCs 
For quantification of neuronal survival, RGCs were retrogradely labeled with DiI 
(1,1'-dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate; Molecular Probes, 
Junction City, OR) for the glaucoma model, or with Fluorogold (2%, Fluorochrome, 
Englewood, CO) for the axotomy model. DiI crystals (3%) or Fluorogold (2%) were 
dissolved in 0.9% NaCl containing 10% dimethyl sulfoxide (DMSO) and 0.5% Triton X-
100. The superior colliculus was exposed and a small piece of gelfoam (Pharmacia and 
Upjohn Inc., Mississauga, ON) soaked in tracer was applied to the surface. Seven days 
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after tracer application, the time required for labeling the entire RGC population, animals 
were subjected to ocular hypertension surgery or axotomy. 
II.3.3. Ocular hypertension surgery and optic nerve axotomy 
Surgical procedures were performed under general anesthesia by intraperitoneal 
(i.p.) injection of 1 ml/kg standard rat cocktail consisting of ketamine (100 mg/ml, 
Bimeda-MTC Animal Health Inc., Cambridge, ON), xylazine (20 mg/ml, Bimeda-MTC 
Animal Health Inc., Cambridge, ON), and acepromazine (10 mg/ml, Ayerst Veterinary 
Laboratories, Guelph, ON). Unilateral elevation of IOP was induced as previously 
described (Morrison et al., 1997) by a single injection of a hypertonic saline solution into 
an episcleral vein. A plastic ring was applied to the ocular equator to confine the injection 
to the limbal plexus and a microneedle was then used to inject 50 µl of sterile 1.85 M 
NaCl solution through an episcleral vein. The plastic ring temporarily blocks off other 
episcleral veins forcing the saline solution into the Schlemm’s canal to create isolated 
scarring. Following injection, the plastic ring was removed and the eyes were examined 
to assess the extent to which the saline solution traversed the limbal vasculature. 
Polysporin ophthalmic ointment (Pfizer Canada Inc., Kirkland QC) was applied to the 
operated eye and the animal was allowed to recover from the surgery. Animals were kept 
in a room with constant low fluorescent light (40-100 lux) to stabilize circadian IOP 
variations. For optic nerve axotomies, animals were deeply anesthetized (2% Isoflurane, 
0.8 liter/min), the left optic nerve was exposed and carefully transected at 0.5-1 mm from 
the optic nerve head avoiding injury to the ophthalmic artery. Fundus examination was 
routinely performed immediately after axotomy and 3-5 days later to check the integrity 
of the retinal circulation after surgery. Animals showing signs of compromised blood 
supply were excluded from the study. 
II.3.4. Measurement of intraocular pressure (IOP) 
IOP from glaucomatous and normal eyes was measured in awake animals because 
general anesthetics cause a marked IOP reduction (Jia et al., 2000). A calibrated 
tonometer (TonoPen XL, Medtronic Solan, Jacksonville, FL) was used to measure IOP 
after application of one drop of proparacaine hydrochloride (0.5%, Alcon Laboratories, 
Inc., Fort Worth, TX) per eye. The tonometer was held exactly perpendicular to the 
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corneal surface and ~10 consecutive readings per eye were taken and averaged to obtain 
an accurate IOP measurement. IOP was measured daily for two weeks after ocular 
hypertension surgery, then every other day for the entire duration of the experiment. The 
mean and peak (maximum) IOP for each eye were calculated and these values were used 
to estimate the mean and peak IOP for experimental and control groups.    
II.3.5. Drug delivery   
Drug delivery in the glaucoma model was carried out by daily intraperitoneal 
(i.p.) injection to avoid multiple intraocular injections, which lead to IOP reduction in 
glaucomatous eyes. For this purpose, the following compounds that cross the blood-
brain/retinal barrier were administered alone or in combination: galantamine 
hydrobromide (3.5 mg/kg, Tocris Bioscience, Ellisville, MO), memantine hydrochloride 
(4 mg/kg, Sigma-Aldrich, St. Louis, MO), donepezil hydrochloride (4 mg/kg, Jubilant 
Organosys Inc., Stamford, CT), or scopolamine hydrobromide (1 mg/kg, Tocris 
Bioscience). Control animals received daily i.p. injections of sterile vehicle (phosphate-
buffered saline: PBS). In some experiments, animals were treated with the ß-adrenergic 
receptor blocker timolol maleate (0.5%, Sabex Inc., Boucherville, QC) applied daily on 
the cornea of the glaucomatous eye to control IOP increase.   
In the axotomy model, drug delivery was carried out by intravitreal injection of 
the following compounds in a total volume of 5 µl: galantamine hydrobromide (100 
mM), methyllycaconitine citrate (MLA, 10 µM, Sigma-Aldrich), dihydro-ß-erythroidine 
hydrobromide (DHß-E, 100 µM, Sigma-Aldrich), mecamylamine hydrochloride (MMA, 
10 mM, Sigma-Aldrich), scopolamine hydrobromide (10 mM, Tocris Bioscience), 
pirenzepine dihydrochloride (1 mM, Tocris Bioscience), 11-[[2-[(Diethylamino)methyl]-
1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one (DX116, 1 
mM, Tocris Bioscience), Diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP, 1 
mM, Tocris Bioscience), or tropicamide (1 mM, Tocris Bioscience). Control eyes 
received an intravitreal injection of sterile vehicle (PBS). Drugs were injected into the 
vitreous chamber using a 10-µl Hamilton syringe adapted with a 32-gauge glass 
microneedle, the tip of which was inserted into the superior hemisphere of the eye, at a 
~45° angle, through the sclera into the vitreous body. This route of administration 
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avoided retinal detachment or injury to eye structures, including the iris and lens that 
release factors that may induce RGC survival. Surgical glue (Indermill, Tyco Health 
Care, Mansfield, MA) was used to seal the injection site.  
II.3.5. Quantification of RGC soma and axons  
Quantification of RGC bodies and axons was performed in duplicate by an 
observer masked to the treatment assignments. For RGC density counts, rats were deeply 
anesthetized and perfused transcardially with 4% paraformaldehyde (PFA) in 0.1 M 
phosphate buffer following which both eyes were immediately enucleated. Retinas were 
dissected and flat-mounted on a glass slide with the ganglion cell layer side up. RGCs 
were counted within three square areas at distances of 1, 2 and 3 mm from the optic disc 
in each of the four retinal quadrants (superior, inferior, nasal and temporal) for a total of 
12 retinal areas. Macrophages and microglia that may have incorporated fluorescent 
tracer after phagocytosis of dying RGCs were excluded from our quantitative analysis 
based on cell-specific markers and morphology (Lebrun-Julien et al., 2009). For axon 
counts, animals received a transcardial injection of heparin (1,000 u/kg) and sodium 
nitroprusside (10 mg/kg) followed by perfusion with 2% PFA and 2.5% glutaraldehyde in 
0.1 M phosphate buffer. Optic nerves were dissected, fixed in 2% osmium tetroxide, and 
embedded in epon resin. Semi-thin sections (0.7-µm-thick) were cut on a microtome 
(Reichert, Vienna, Austria) and stained with 1% toluidine blue. RGC axons were counted 
at 1 mm from the optic nerve head in five non-overlapping areas of each optic nerve 
section, encompassing a total area of 5,500 µm2 per nerve. The five optic nerve areas 
analyzed included: one in the center of the nerve, two peripheral dorsal and two 
peripheral ventral regions. The total area per optic nerve cross-section was measured 
using Northern Eclipse image analysis software (Empix Imaging, Toronto, ON), and this 
value was used to estimate the total number of axons per optic nerve.    
II.3.6. Visual evoked potential (VEP) and electroretinogram (ERG) recordings  
For VEP recordings, animals were anesthetized with isoflurane (3% for induction 
and 1.5% for maintenance) and placed in a stereotaxic head holder. The 
electrocardiogram was continuously monitored and the core body temperature was 
maintained at 37°C using a feedback controlled heating pad. Atropine sulfate eye drops 
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(1%, Allergan Canada, Markham, ON) were used to dilate the pupils and the corneas 
were protected by application of artificial tears (Allergan Canada). A bilateral craniotomy 
was performed anterior to the lambda, at bregma coordinates -6.8 and 1.5 mm lateral to 
the sagittal suture, to expose the cerebral cortex overlying the superior colliculus of each 
hemisphere. The dura was then incised and a tungsten multiunit recording microelectrode 
(impedance 0.8Ω Microprobe, Gaithersburg, MD, USA) was lowered under microscopic 
view until the tip touched the surface of the cortex. The skull opening was then filled 
with agar to protect the tissue from desiccation and, using a micromanipulator (Motorized 
Microdrive, FHC Inc., Bowdoinham ME), the microelectrode was advanced vertically to 
300 µm from the superficial layer of the superior colliculus into the stratum griseum 
superficiale. Visual stimulation was provided by a diffuse flash (f = 1 Hz, Grass 
photostimulator, Astro-Med Inc, Brossard, QC) placed 30 cm away from the contralateral 
eye. Triggered evoked potentials were averaged over 40 successive presentations. VEP 
signals were amplified and bandpass filtered between 10 and 1,000 Hz and acquired via 
an analogue/digital interface (CED 1401 plus) to a PC running acquisition software 
(Signal 2, CED, Cambridge, UK). At the end of the experiment, the final electrode 
location was marked by passing a direct current (D.C.) of 10 mA for 5 sec through the 
recording electrode. The animals were then perfused with 4% PFA, the brains were 
removed and processed for serial sectioning. Sections (50 µm) were stained with cresyl 
violet and the electrode location mark was visualized as an iron precipitate following 
incubation in a 2% K4Fe (CN)6 solution. The depth of recording was confirmed by the 
position of the mark and the depth reading of the micromanipulator.   
For ERG recordings, animals were dark adapted for a 12-hour period. Under dim 
red light illumination, the animals were anesthetized with a mixture of ketamine 
hydrochloride (80 mg/kg) and xylazine (6 mg/kg) and the pupils were dilated with 
cyclopentolate hydrochloride 1%. ERGs were recorded with a Dawson, Trick and 
Litzkow (DTL) fibre electrode (27/7X-Static, silver coated conductive nylon yarn, 
Sauquoit Industries, Scranton, PA) that was positioned and maintained on the cornea 
using a drop of 1% methylcellulose. The ERG (bandwidth: 1-1,000 Hz; x 10,000; Grass, 
P511 amplifier) and oscillatory potentials (bandwidth: 100-1000 Hz; x 50,000) were 
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recorded simultaneously with the Acknowledge data acquisition system (Biopac MP 100 
WS, BIOPAC System Inc., Goleta, CA, USA).    
II.3.7. Statistical analysis   
Data analysis and statistics were performed using the GraphPad Instat software 
(GraphPad Software Inc., San Diego, CA) by a one-way (two-way for IOP measurments) 
analysis of variance (ANOVA) test followed by Bonferroni's multiple comparison post-
test.  
II.4. RESULTS   
II.4.1. Galantamine protects RGC soma and axons from hypertension-induced 
death  
We tested the neuroprotective effect of galantamine in vivo in a rat ocular 
hypertension (OHT) model of glaucoma. Unilateral elevation of IOP was induced after a 
single injection of hypertonic solution into an episcleral vein, a procedure named OHT 
surgery. Gradual increase of eye pressure and progressive death of RGCs are observed in 
this model, with an excellent linear correlation between IOP increase and degree of RGC 
loss and optic nerve damage (Morrison et al., 1997). Inner retinal atrophy, optic nerve 
degeneration, and optic nerve head remodeling in this model are similar to those seen in 
human glaucoma, making this model one of the best experimental in vivo paradigms to 
study glaucoma.   
RGCs were visualized with the fluorescent tracer DiI, which was applied to the 
superior colliculus at least 1 week before OHT surgery to ensure retrograde labeling prior 
to any changes in optic nerve function caused by experimental glaucoma (Figure 1a). 
Unlike other retrograde markers that leak from the cell body after several weeks, DiI has 
been shown to persist in RGCs in vivo for periods of up to 9 months without fading or 
leakage (Vidal-Sanz et al., 1988). Consistent with previous studies, the average total 
RGC population detected by DiI in intact, non-injured Brown-Norway rat retinas was 
1841 ± 15 RGCs/mm2 (mean ± S.E.M., n = 9) (Figure 1b). Galantamine is a small 
molecule capable of crossing the blood-brain and blood-retinal barriers; therefore its 
neuroprotective effect was evaluated following daily intraperitoneal (i.p.) injection of 3.5 
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mg per kg of body weight (mg/kg), a dose selected based on previous studies showing 
efficacy in vivo (Lorrio et al., 2007; Yanagida et al., 2008). Galantamine treatment was 
initiated once IOP elevation was detected (~1 week after OHT surgery, Figure 1a) and 
continued thereafter for the entire duration of the experiment.   
Analysis of DiI-positive RGCs in retinal whole mounts showed that galantamine 
led to higher neuronal densities in glaucomatous eyes compared to control eyes treated 
with vehicle (PBS) (Figure 1b-d). Quantitative analysis confirmed that daily galantamine 
treatment led to a robust increase in survival of injured RGCs at 3 weeks after OHT 
surgery (90%: 1,627 ± 29 RGCs/mm2, mean ± S.E.M., n=11) compared to vehicle (55%: 
1,025 ± 22 RGCs/mm2, n=9) (ANOVA, p < 0.001). Although neuronal damage was more 
severe at 5 weeks after OHT surgery, galantamine still protected 70% of RGC soma 
(1,270 ± 74 RGCs/mm2, n=10) compared to only 37% with PBS (657 ± 52 RGCs/mm2, 
n=9) (ANOVA, p < 0.001) (Figure 1e). We carried out a comparative study on the 
neuroprotective effect of galantamine with respect to memantine, an N-Methyl-D-
Aspartic acid (NMDA) channel blocker, and donepezil, another acetylcholinesterase 
inhibitor, both currently used in Alzheimer’s disease. Our results show that galantamine 
was more effective than memantine or donepezil at preventing RGC loss in experimental 
glaucoma (Figure 2).  
Glaucoma is characterized by the degeneration of RGC axons in the optic nerve 
posterior to the lamina cribrosa; hence we also investigated the effect of galantamine on 
RGC axon protection. Analysis of optic nerve cross-sections demonstrated a larger 
number of RGC axon fibers with normal morphology in galantamine-treated eyes 
compared to PBS-treated control eyes (Figure 3a-c), the latter showing extensive axon 
degeneration including disarray of fascicular organization and degradation of myelin 
sheaths. Quantitative analysis confirmed that galantamine promoted substantial 
protection of RGC axons from glaucomatous damage (Figure 3d). Collectively, these 
results indicate that galantamine effectively protects both RGC soma and axons in 
experimental glaucoma.   
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II.4.2. Galantamine-mediated neuroprotection is not due to decreased IOP    
To investigate if daily treatment with galantamine led to IOP reduction, which 
could account for the observed neuroprotective effect, we measured eye pressure daily 
for two weeks after ocular hypertension surgery and then every other day for the entire 
duration of the experiment. Our results demonstrate that daily i.p. administration of 
galantamine did not reduce IOP over a period of several weeks (Figure 4a). The mean 
sustained pressure elevation among galantamine-treated and PBS-treated groups was 
similar: ~34 mm Hg at 3 weeks after OHT surgery and ~40 mm Hg at 5 weeks after OHT 
surgery (Table 1), well within the range of IOP increases observed in this model 
(Morrison et al., 1997). Given that the rate of RGC death is proportional to IOP, the 
similar elevation in IOP among groups allowed for reliable comparison of the 
neuroprotective effect of galantamine versus vehicle.  
To further test whether galantamine-mediated neuroprotection was independent of 
IOP-induced damage, we examined the effect of galantamine after axotomy of the optic 
nerve (Figure 4b-e), an acute insult that leads to rapid apoptotic death of RGCs 
(Berkelaar et al., 1994). RGCs were retrogradely labeled with Fluorogold and subjected 
to optic nerve transection with concomitant intraocular injection of galantamine. The 
average total RGC population detected with Fluorogold in intact, non-injured Sprague-
Dawley rat retinas was 2,223 ± 24 RGCs/mm2 (mean ± S.E.M., n=5), a slightly higher 
density than in Brown-Norway rats, consistent with previous studies (Mansour-Robaey et 
al., 1994; Pernet and Di Polo, 2006). After axotomy, all RGCs survive for 5 days and 
then die abruptly: the population of RGCs is reduced to approximately 50% by 1 week 
and to ~10% at 2 weeks post-axotomy. In galantamine-treated eyes, 75% of RGCs 
survived at 1 week after axotomy compared to 50% that survived in the PBS-treated 
group (1,611 ± 47 RGCs/mm2, n=6, and 920 ± 32 RGCs/mm2, n=5, respectively, 
ANOVA, P < 0.001). The effect of galantamine was still marked at 2 weeks after 
axotomy: 30% of all RGCs remained alive compared to only 10% survival in PBS-treated 
eyes (616 ± 30 RGCs/mm2, n=5, and 216 ± 15 RGCs/mm2, n=5, respectively, ANOVA, 
P < 0.01) (Figure 4E). Collectively, these results demonstrate that galantamine can delay 
RGC loss following chronic (glaucoma) or acute (axotomy) optic nerve injury.    
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II.4.3. RGC functional deficits in glaucoma are improved by galantamine  
Our results show structural protection of RGCs, both at the level of the cell bodies 
and axons, but are these neurons functional? To investigate whether galantamine 
preserved RGC function in glaucoma, we measured visual evoked potentials (VEPs) 
following flash stimulation. The main target of RGCs in the rat brain is the superior 
colliculus, thus VEPs recorded from this region provide a faithful representation of 
surviving RGC function and were used as the primary outcome to assess functional 
neuroprotection. The flash electroretinogram (ERG) provides information about the outer 
retina and was not used to assess RGC function. ERGs were routinely performed prior to 
VEPs to ensure that the outer retina was functioning properly and that RGCs received 
adequate input following visual stimulation. All the animals in this study had normal 
ERGs.  
First, we investigated whether galantamine daily treatment had any effect on the 
VEP response to flash stimulation in normal, non-glaucomatous eyes. Our data 
demonstrate that VEPs recorded from galantamine-treated normal brains were 
indistinguishable from those treated with PBS or without treatment (Figure 5a), 
indicating that galantamine by itself does not alter the response of normal RGCs or target 
neurons in the superior colliculus. At 3 weeks after OHT surgery, examination of VEP 
responses to flash stimulation showed substantial reduction in evoked currents recorded 
from PBS-treated eyes compared to intact, non-glaucomatous controls (Figure 5b). In 
contrast, galantamine administration led to marked preservation of the VEP. 
Quantification of peak-to-peak VEP amplitudes demonstrated that galantamine preserved 
66% of the intact VEP response compared to only 30% in PBS-treated controls 
(ANOVA, p < 0.001).   
At 5 weeks after OHT surgery, both PBS-treated and galantamine-treated 
glaucomatous eyes showed complete obliteration of the VEP (Figure 5c). This lack of 
response could not be solely attributed to RGC degeneration because galantamine 
protected almost 70% of RGC soma and axons at 5 weeks after OHT (Figures 1and 3). 
We then hypothesized that sustained high IOP impairs the visual function of the 
surviving RGCs. To test this idea, we evaluated the effect of galantamine on the VEP 
response using a protocol in which IOP in the glaucomatous eye was controlled by 
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topical (corneal) application of timolol, a commonly used ß-adrenergic receptor blocker. 
Treatment with timolol began at 3 weeks after OHT and continued for the entire duration 
of the experiment. Timolol limited the IOP increase in galantamine-treated glaucomatous 
eyes to a mean IOP of 35.6 mm Hg compared to 42.7 mm Hg in eyes without timolol 
(Table 1). Interestingly, this difference in IOP (7 mm Hg) was sufficient to restore 47% 
of the VEP response in galantamine-treated eyes, but not in PBS-treated eyes (Figure 5c), 
indicating that IOP reduction only rescued RGC function when combined with 
galantamine. The recovery of VEP was not due to a neuroprotective effect of timolol 
because animals treated with PBS and timolol did not show any functional improvement. 
Furthermore, VEP recovery was not due to increased survival because RGC densities in 
the presence of timolol and galantamine (1,387 ± 50 RGCs/mm2, mean ± S.E.M., n=8) 
were not statistically different from those in eyes treated with galantamine alone (1,270 ± 
85 RGCs/mm2, n=10, p > 0.05). The absence of VEP responses in eyes treated with PBS 
also confirmed that topical application of timolol, by itself, was not neuroprotective. 
Taken together, these results indicate that high IOP leads to dramatic deficits in retinal 
function that can be markedly attenuated by galantamine, and highlight the importance of 
combining galantamine with IOP lowering drugs to achieve long-term functional RGC 
protection.    
II.4.4. ACh muscarinic, but not nicotinic, receptors mediate the neuroprotective 
effect of galantamine in experimental glaucoma   
In the nervous system, there are two major types of ACh receptors: i) nicotinic 
receptors (nAChR) including the α7 and the α4ß2 nAChR, which are the most abundant 
subtypes in the brain, and metabotropic muscarinic receptors (mAChR), which are 
selectively activated by muscarine-like ligands and include five distinct isoforms (M1-
M5) corresponding to the products of five separate genes (Bonner et al., 1987). To gain 
mechanistic insight into how galantamine promotes RGC neuroprotection in vivo, we 
asked whether blockade of nAChR or mAChR would compromise galantamine-induced 
RGC survival. For this purpose, we first assessed the survival of axotomized RGCs 
following intraocular injection of galantamine in combination with selective 
pharmacological blockers of nAChR or mAChR. Co-injection of galantamine with 
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scopolamine, an inhibitor of all mAChR types, abrogated the pro-survival effect of 
galantamine. In contrast, co-administration of galantamine with either methyllycaconitine 
(MLA), a specific antagonist of α7 nAChR, dihydro-ß-erythroidine (DHß-E), a specific 
antagonist of α4ß2 nAChR, or mecamylamine (MMA), a blocker of all neuronal nAChR, 
did not reduce galantamine-induced RGC survival (Figure 6a). A range of concentrations 
of these nAChR inhibitors was tested (10 µM to 10 mM) with similar outcome, indicating 
that their lack of effect was not the result of suboptimal doses of these drugs. Consistent 
with these findings, daily i.p. injection of galantamine and scopolamine, which readily 
cross the blood-brain/retinal barrier, completely inhibited RGC neuroprotection in 
glaucomatous eyes at 5 weeks after OHT (Figure 6b). Administration of MLA, DHß-E, 
MMA or scopolamine, by themselves, did not cause RGC death or adverse effects in non-
injured retinas, nor did they promote survival in injured rat retinas at the doses used here 
(Figure 6c and d). 
To establish which mAChR were involved in RGC survival, the following 
selective antagonists of mAChR subtypes were co-administered with galantamine: 
pirenzepine (M1), DX116 (M2), 4-DAMP (M3) or tropicamide (M4). These mAChR 
antagonists do not cross the blood-brain/retinal barrier or exhibit extremely low barrier 
permeability (Mickala et al., 1996; Stein et al., 1995; van Waarde et al., 1994), thus their 
effect was tested on galantamine-induced protection of axotomized RGCs after 
intraocular injection. Figure 6e shows that while blockade of M2 by DX116 or M3 by 4-
DAMP did not have any effect on RGC survival mediated by galantamine, blockade of 
M1 with pirenzepine completely abrogated RGC neuroprotection. The M4 antagonist 
tropicamide also reduced RGC survival, albeit to a lesser extent than pirenzepine. 
Collectively, these data strongly suggest that M1 and M4 mAChR are mediators of 
galantamine-induced RGC neuroprotection.   
 
II.5. DISCUSSION  
This study supports four major findings. First, galantamine treatment leads to 
survival of RGC somata and axons in experimental glaucoma. Second, RGC structural 
protection is independent of IOP-induced damage, as evidenced by the neuroprotective 
action of this drug after optic nerve axotomy. Third, functional deficits caused by high 
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IOP are markedly improved by galantamine. Fourth, galantamine-mediated 
neuroprotection occurs primarily through activation of retinal mAChR M1, and is 
independent of nAChR.  
Several recent clinical studies have suggested a correlation between glaucoma and 
Alzheimer’s disease (Wostyn et al., 2009), but the most compelling evidence supporting 
such link stems from laboratory work. For example, neuronal loss in both glaucoma and 
Alzheimer’s disease occurs by apoptosis (Tatton et al., 2003), caspases are activated both 
in Alzheimer’s disease and in injured RGCs (McKinnon, 2003), and intraocular injection 
of ß-amyloid has been shown to induce RGC degeneration (Cordeiro et al., 2006). More 
recently, ß-amyloid deposition was associated with RGC death in experimental glaucoma 
and blockade of the ß-amyloid pathway reduced glaucomatous damage (Guo et al., 
2007). Although the etiology of glaucoma and Alzheimer’s disease may differ, their 
common features raise the provocative idea that drugs currently used to treat Alzheimer’s 
disease may also have utility in glaucoma. Here, we show that one such drug, 
galantamine, is a powerful neuroprotectant for injured RGCs. Daily galantamine 
treatment promoted the survival of RGC somata and axons in glaucoma. Importantly, 
administration of galantamine by intravitreal injection also led to robust RGC protection 
after axotomy of the optic nerve. These data highlight several important properties of 
galantamine: it is effective when administered systemically or by intraocular injection, it 
promotes structural protection of RGCs in an IOP-independent manner, and it delays 
RGC loss in different models, both acute and chronic, of optic nerve damage.   
The neuroprotective effect of galantamine was superior to that conferred by 
memantine or donepezil. Galantamine has been shown to be a weaker AChE inhibitor 
than donepezil (Geerts et al., 2005), therefore other factors likely account for this 
difference in neuroprotective efficacy. First, donepezil is a non-competitive inhibitor of 
AChE, which may result in the development of tolerance to donepezil and consequent 
downregulation of ACh receptors (Wilkinson, 1999). In contrast, galantamine is a 
competitive AChE inhibitor and the galantamine-AChE complex follows the typical 
kinetics of reversible inhibitors, dissociating readily in the presence of excess ACh, with 
a reduced potential for tolerance (Farlow, 2003). Second, galantamine acts more broadly 
on other neurotransmitter systems and has been shown to regulate the release of 
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glutamate, serotonin and α-aminobutyric acid (Albuquerque et al., 2000; Alkondon et al., 
2000), thus potentially modulating neural activity and delaying neurodegeneration. Third, 
mAChR are amenable to modulation at allosteric sites (Gregory et al., 2007) hence it is 
possible that galantamine may activate mAChR directly, although this possibility 
presently remains unknown.   
Patients with glaucoma experience diminished visual function and poor quality of 
life; therefore an ideal neuroprotective drug should preserve the structural viability of 
RGCs while retaining their ability to respond to visual stimulation. In this study, we 
aimed to provide a structure-function link based on the neuroprotective effect of 
galantamine. Our results demonstrate that there are major visual deficits in glaucomatous 
eyes treated with PBS, while galantamine treatment led to substantial preservation of the 
VEP amplitude at 3 weeks after OHT. Of interest, following longer periods of OHT (5 
weeks) galantamine-protected RGCs (70%) did not respond to light stimulation unless 
IOP was also reduced. An IOP decrease of just a few mm Hg was sufficient to restore 
almost 50% of the VEP response in galantamine-treated eyes, but not in PBS-treated 
controls. The observation that the majority of RGCs exposed to galantamine remained 
alive at 5 weeks of OHT but did not respond to light stimulation suggests that sustained 
high IOP has additional deleterious effects on RGC function. We conclude that, in the 
long-term, structural protection alone is not sufficient to restore visual function unless 
IOP is also controlled.    
Galantamine increases the availability of ACh through its inhibitory action on 
AChE, the enzyme responsible for ACh breakdown, and it is also an allosteric modulator 
of nAChR enhancing their sensitivity to ACh (Albuquerque et al., 1997; Schrattenholz et 
al., 1996). ACh in the retina is released by starburst cholinergic amacrine cells onto RGC 
dendrites and plays a crucial role in visual information processing (Beelke and Sannita, 
2002). Therefore, we postulated that galantamine-induced neuroprotection might result 
from stimulation of ACh receptors. Since galantamine is an allosteric modulator of 
nAChR, its neuroprotective effect has been compared to that of nicotine. In fact, nicotine 
has been shown to promote neuronal survival in different models of neurodegeneration 
via nAChR and downstream activation of survival pathways (Picciotto and Zoli, 2008; 
Shimohama, 2009 ). Previous in vitro studies showed that galantamine promoted the 
69 
 
 
 
survival of cortical neurons or neuroblastoma cells via α7nAChR and stimulation of 
phosphatidylinositol-3-kinase (Arias et al., 2004; Kihara et al., 2004). As RGCs express 
several nAChR subtypes including α7nAChR (Cox et al., 2008; Gilbert et al., 2009), we 
initially postulated that nAChR activation would contribute to galantamine-mediated 
neuroprotection. Surprisingly, our data show that blockade of nAChR had no effect 
whereas inhibition of mAChR completely curtailed the neuroprotective effect of 
galantamine in vivo. The total blockade of galantamine-induced neuroprotection in the 
presence of mAChR inhibitors indicates that these receptors are the primary locus of the 
specific action of galantamine in the retina.  
Immunocytochemical studies on the localization of mAChR subtypes in primate, 
rat and chick retinas showed that M2 and M4 are expressed by amacrine cells, and M3 is 
expressed primarily by bipolar cells (Fischer et al., 1998; Wassélius et al., 1998; Yamada 
et al., 2003). In addition, Müller cells, the most abundant glial cell type in the mammalian 
retina, express M1 and M4 mAChR types (Da Silva et al., 2008). Muscarine was shown 
to increase intracellular Ca+2 in rabbit RGCs (Baldridge, 1996), however, this effect was 
thought to be indirect because expression of mAChR has not been detected in isolated rat 
or cat RGCs, and muscarine did not elicit membrane currents measured in whole-cell 
patch clamp preparations (Kaneda et al., 1995; Lipton et al., 1987 ). Our results indicate 
that galantamine-mediated RGC neuroprotection in vivo occurs primarily via activation 
of M1, a mAChR subtype expressed by Müller cells. The M4 mAChR subtype, expressed 
by both Müller glia and amacrine cells, also contributes to this effect but to a lesser extent 
than M1 mAChR. Collectively, these data support a model in which non-cell-autonomous 
signaling events downstream of mAChR play a major role in galantamine-induced RGC 
neuroprotection. Activation of M1/M4 mAChR on neighboring Müller glia and amacrine 
cells may lead to stimulation of signaling pathways and production of pro-survival factors 
that protect injured RGCs. Other retinal cell types that express these mAChR subtypes, 
including endothelial cells (Sastry, 1985; Wu et al., 2003), may also participate in 
galantamine-mediated RGC survival.   
M1 and M4 mAChR are G-protein-coupled receptors linked to different signal 
transduction pathways. M1 mAChR are preferentially coupled to pertussis toxin (PTX)-
insensitive Gq/G11 proteins that stimulate phospholipase C (PLC) and 
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phosphatidylinositol hydrolysis with subsequent Ca+2 mobilization from intracellular 
stores (Felder, 1995). M4 mAChR, on the other hand, are preferentially coupled to PTX-
sensitive Gi/o proteins that inhibit adenylate cyclase and regulate intracellular cAMP 
levels (Felder, 1995; Migeon and Nathanson, 1994). It has become increasingly clear that 
mAChR downstream signaling pathways converge or intersect with mediators of cell 
survival. For example, M4 mAChR interacts with the nerve growth factor receptor, via 
Gβγ complexes, to enhance phosphatidylinositol 3-kinase (PI3K)/Akt activation and 
neuronal survival (Wu and Wong, 2006). Of interest, M1 mAChR via Gαq and PLC leads 
to activation of Nrf2, a transcription factor involved in redox homeostasis, which may 
increase the cellular anti-oxidant defenses and confer neuroprotection against oxidative 
stress (Espada et al., 2009). Moreover, M1 mAChR activation also regulates the activity 
of the hypoxia-inducible factor-1 (HIF-1), a transcription factor involved in the cellular 
response to hypoxia (Hirota et al., 2004). Oxidative stress and ischemia/hypoxia have 
been proposed to be major contributors to glaucomatous neurodegeneration. An 
important priority in future studies will be to determine the M1- and M4-coupled 
signaling pathways underlying galantamine-induced RGC neuroprotection. The precise 
delineation of these molecular events should be useful for the design of novel therapeutic 
interventions applicable to glaucoma.   
In summary, our study reveals the potent role of galantamine in the protection of 
RGC structure and function in glaucoma, which could be used in conjunction with 
standard pressure controlling drugs. Our data also identifies retinal mAChR as a novel 
therapeutic target for prevention of neuronal death and vision loss in optic neuropathies.   
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Figure 1. Galantamine protects RGC somata in glaucoma.  
(A) Outline of the experimental protocol used to test the effect of galantamine on RGC 
survival in experimental glaucoma. RGCs were retrogradely labeled with the fluorescent 
tracer DiI and ocular hypertension (OHT) surgery was performed a week later. 
Galantamine treatment (3.5 mg/kg, i.p.) was initiated at ~1 week after OHT surgery, and 
continued thereafter for the entire duration of the experiment. Retinas and optic nerves 
were examined at 3 and 5 weeks following OHT surgery. (B) DiI-labeled RGCs in a flat 
mount preparation from intact, uninjured Brown Norway rat retina. At 5 weeks after 
OHT surgery galantamine treatment (C) led to higher neuronal densities compared to 
eyes treated with PBS (D). (E) Quantitative analysis of RGC survival in experimental 
glaucoma following treatment with galantamine (solid bars) or vehicle (PBS, hatched 
bars) (n = 8-11 rats per group). The density of RGCs in intact, untreated Brown Norway 
rat retinas (open bars) is shown as reference. Galantamine markedly increased the 
number of RGCs that survived at 3 and 5 weeks after OHT surgery (ANOVA, ***: 
P<0.001). Data are expressed as the mean ± S.E.M. Scale bars (B-D): 100 µm. 
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Figure 2. Comparative analysis of RGC survival in experimental glaucoma.  
Mediated by galantamine (solid bars), memantine (crossed hatched bars), donepezil 
(vertical lines) or vehicle (PBS, hatched bars) at 3 and 5 weeks after OHT (n=7–11 rats 
per group) (ANOVA, ***P<0.001). Data are expressed as the mean±S.E.M. 
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Figure 3. Galantamine protects RGC axons in glaucoma.  
Cross-sections of optic nerve segments from intact (A) and glaucomatous eyes treated 
with galantamine (B) or PBS (C) at 5 weeks after ocular hypertension (OHT) surgery. 
Galantamine-treated eyes displayed a larger number of axonal fibers with normal 
morphology compared to PBS-treated control eyes, which showed extensive axon 
degeneration. Panel D shows the quantitative analysis of RGC axons in the optic nerve 
following daily i.p. injection of galantamine (solid bar), or PBS (hatched bar) (n = 8-9 
rats per group) (ANOVA, ***: P<0.001). The number of axons in the intact, uninjured 
Brown Norway rat optic nerve is shown as reference (open bar). Data are expressed as 
the mean ± S.E.M. Scale bars (A-C): 20 µm. 
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Figure 4. Galantamine-mediated neuroprotection is not due to decreased 
intraocular pressure.  
(A) Daily i.p. administration of galantamine did not reduce intraocular pressure (IOP) 
over a period of several weeks. (B) Fluorogold-labeled RGCs in a flat mount preparation 
from intact, uninjured Sprague-Dawley rat retina. (C) Galantamine treatment led to 
marked survival of axotomized RGCs with respect to PBS-treated eyes (D). (E) 
Quantitative analysis of RGC survival following intraocular injection of galantamine 
(solid bars) or PBS (hatched bars) (n = 8-11 rats per group) (ANOVA, ***: P<0.001). 
The density of RGCs in intact, uninjured Sprague-Dawley rat retinas is shown as 
reference (open bar). Data are expressed as the mean ± S.E.M. Scale bars (A-C): 100 µm. 
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Figure 5. RGC functional deficits in glaucoma are improved by galantamine.  
(A) Visual evoked potentials (VEP) recorded from galantamine-treated normal brains 
were indistinguishable from those treated with PBS or without treatment. (B) At 3 weeks 
after OHT surgery, galantamine administration led to marked preservation of the VEP 
responses (ANOVA, *: p < 0.001). (C) At 5 weeks after OHT surgery, both PBS-treated 
and galantamine-treated glaucomatous eyes showed complete obliteration of the VEP 
response. Daily application of timolol drops on the cornea was sufficient to restore the 
VEP response in galantamine-treated eyes but not in PBS-treated eyes (ANOVA, *: p < 
0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
 
Figure 6. The neuroprotective effect of galantamine in glaucoma is mediated by 
activation of muscarinic ACh receptors.  
(a) Intraocular co-injection of galantamine with scopolamine, an inhibitor of all mAChR 
types, abrogated the prosurvival effect of galantamine. In contrast, the α7nAChR 
antagonist methyllycaconitine (MLA), the α4β2 nAChR antagonist dihydro-b-
erythroidine (DHβ-E) or the antagonist of all nAChR mecamylamine (MMA) did not 
reduce galantamine-induced survival of axotomized RGCs (ANOVA, *P<0.001). (b) 
Intraperitoneal co-administration of galantamine and scopolamine (SCO) completely 
inhibited galantamine-induced RGC neuroprotection in glaucomatous eyes at 5 weeks 
after OHT (ANOVA, *P<0.001). Intraocular administration of MLA, DHβ-E, MMA or 
SCO, by themselves, did not cause RGC death or adverse effects in non-injured retinas 
(c), nor did they promote survival in injured rat retinas (d) (n=3-6). (e) Intraocular 
injection of galantamine in combination with the M1 mAChR blocker pirenzepine (PRZ), 
the M2 mAChR antagonist DX116, the M3 mAChR blocker 4-DAMP or the M4 mAChR 
antagonist tropicamide (TRO), showed that galantamine-induced neuroprotection is 
mediated through activation of M1 and M4 mAChR (ANOVA, *P<0.001). 
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II.7. TABLES 
 
Table 1. Intraocular pressure (IOP) elevation in glaucomatous eyes. 
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III.1. ABSTRACT 
The relationship between neuronal and vasculature degeneration in glaucoma is 
not well understood. We previously demonstrated that the acetylcholinesterase inhibitor 
galantamine protects retinal ganglion cells (RGCs) in experimental glaucoma. Here, we 
asked whether galantamine-induced neuroprotection correlates with changes in the retinal 
microvasculature and blood flow. The retinal microvasculature density was quantified 
using isolectin, and the regional ocular blood flow was assessed by quantitative 
autoradiography using N-isopropyl-p-14C-iodoamphetamine ([14C]-IMP). Ex vivo 
experiments were carried out on isolated retinal arterioles. RGC death was accompanied 
by a dramatic reduction in the density of the retinal microvasculature and blood flow. 
Galantamine-mediated protection of RGCs correlated with the preservation of retinal 
capillaries at 5 weeks of OHT. Furthermore, vasculature protection correlated with 
marked restoration of blood flow in glaucomatous eyes compared to control eyes. 
Consistent with an increase in blood flow, galantamine induced vasodilation in isolated 
retinal arterioles pre-constricted with endothelin-1 in an endothelial cells dependent 
manner. Blockers of muscarinic ACh receptors (mAChRs) inhibited the neuro- and vaso-
protective effects of galantamine. Our study supports a tight relationship between 
neuronal and vascular preservation in experimental glaucoma. We also demonstrate a role 
for galantamine in RGC and vascular protection mediated by mAChRs activation. 
 
Keywords: glaucoma, retinal microvasculature, inner retinal capillaries, retinal blood 
flow, retinal ganglion cells, isolated retinal vessels, acetylcholinesterase, muscarinic. 
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III.2. INTRODUCTION 
 Glaucoma is the second cause of irreversible blindness worldwide (Resnikoff et 
al. 2004) and its incidence increases dramatically with age (Coleman & Miglior 2008). 
Loss of vision in glaucoma is caused by the selective death of retinal ganglion cells 
(RGCs) (Quigley 1999). The only modifiable risk factor in the development of glaucoma 
is high intraocular pressure (IOP), thus current standard therapies rely solely on lowering 
IOP by medication or surgery. A significant proportion of patients, however, continue to 
experience visual loss despite responding well to treatments that lower eye pressure. In 
addition, >30% of glaucoma patients show optic nerve degeneration in the absence of 
high intraocular pressure, also known as normal (or low) tension glaucoma (NTG)  
(Nemesure et al. 2007). Therefore, a pressing medical need exists to identify underlying 
molecular mechanisms contributing to RGC death and to develop effective 
neuroprotective therapies to prevent vision loss in glaucoma.   
It has been proposed that deregulations of the vascular system may contribute to 
glaucoma onset and progression (Tielsch et al. 1995). Insufficient retinal blood flow in 
NTG patients has been correlated with visual field loss suggesting a role for vascular 
dysfunction in glaucoma (Chung et al. 1999, Harris et al. 1994). Capillary deficits have 
been observed in glaucoma patients including slower arteriovenous passage time within 
the retinal vasculature (Kaiser et al. 1997, Duijm et al. 1997, Wolf et al. 1993). Both 
NTG and primary open angle glaucoma (POAG) individuals have high rates of capillary 
non-perfusion in the optic disc (Plange et al. 2006) suggesting that the microvasculature 
undergoes pathological changes during glaucomatous damage. RGCs are in close contact 
with capillaries and depend on the retinal microvasculature for metabolic support and 
nutrition. Conversely, RGCs provide growth factors including angiopoietins and vascular 
endothelial growth factor (VEGF) that stimulate vessel growth and endothelial cell 
survival (Sapieha et al. 2008, Hata et al. 1995). In spite of this, a clear correlation 
between vascular deficiency and RGC death in glaucoma has not been established.   
In this study, we asked whether there is a loss of retinal capillaries in 
experimental glaucoma and, if so, whether it occurs early in the disease. We also sought 
to determine whether capillary loss occurred prior, concomitantly or after RGC death. 
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Finally, we asked if neuroprotective strategies that promote RGC survival would also 
lead to vascular protection. 
 
III.3. MATERIAL AND METHODS 
III.3.1. Experimental animals 
Male Brown Norway rats, 10-12 months old (Charles River Canada, 300-400 g) 
were used for ocular hypertension (OHT) surgery, retinal microvasculature isolation and 
blood flow experiments. All procedures were performed in compliance with the Canadian 
Council on Animal Care for the use of experimental animals and the guidelines of the 
Association for Research in Vision and Ophthalmology. The number of animals used in 
each experiment is indicated above the bar in the corresponding graph. 
III.3.2. Retrograde labeling of RGCs 
 RGCs were retrogradely labeled with DiI (1,1'-dioctadecyl-3,3,3’,3’-tetramethyl-
indocarbocyanine perchlorate; Molecular Probes, Junction City, OR) or with Fluorogold 
(2%, Fluorochrome, Englewood, CO). DiI crystals (3%) or Fluorogold (2%) were 
dissolved in 0.9% NaCl containing 10% dimethyl sulfoxide (DMSO) and 0.5% Triton X-
100. The superior colliculus was exposed and a small piece of gelfoam (Pharmacia and 
Upjohn Inc., Mississauga, ON) soaked in tracer was applied to the surface as previously 
described (Almasieh et al. 2010). Seven days after tracer application, the time required 
for labeling the entire RGC population, animals were subjected to ocular hypertension 
surgery.  
III.3.3. Ocular hypertension surgery and measurement of intraocular pressure 
Unilateral elevation of IOP was induced as previously described (Morrison et al. 
1997) by a single injection of a hypertonic saline solution (1.85 M NaCl) into an 
episcleral vein. Animals were kept in a room with constant low fluorescent light (40-100 
lux) to stabilize circadian IOP variations. IOP from glaucomatous and normal eyes was 
measured in awake animals because general anesthetics lower IOP (Jia et al. 2000). A 
calibrated tonometer (TonoPen XL, Medtronic Solan, Jacksonville, FL) was used to 
measure IOP after application of one drop of proparacaine hydrochloride (0.5%, Alcon 
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Laboratories, Inc., Fort Worth, TX) per eye. The tonometer was held exactly 
perpendicular to the corneal surface and ~10 consecutive readings per eye were taken and 
averaged to obtain an accurate IOP measurement. IOP was measured daily for two weeks 
after ocular hypertension surgery, then every other day for the entire duration of the 
experiment. The mean and peak (maximum) IOP for each eye were calculated and these 
values were used to estimate the mean and peak IOP for experimental and control groups.  
III.3.4. In vivo drug delivery 
Galantamine hydrobromide (3.5 mg/kg, Tocris Bioscience, Ellisville, MO) and 
scopolamine hydrobromide (1 mg/kg, Tocris Bioscience, Ellisville, MO), both of which 
readily cross the blood-brain barrier, were delivered by daily intraperitoneal (i.p.) 
injection.  Drug delivery started immediately after IOP stabilization following ocular 
hypertension surgery and continued for the entire duration of the experiment. Control 
animals received daily i.p. injections of vehicle (PBS).  In some experiments, 
galantamine (100 mM), mecamylamine (10 mM, Sigma-Aldrich, St. Louis, MO) or 
scopolamine (10 mM, Tocris Bioscience, Ellisville, MO) were injected intraocularly in a 
total volume of 5 µl. For intraocular delivery, drugs were injected into the vitreous 
chamber using a 10-µl Hamilton syringe adapted with a 32-gauge glass microneedle, the 
tip of which was inserted into the superior hemisphere of the eye at a ~45° angle through 
the sclera into the vitreous body. This route of administration avoided retinal detachment 
or injury to eye structures, including the iris and lens. Surgical glue (Indermill, Tyco 
Health Care, Mansfield, MA) was used to seal the injection site. 
III.3.5. Quantification of RGC soma 
  For RGC density counts, rats were deeply anesthetized and perfused 
transcardially with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer. Eyes were 
quickly enucleated and retinas were dissected out and flat-mounted on a glass slide with 
the ganglion cell layer side up. RGCs were counted in three square areas at distances of 1, 
2 and 3 mm from the optic disc in each of the four retinal quadrants (superior, inferior, 
nasal and temporal) for a total of 12 retinal areas encompassing a total area of 1 mm2. 
Macrophages and microglia that may have incorporated fluorescent tracer after 
phagocytosis of dying RGCs were excluded from our quantitative analysis based on cell-
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specific markers and morphology (Lebrun-Julien et al. 2009). Data analysis and statistics 
were performed using the GraphPad Instat software (GraphPad Software Inc., San Diego, 
CA) by a one-way analysis of variance (ANOVA) test followed by Bonferroni's multiple 
comparison post-test. 
III.3.6. Isolectin staining 
 Dissected retinas were placed in a 24-well plate, washed twice with PBS and then 
permeabilized with 100% ice cold methanol for 10 minutes. TRITC-labeled isolectin 
antibody (4µg/ml Sigma-Aldrich, St. Louis, MO) was prepared in PBS containing 1% 
Triton X-100 and incubated at room temperature overnight. Retinas were flat-mounted on 
a glass slide with the ganglion cell layer side up and visualized using a Zeiss Axiovert 
fluorescent microscope. The total length of the retinal microvasculature was measured 
per mm2 of retinal surface using Northern Eclipse image analysis software (Empix 
Imaging, Toronto, ON). 
III.3.7. Quantitative autoradiography 
Retinal blood flow measurements were performed by quantitative 
autoradiography using the diffusible blood flow tracer N-isopropyl-p-[14C]-
iodoamphetamine ([14C]-IMP) as previously described (Pouliot et al. 2009). Briefly, 
[14C]-IMP (100 μCi/kg; PerkinElmer, Boston, MA,) was dissolved in saline solution and 
infused through a femoral vein catheter over a 30 sec period at a constant rate of 
1.2 ml/min. Arterial blood samples were collected from the femoral artery catheter at a 
continuous rate until animal was sacrificed (2 min after  [14C]-IMP infusion onset). The 
eyes were quickly removed and post-fixed in 4% PFA for 1 hr. The retinas were dissected 
out, flat-mounted on a glass slide with the ganglion cell layer side up and exposed to X-
ray film for 4 days alongside [14C] standards (ARC, St. Louis, MO). Retinal blood flow 
was calculated by implementing the principle of indicator-fractionation technique using 
the equations F= [CIMP (T) × 10-1 / ׬ ܥܽ ሺݐሻ்଴  ] for autoradiographic analysis of flat-mount 
retinas as previously described (Pouliot et al. 2011, Pouliot et al. 2009, Lear et al. 1982). 
F represents the blood flow (ml/100 g/min), CIMP (T) is the radioactivity measured from 
the autoradiogram (μCi/g) at the time T (min) after sampling and Ca (t) is arterial blood 
sample radioactivity (μCi/ml). To obtain CIMP(T) values, a computerized image analysis 
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system (MCID Basic Software, v7.0, Interfocus Imaging, Linton, England) was used to 
collect readings from a 0.8 mm2 circular area acquired at 1, 2 and 3 mm (isopters) from 
the optic nerve in each eye quadrant (Pouliot et al. 2009). The Ca (t) value was obtained 
by measuring radioactivity in the collected blood samples using a scintillation counter 
(LS6500, Beckman Coulter, Mississauga, ON). 
III.3.8. Retinal arteriole isolation and vessel diameter measurements 
  Following transcardial perfusion with heparin (16 u/ml, Sigma-Aldrich, St. Louis, 
MO), the  retinas were dissected out and placed in a low Mg2+/low Ca2+ dissociation 
buffer. Each retina was cut into small pieces with surgical scissors and triturated gently 
with a fire-polished pipette. Dissociated retinal tissue containing retinal vessel segments 
were plated onto laminin-coated dishes and allowed to adhere for 15 min before 
superfusion with bath solution (145 NaCl, 5 KCl, 10 HEPES, 5 D-Glucose, 2 mM CaCl2, 
1 mM MgCl2, pH 7.3). Isolated retinal arterioles were identified under an inverted light 
microscope and vessel diameter was recorded at 120 Hz with a video edge detector 
(Crescent Electronics, Sandy, UT).  Human endothelin-1 (ET-1, 10 nM, Peptide Institute 
Inc., OSAKA, Japan), galantamine hydrobromide ( Gal, 50 µM, Tocris Bioscience, 
Ellisville, MO), scopolamine hydrobromide ( SCO, 10 µM, Tocris Bioscience, Ellisville, 
MO), mecamylamine hydrochloride (MMA, 10 µM, Sigma-Aldrich, St. Louis, MO ), 
pirenzepine dihydrochloride (PRZ, 1 µM, Tocris Bioscience, Ellisville, MO), 
diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP, 1 µM, Tocris Bioscience, 
Ellisville, MO), tropicamide (1-10 µM, Tocris Bioscience, Ellisville, MO) or 11-[[2-
[(Diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido [2,3-b] [1,4] 
benzo-diazepin-6-one (DX116, 1-10 µM, Tocris Bioscience, Ellisville, MO) were applied 
to isolated retinal vessels using a rapid solution switcher device that allowed the 
application of drugs at 37oC. Vessels were superfused with bath solution for 10 min 
followed by application of 10 nM ET-1 until a stable contraction was obtained (1- 2 min) 
after which vessel diameter was recorded for an additional 10 min. Some experiments 
were conducted on vessels denuded of endothelium by application of CHAPS (0.3%, 
Sigma-Aldrich St. Louis, MO) at the time of perfusion Digital photomicrographs of 
vessels were captured with an Infinity 3-1C digital camera (Lumenera Corp.) mounted on 
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a Nikon Eclipse E800 microscope, and analyzed with Infinity Analyze (Lumenera Corp.) 
and Adobe Photoshop CS3 (Adobe Systems, Inc., San Jose, CA). Data were analyzed 
using two-tailed unpaired t-tests and one-way analyses of variance (ANOVA) with a 
Newman-Keuls post hoc test.  
 
III.4. RESULTS 
III.4.1. Loss of the retinal microvasculature occurs concomitantly with RGC death 
in experimental glaucoma 
Nerve fiber layer capillaries play crucial physiological roles by supplying oxygen 
and nutrients to RGCs and their axons. We sought to determine whether there is loss of 
inner retinal capillaries in experimental glaucoma and, if so, whether this damage occurs 
prior, concurrently or after RGC death. To achieve this, we carried out a detailed 
temporal analysis of glaucomatous retinas in which we simultaneously visualized retinal 
capillaries using TRITC-labeled isolectin, a marker of functional endothelial cells 
(Laitinen 1987; Goldstein et al., 1981), while identifying RGCs with the fluorescent 
retrograde tracer DiI (Figure 1).  
Quantification of the retinal microvascular density at three days after OHT 
surgery, a time when there is no detectable increase in IOP, revealed a small (~10%) but 
significant reduction in capillary density (17,837 ± 410 µm/mm2, n=6) compared to non-
injured retinas (19,710 ± 594 µm/mm2, n=6) (Figure 1A, 1B, 1M).  In these same retinas, 
a significant reduction in the density of RGC soma (1,646 ± 31 RGCs/mm2, n=6) 
compared to control retinas (1,803 ± 24 RGCs/mm2, n=6) was also found, confirming 
that degenerative changes occur in both neuronal and vascular compartments early after 
glaucomatous damage and prior to a detectable increase in IOP (Fig 1G, 1H, 1M). 
Weekly analysis of retinal capillary density throughout the entire duration of the study 
(up to 5 weeks after OHT) demonstrated a steady loss of the microvasculature that 
occurred concomitantly with RGC death (Fig. 1C-F, 1I-L, 1M). These data indicate a 
tight neurovascular relationship between RGCs and retinal capillaries, and demonstrate 
that both neurons and the microvasculature are similarly affected in experimental 
glaucoma.   
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III.4.2. Galantamine mediates vasoprotection in experimental glaucoma 
The observation that RGC death occurs concomitantly with microvasculature loss 
puts forward the idea that protective therapies for glaucoma should ideally target both the 
neuronal and the vascular compartments. We previously demonstrated that galantamine, a 
small molecule acetylcholinesterase (AChE) inhibitor, promotes robust structural and 
functional protection of RGC soma and axons (Almasieh et al., 2010). To establish 
whether galantamine had a vasoprotective effect, we examined capillary density in 
experimental animals subjected to OHT surgery followed by daily intraperitoneal 
injection of galantamine (treatment onset: ~1 week after OHT) (Fig. 2). Galantamine 
treatment resulted in robust preservation of capillary density at three weeks (~80%: 
15,423 ± 290 µm/mm2, n=4) and five weeks (~40%: 13,986 ± 602 µm/mm2, n=5) after 
OHT, compared to PBS-treated control groups (3 weeks: 13,421 ± 685 µm/mm2, n=5; 5 
weeks: 7,901 ± 618 µm/mm2, n=5). The vasoprotective effect of galantamine was most 
apparent at five weeks of OHT when considerable loss of retinal capillaries has already 
occurred in non-treated eyes. Importantly, galantamine treatment virtually prevented 
further retinal capillary degeneration between three and five weeks after OHT (Fig. 2E). 
These data demonstrate that in addition to neuroprotection, galantamine also confers 
robust vascular protection in experimental glaucoma.  
III.4.3. Retinal blood flow impairment in experimental glaucoma is partially 
restored by galantamine  
To assess the functional status of the microvascular network in glaucomatous 
versus control eyes and in the presence or absence of galantamine, we investigated 
regional blood flow using [14C]-IMP as previously described by us (Pouliot et al., 2009) 
(Fig. 3). A significant reduction of retinal blood flow was observed in glaucomatous eyes, 
visualized in pseudo-colored autoradiograms, at five weeks after OHT compared to non-
injured eyes (Figs. 3B, 3D). Galantamine treatment markedly restored retinal blood flow 
in experimental glaucoma (82% of intact) compared to PBS-treated control animals (50% 
of intact) (Figs 3C, 3D, 3E). To establish whether restoration of blood flow occurred 
locally or throughout the retina, regional blood flow was quantified in three consecutive 
isopters at 1, 2 and 3 mm from the optic nerve head (Fig. 3A, 3F, Table 1). In non-injured 
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retinas, higher blood perfusion was measured in central regions compared to the 
periphery (Fig. 3B, 3F). In experimental glaucoma, the central retina underwent the most 
dramatic reduction in blood flow at five week after OHT (Fig. 3D, 3F). Nonetheless, the 
galantamine-mediated restoration of blood flow was proportional in central and 
peripheral retinal regions (Fig. 3F, Table 1). Our data indicate that retinal blood flow is 
markedly reduced in experimental glaucoma, a response that is most prominent in the 
central retina. Treatment with galantamine not only significantly increased global retinal 
blood flow in hypertensive eyes, but it was particularly beneficial in central regions of the 
retina which undergo marked hypoperfusion during glaucomatous damage.  
III.4.4. Galantamine stimulates retinal arteriole relaxation  
To evaluate the mechanisms of galantamine-mediated vascular protection, we 
carried out studies on isolated retinal vessels pre-contracted with endothelin (ET-1).  ET-
1 treatment alone led to a stable reduction in vessel diameter (32% contraction), while 
application of galantamine promoted significant relaxation of pre-contracted vessels 
(Figure 4A-C). A concentration of galantamine as low as 5 µM was sufficient to promote 
vessel relaxation, however, the optimal relaxation-promoting dose of galantamine was 50 
µM leading to maximum relaxation and increased the diameter of vessels by 50% (17% 
contraction). In a second group of experiments, we used isolated retinal arterioles in 
which endothelial cells were removed by application of CHAPS at the time of perfusion. 
Application of ET-1 resulted in a higher pre-contraction level (45% contraction) 
compared to vessel preparations with intact endothelial cells (Fig. 4C). Furthermore, 
addition of galantamine (50 µM) to pre-contracted vessels devoid of endothelium failed 
to undergo relaxation (Fig. 4C). Collectively, these data demonstrate that a moderate dose 
of galantamine effectively leads to vasodilation of pre-contracted retinal vessels ex vivo, 
and that galantamine-mediated relaxation requires the presence of endothelial cells.  
III.4.5. Muscarinic acetylcholine receptors mediate the vasodilator and 
vasoprotective effects of galantamine in experimental glaucoma  
We previously demonstrated that galantamine-mediated RGC protection in 
experimental glaucoma requires activation of muscarinic acetylcholine receptors 
(mAChRs) (Almasieh et al., 2010). To establish whether this mechanism played a role in 
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vasoprotection, we carried out experiments using isolated pre-contracted vessels exposed 
to galantamine alone or in combination with pharmacological inhibitors of mAchR. 
Combined application of galantamine and scopolamine (SCO), a pan-inhibitor of all 
mAChR sub-types, arrested its vasodilator effect on pre-contracted vessels (Fig. 4D). In 
contrast, combined application of galantamine with mecamylamine (MMA), a blocker of 
all neuronal nicotinic acetylcholine receptors (nAChRs), did not significantly alter 
galantamine-induced vasodilation (Fig. 4D). These results indicate that galantamine 
mediates retinal arteriole relaxation through mAChRs activation. To further establish 
which mAChR sub-type was involved in this response; we used selective mAChR 
antagonists co-administered with galantamine. Application of pirenzepine, a selective 
blocker of the M1 mAChR subtype, or 4-DAMP, an inhibitor of the M3 mAChR subtype, 
abolished galantamine-mediated relaxation of pre-contracted vessels (Fig. 4E). In 
contrast, tropicamide or DX116, blockers of M4 or M2 mAChRs respectively, did not 
have a significant effect on galantamine-induced vasodilation (not shown). These data 
indicate that M1 and M3 mAChRs are molecular mediators of the relaxation effect of 
galantamine on retinal vessels. 
To assess whether mAChRs played a role in the microvasculature protection 
conferred by galantamine in experimental glaucoma in vivo, we tested the effect of 
galantamine in combination with MMA or SCO. Since these AChR antagonists do not 
cross the blood-brain/retinal barrier or exhibit extremely low barrier permeability 
(Mickala et al., 1996; Stein et al., 1995), they were administered by intravitreal injection 
at one week after OHT as previously described by us (Almasieh et al., 2010) and analysis 
of microvasculature density was performed two weeks later. Co-administration of 
galantamine and SCO completely inhibited the vasoprotective effect of galantamine. 
Although combination of galantamine and MMA led to a slight reduction in capillary 
density, this effect was not significantly different from that of galantamine alone (Fig. 
4F). Thus, we conclude that the vasoprotective effect of galantamine in vivo is mediated 
primarily through activation of mAChRs in experimental glaucoma. 
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III.5. DISCUSSION 
This study reports a number of important findings. First, we detected substantial 
loss of small capillaries in the inner retina early during glaucomatous degeneration. 
Second, we found that loss of retinal capillaries occurred concomitantly with the death of 
RGCs following OHT. The onset of microvasculature and RGC loss occurred at the same 
time and proceeded at the same rate for at least three weeks after the initial insult. Lastly, 
systemic administration of the neuroprotective drug galantamine increased 
microvasculature density and improved blood flow in experimental glaucoma. 
Galantamine-mediated protection of the retinal microvasculature occurred through 
activation of M1 and M3 mAChR subtypes. 
Although retinal and ONH blood flow defects have been suggested to play a role 
in glaucoma (Flammer et al., 2002; Osborne et al., 2001), a clear correlation between 
neuronal and vascular compartments in this disease has not been established. 
Quantification of retinal capillary density demonstrated that retinal microvasculature loss 
occurs as early as three days after OHT surgery and continues to progress thereafter. 
Intriguingly, we did not detect a significant increase in IOP at this early time point as 
measured using a calibrated TonoPen, consistent with the gradual increase in IOP that 
occurs over 7-10 days reported in this rat glaucoma model (Morrison et al., 1997). A 
likely explanation is that a subtle increase in IOP, not detectable using conventional 
tonometry, is sufficient to trigger a cascade of events leading to capillary and RGC loss. 
Furthermore, an IOP increase below a detectable threshold can lead to small but 
significant changes in endogenous factors that threaten the integrity of the retinal 
vasculature including reactive oxygen species, tumor necrosis factor alpha (TNFα) and 
glutamate, triggering endothelial cell apoptosis. The identification of the endogenous 
signals leading to loss of retinal capillaries early after glaucomatous damage should be a 
priority of future studies. 
Importantly, our data also demonstrate that the time-course of retinal capillary 
loss is indistinguishable from that of RGC death. Given the tight functional relationship 
between RGCs and the retinal microvasculature during disease onset and progression, we 
asked whether strategies that promote RGC neuroprotection can be used to sustain the 
retinal capillary bed and enhance blood flow. We previously demonstrated that 
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galantamine, an acetylcholinesterase inhibitor, promotes robust structural and functional 
RGC protection of RGCs in experimental glaucoma (Almasieh et al., 2010). In the 
present study, we show that galantamine treatment resulted in a substantial preservation 
of capillary density that correlated with increased retinal blood flow in the central and 
peripheral retina. Therefore, in addition to neuronal protection, galantamine has marked 
vasoprotective properties. 
Due to the tight relationship between RGC and capillary loss in glaucoma, it is 
not clear whether galantamine first promotes the neuroprotection which then leads to 
vasoprotection or vice versa. To address the mechanism of action of galantamine-induced 
vasoprotection, we first used an ex vivo preparation of isolated retinal vessels. Our data 
show that galantamine superfusion led to marked relaxation of pre-contracted vessels, a 
response that was lost after removal of their endothelium with CHAPS. This finding 
suggests a direct effect of galantamine on retinal arteries that is dependent on the 
presence of healthy endothelial cells. Moreover, our results demonstrate that 
galantamine-mediated vessel relaxation in vitro and vasoprotection in experimental 
glaucoma in vivo occur primarily through mAChRs activation. We previously 
demonstrated that galantamine-induced RGC protection in experimental glaucoma also 
occurs via mAChRs, primarily the M1 and M4 subtypes (Almasieh et al. 2010). Here, we 
show that vasoprotection following galantamine administration involves M1 and M3 
mAChR subtypes. Intriguingly, RGCs do not express mAChRs (Da Silva et al., 2008), 
whereas retinal and brain endothelial cells abundantly express M1 and M3 mAChR 
subtypes (Elhusseiny et al., 1999; Sastry, 1985). Both M1 and M3 mAChRs have been 
implicated in cholinergic mediated vasomodulation in the brain (Dauphin et al., 1994) 
and ACh-dependent vascular relaxation is lost in M3 mAChR knockout mice (Bény et 
al., 2008), thus supporting our finding that galantamine relaxes pre-contracted isolated 
retinal arterioles via M1 and M3 mAChRs. Since RGCs lack mAChR while endothelial 
cells can directly respond to galantamine, it is tempting to speculate that vasoprotection is 
a pre-requisite for galantamine-mediated neuroprotection in experimental glaucoma. 
However, we cannot rule out the contribution of other retinal cells expressing M1, M3 or 
M4 mAChRs, including Müller glia, bipolar and horizontal cells (Da Silva et al., 2008; 
Fischer et al., 1998; Yamada et al., 2003). Indeed, activation of retinal M1 and M3 
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mAChRs subtypes stimulates nNOS levels and activity leading to vasodilation (Borda et 
al., 2005), thus activation of mAChRs in retinal cells other than endothelial might help 
restore retinal blood flow in experimental glaucoma. 
In summary, in this study we demonstrate an early and significant loss of the 
retinal microvasculature intimately associated with RGC death in experimental glaucoma. 
We demonstrated that a clinically approved drug, galantamine, promotes effective 
vasoprotection and restores retinal blood flow following ocular hypertension damage. 
These findings are particularly important for the treatment of glaucomatous neuropathies 
because while RGC death is irreversible, the retinal microvasculature retains the capacity 
to regenerate. Therefore, therapeutic strategies based on vascular protection and vessel 
regeneration may provide essential, long-term support to neurons and improve visual 
outcome in glaucoma. 
    
Acknowledgements: We thank Jessica McIntyre and Dara O'connor for their 
collaboration and technical assistance. 
 
 
III.6. REFERENCES 
Almasieh, M., Zhou, Y., Kelly, M.E., Casanova, C., Di Polo, A., 2010. Structural and 
functional neuroprotection in glaucoma: role of galantamine-mediated activation 
of muscarinic acetylcholine receptors. Cell Death Dis 1, e27-e27.  
Bény, J.-L., Nguyen, M., Marino, M., Matsui, M., 2008. Muscarinic receptor knockout 
mice confirm involvement of M3 receptor in endothelium-dependent 
vasodilatation in mouse arteries. J Cardiovasc Pharmacol 51, 505-512.  
Borda, E., Berra, A., Saravia, M., Ganzinelli, S., Sterin Borda, L., 2005. Correlations 
between neuronal nitric oxide synthase and muscarinic M3/M1 receptors in the rat 
retina. Exp Eye Res 80, 391-399.  
Chung, H.S., Harris, A., Kagemann, L., Martin, B., 1999. Peripapillary retinal blood flow 
in normal tension glaucoma. Br J Ophthalmol 83, 466-469.  
Coleman, A.L., Miglior, S., 2008. Risk Factors for Glaucoma Onset and Progression. 
Surv Ophthalmol 53, S3-S10.  
Da Silva, N., Herron, C., Stevens, K., Jollimore, C.A.B., Barnes, S., Kelly, M.E.M., 
2008. Metabotropic receptor-activated calcium increases and store-operated 
calcium influx in mouse Müller cells. Invest Ophthalmol Vis Sci 49, 3065-3073.  
Dauphin, F., Linville, D.G., Hamel, E., 1994. Cholinergic dilatation and constriction of 
feline cerebral blood vessels are mediated by stimulation of phosphoinositide 
103 
 
 
 
metabolism via two different muscarinic receptor subtypes. J Neurochem 63, 544-
551.  
Duijm, H.F., van den Berg, T.J., Greve, E.L., 1997. A comparison of retinal and 
choroidal hemodynamics in patients with primary open-angle glaucoma and 
normal-pressure glaucoma. Am J Ophthalmol 123, 644-656.  
Elhusseiny, A., Cohen, Z., Olivier, A., Stanimirović, D.B., Hamel, E., 1999. Functional 
acetylcholine muscarinic receptor subtypes in human brain microcirculation: 
identification and cellular localization. J Cereb Blood Flow Metab 19, 794-802.  
Fischer, A.J., McKinnon, L.A., Nathanson, N.M., Stell, W.K., 1998. Identification and 
localization of muscarinic acetylcholine receptors in the ocular tissues of the 
chick. J Comp Neurol 392, 273-284.  
Flammer, J., Orgül, S., Costa, V.P., Orzalesi, N., Krieglstein, G.K., Serra, L.M., Renard, 
J.-P., Stefánsson, E., 2002. The impact of ocular blood flow in glaucoma. Prog 
Retin Eye Res 21, 359-393.  
Goldstein, I.J., Blake, D.A., Ebisu, S., Williams, T.J., Murphy, L.A., 1981. Carbohydrate 
binding studies on the Bandeiraea simplicifolia I isolectins. Lectins which are 
mono-, di-, tri-, and tetravalent for N-acetyl-D-galactosamine. J Biol Chem 256, 
3890-3893.  
Harris, A., Sergott, R.C., Spaeth, G.L., Katz, J.L., Shoemaker, J.A., Martin, B.J., 1994. 
Color Doppler analysis of ocular vessel blood velocity in normal-tension 
glaucoma. Am J Ophthalmol 118, 642-649.  
Hata, Y., Nakagawa, K., Ishibashi, T., Inomata, H., Ueno, H., Sueishi, K., 1995. 
Hypoxia-induced expression of vascular endothelial growth factor by retinal glial 
cells promotes in vitro angiogenesis. Virchows Archiv 426, 479-486.  
Jia, L., Cepurna, W.O., Johnson, E.C., Morrison, J.C., 2000. Effect of general anesthetics 
on IOP in rats with experimental aqueous outflow obstruction. Invest. 
Ophthalmol. Vis. Sci. 41, 3415-3419.  
Kaiser, H.J., Schoetzau, A., Stmpfig, D., Flammer, J., 1997. Blood-flow velocities of the 
extraocular vessels in patients with high-tension and normal-tension primary 
open-angle glaucoma. Am J Ophthalmol 123, 320-327.  
Laitinen, L., 1987. Griffonia simplicifolia lectins bind specifically to endothelial cells and 
some epithelial cells in mouse tissues. Histochem J 19, 225-234.  
Lear, J.L., Ackermann, R.F., Kameyama, M., Kuhl, D.E., 1982. Evaluation of [123I] 
isopropyliodoamphetamine as a tracer for local cerebral blood flow using direct 
autoradiographic comparison. J Cereb Blood Flow Metab 2, 179-185.  
Lebrun-Julien, F., Duplan, L., Pernet, V., Osswald, I.K., Sapieha, P., Bourgeois, P., 
Dickson, K., Bowie, D., Barker, P.A., Di Polo, A., 2009. Excitotoxic death of 
retinal neurons in vivo occurs via a non-cell-autonomous mechanism. J. Neurosci. 
29, 5536-5545.  
Mickala, P., Boutin, H., Bellanger, C., Chevalier, C., MacKenzie, E.T., Dauphin, F., 
1996. In vivo binding, pharmacokinetics and metabolism of the selective M2 
muscarinic antagonist Nucl. Med. Biol. 23, 173-179.  
Morrison, J.C., Moore, C.G., Deppmeier, L.M.H., Gold, B.G., Meshul, C.K., Johnson, 
E.C., 1997. A rat model of chronic pressure-induced optic nerve damage. Exp. 
Eye Res. 64, 85-96.  
104 
 
 
 
Nemesure, B., Honkanen, R., Hennis, A., Wu, S.Y., Leske, M.C., 2007. Incident open-
angle glaucoma and intraocular pressure. Ophthalmology 114, 1810-1815.  
Osborne, N.N., Melena, J., Chidlow, G., Wood, J.P., 2001. A hypothesis to explain 
ganglion cell death caused by vascular insults at the optic nerve head: possible 
implication for the treatment of glaucoma. Br J Ophthalmol 85, 1252-1259.  
Plange, N., Kaup, M., Huber, K., Remky, A., Arend, O., 2006. Fluorescein filling defects 
of the optic nerve head in normal tension glaucoma, primary open-angle 
glaucoma, ocular hypertension and healthy controls. Ophthalmic Physiol Opt 26, 
26-32.  
Pouliot, M., Deschênes, M.C., Hétu, S., Chemtob, S., Lesk, M.R., Couture, R., Vaucher, 
E., 2009. Quantitative and regional measurement of retinal blood flow in rats 
using N-isopropyl-p-[14C]-iodoamphetamine ([14C]-IMP). Exp Eye Res 89, 960-
966.  
Pouliot, M., Hétu, S., Lahjouji, K., Couture, R., Vaucher, E., 2011. Modulation of retinal 
blood flow by kinin B1 receptor in Streptozotocin-diabetic rats. Exp Eye Res 92, 
482-489.  
Quigley, H.A., 1999. Neuronal death in glaucoma. Prog Retin Eye Res18, 39-57.  
Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I., Pararajasegaram, R., Pokharel, G., 
Mariotti, S., 2004. Global data on visual impairment in the year 2002. Bull World 
Health Organ 82, 844-851.  
Sapieha, P., Sirinyan, M., Hamel, D., Zaniolo, K., Joyal, J.-S., Cho, J.-H., Honor, J.-C., 
Kermorvant Duchemin, E., Varma, D., Tremblay, S., Leduc, M., Rihakova, L., 
Hardy, P., Klein, W., Mu, X., Mamer, O., Lachapelle, P., Di Polo, A., Beausjour, 
C., Andelfinger, G., Mitchell, G., Sennlaub, F., Chemtob, S., 2008. The succinate 
receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med 14, 
1067-1076.  
Sastry, B.V., 1985. Cholinergic systems and multiple cholinergic receptors in ocular 
tissues. J Ocul Pharmacol. 1, 201-226.  
Stein, R., Bachoo, M., Polosa, C., 1995. Pirenzepine-sensitive component of forelimb 
vascular resistance and heart rate in cats. J. Autonom. Nerv. Syst. 54, 49-58.  
Tielsch, J.M., Katz, J., Sommer, A., Quigley, H.A., Javitt, J.C., 1995. Hypertension, 
perfusion pressure, and primary open-angle glaucoma. A population-based 
assessment. Arch Ophthalmol 113, 216-221.  
Wolf, S., Arend, O., Sponsel, W.E., Schulte, K., Cantor, L.B., Reim, M., 1993. Retinal 
hemodynamics using scanning laser ophthalmoscopy and hemorheology in 
chronic open-angle glaucoma. Ophthalmology 100, 1561-1566.  
Yamada, E., Dmitrieva, N., Keyser, K., Lindstrom, J., Hersh, L., Marshak, D., 2003. 
Synaptic connections of starburst amacrine cells and localization of acetylcholine 
receptors in primate retinas. J Comp Neurol 461, 76-90. 
 
 
 
 
 
 
105 
 
 
 
Figure 1. Loss of inner retinal capillaries along with RGCs in experimental 
glaucoma.  
Retinal flat-mounts show isolectin-labeled retinal capillaries from non-injured, non-
treated eye (A, Intact) and glaucomatous non-treated eyes (B-F) and DiI-labeled retinal 
ganglion cells from non-injured, non-treated eyes (G, Intact) and glaucomatous non-
treated eyes (H-L); Scale bars: 100 µm. (M) Quantitative analysis of capillary length in 
the nerve fiber layer of retinas from glaucomatous eyes; retinas were examined at 3 days, 
1, 2, 3, and 5 weeks after OHT surgery, the average total values for each group (hatched 
bars) is presented as percentage of capillary density value for non-injured, non-treated 
retinas from Brown-Norway rat retinas (19710 ± 594 µm/mm2, mean ± S.E.M., n = 6). 
Quantitative analysis of RGC survival also was examined in the same retinas (solid bars) 
and results are presented as percentage of the average total RGC population in non-
injured, non-treated retinas from Brown-Norway rat retinas (1830 ± 24 RGCs/mm2, mean 
± S.E.M., n = 6) (M). Number of animals in each group is indicated above the related bar. 
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Figure 2. Galantamine protects inner retinal capillaries in experimental glaucoma.  
Isolectin-labeled retinal vasculatures in flat-mount preparation of glaucomatous retinas 
demonstrating galantamine treated (3.5 mg/kg, i.p.) (A, 3 weeks and C, 5 weeks) and 
vehicle (PBS) treated groups (B, 3 weeks and D, 5 weeks). (E) Quantitative analysis of 
capillary length after OHT indicates significant preservation of inner retinal capillaries in 
galantamine treated groups (solid bars) compare to vehicle treated (hatched bars). Data 
are expressed as µm/mm2 ± S.E.M and number of animals in each group is indicated 
above the related bar (ANOVA, **p < 0.01). Scale bars (A-D): 100 µm. 
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Figure 3. Galantamine-mediated improvement of the retinal blood flow in 
glaucomatous retinas.  
(A) Schematic of a flat-mounted retina representing method of sampling; filled circles 
indicate standard sampling probe and light circular lines show same isopters of different 
retinal quadrants. (B) Pseudo-colored autoradiogram of a flat-mounted intact retina, (C) 
galantamine treated and (D) vehicle treated retinas 5 weeks after OHT surgery. (E) 
Measurements of blood flow values indicated a significant decline of global retinal blood 
flow in glaucomatous retinas 5 weeks after OHT (hatched bar), galantamine significantly 
improved global retinal blood flow in glaucomatous retinas (solid bar). (F) Reduction in 
the blood flow was also reflected in each isopter (hatched bars) and was significantly 
improved by galantamine treatment (solid bars) compare to vehicle treated. Data are 
expressed as ml/100 g/min ± S.E.M and number of animals in each group is indicated 
above the related bar (ANOVA, *p < 0.05). 
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Figure 4. Galantamine mediates vasodilation and vasoprotection via signaling 
through muscarinic acetylcholine receptors.  
(A) Contraction of isolated retinal vessels in response to incubation with Endothelin-1. 
(B) Application of galantamine to pre-contracted vessels resulted in relaxation and 
increase of their diameter. (C) Quantitative analysis indicated that presence of endothelial 
cells is necessary for vasodilatory effect of galantamine; as denudation of endothelium by 
CHAPS eliminates the galantamine-mediated relaxation. (D) Muscarinic ACh receptors 
blocker, scopolamine (SCO), abolished vasodilatory effect of galantamine whereas 
nicotinic blocker, Mecamylamine (MMA) did not have significant effect on inhibition of 
galantamine mediated relaxation. (E) Galantamine-mediated vasorelaxation was 
selectively inhibited by blockers of M1 (Pirenzepine, PRZ) and M3 (4-DAMP) subtypes 
of muscarinic receptors. (A-E) Data is presented as percentage of vessels diameter before 
application of Endothelin-1. (F) Intraocular application of muscarinic receptor inhibitor 
(SCO) abolished galantamine-mediated protection of inner retinal capillaries; data are 
expressed as µm/mm2 ± S.E.M and number of animals in each group is indicated above 
the related bar (ANOVA, *p < 0.05). 
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Table 1. Autoradiography values of the blood flow for each retinal isopter. 
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IV.1. ABSTRACT  
The reactive oxygen species superoxide has been recognized as a critical signal 
triggering retinal ganglion cell (RGC) death after axonal injury. Although the 
downstream targets of superoxide are unknown, chemical reduction of oxidized 
sulfhydryls has been shown to be neuroprotective for injured RGCs. Based on this; we 
developed novel phosphine-borane complex compounds that are cell permeable and 
highly stable. Here, we report that our lead compound, bis (3-propionic acid methyl ester) 
phenylphosphine borane complex 1 (PB1), promotes RGC survival in rat models of optic 
nerve axotomy and in experimental glaucoma. PB1-mediated RGC neuroprotection did 
not correlate with inhibition of stress-activated protein kinase signaling, including ASK1, 
JNK or p38. Instead, PB1 led to a striking increase in retinal BDNF levels and 
downstream activation of the ERK1/2 pathway. Pharmacological inhibition of ERK1/2 
entirely blocked RGC neuroprotection induced by PB1. We conclude that PB1 protects 
damaged RGCs through activation of pro-survival signals. These data support a potential 
cross-talk between redox homeostasis and neurotrophin-related pathways leading to RGC 
survival after axonal injury.   
Keywords: Superoxide, Redox Signaling, Retinal Ganglion Cell, Neuroprotection, 
Brain-Derived Neurotrophic Factor, Extracellular Signal-Regulated Kinase 1/2.   
 
Running title: Phosphine-Borane Complex-Induced Neuroprotection of Retinal Neurons.    
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IV.2. INTRODUCTION  
Axonal injury is a common cause of neuronal death in the central nervous system 
(CNS) of adult mammals and is the primary damaging event in most optic nerve diseases, 
including glaucoma. A crucial element in the pathophysiology of optic neuropathies is 
the death of retinal ganglion cells (RGCs), the neurons that convey visual information 
from the retina to the brain. The signals leading to RGC loss in glaucoma are not well 
understood (Nickells, 2007; Wax and Tezel, 2002), but several mechanisms have been 
proposed, including neurotrophic factor deprivation, mechanical compression, 
excitotoxicity, reactive astrocytosis and induction of pro-apoptotic pathways (Carpenter 
et al., 1986; Cui and Harvey, 1995; Kikuchi et al., 2000; Kiryu-Seo et al., 2000; 
Mansour-Robaey et al., 1994; Pearson and Thompson, 1993; Shen et al., 1999; Stys et al., 
1990; Yoles et al., 1997). The relationship between these processes is complex and it is 
likely that more than one signal leads to RGC death induced by axonal damage.   
The hypothesis that neurotrophin deprivation contributes to RGC death after 
axonal injury has received considerable attention because a lack of target-derived brain-
derived neurotrophic factor (BDNF) or nerve growth factor (NGF) leads to apoptotic 
death of developing RGCs (Chau et al., 1992; Nurcombe and Bennett, 1981; Rabacchi et 
al., 1994; Thoenen et al., 1987). Although the role of neurotrophins in the maintenance of 
adult RGCs is less clear, there is substantial evidence showing that administration of 
exogenous BDNF promotes robust RGC survival in a variety of optic nerve injury 
paradigms (Chen and Weber, 2001; Di Polo et al., 1998; Klöcker et al., 2000; Mansour-
Robaey et al., 1994; Mey and Thanos, 1993; Peinado-Ramon et al., 1996). Upon binding 
of BDNF to its cognate receptor TrkB, multiple signaling pathways are activated 
including the extracellular signal-regulated kinases 1/2 (ERK1/2) and the 
phosphatidylinositol-3 kinase (PI3K)/Akt pathways (Kaplan and Miller, 2000). 
Endogenous activation of ERK1/2 and PI3K has been reported in RGCs in response to 
BDNF and other protective agents, and pharmacological inhibition of these molecules 
effectively blocks their survival effect (Cheng et al., 2002; Diem et al., 2001; Kermer et 
al., 2000; Schallenberg et al., 2009). Furthermore, we previously showed that viral 
vector-mediated stimulation of ERK1/2 was sufficient to protect RGCs from death 
induced by axotomy or ocular hypertension (Pernet et al., 2005; Zhou et al., 2005).  
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Oxidative signaling, caused by the imbalance between the production of reactive 
oxygen species (ROS) and their elimination by antioxidants, has been recognized as 
another central contributor to neuronal injury and death. ROS can modulate protein 
function by altering redox states leading to cysteine sulfhydryl oxidation. Oxidative 
cross-linking creates new disulfide bonds causing protein conformational changes and 
subsequent activation of cell death signals (Carugo et al., 2003; Park and Raines, 2001). 
Consistent with this, RGC viability has been shown to depend on the intracellular 
sulfhydryl redox state, with survival observed under mildly reducing conditions and 
increased death rates induced by sulfhydryl oxidation (Castagne and Clarke, 1996; 
Castagne et al., 1999; Geiger et al., 2002; Swanson et al., 2005).   
We recently demonstrated that ROS superoxide is a key signal triggered by 
axonal injury leading to RGC apoptosis. Using live imaging, we showed that there is a 
marked elevation of superoxide in RGCs soon after optic nerve axotomy, and that a 
decrease in intracellular superoxide levels delays RGC death in vivo (Kanamori et al., 
2010). Based on this, we hypothesized that reduction of oxidized sulfhydryls on critical 
proteins might attenuate the activation of death pathways that influence the fate of RGCs 
after injury. To test this, we developed reducing agents using a borane-protected 
phosphine backbone (Schlieve et al., 2006). Here we characterize a leading compound, 
bis (3-propionic acid methyl ester) phenylphosphine borane reducing complex 1 (PB1), 
and show that PB1 promotes RGC protection in rat paradigms of optic nerve injury. We 
demonstrate that, rather than inhibiting cell death pathways, PB1 leads to increased 
retinal levels of BDNF and that PB1-mediated RGC neuroprotection requires activation 
of ERK 1/2 in vivo. Our data support the conclusion that the reducing agent PB1 protects 
injured RGCs through activation of pro-survival pathways, and suggest a potential cross-
talk between intracellular redox regulation and activation of neurotrophin-related 
neuroprotective signals in retinal neurons. 
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IV.3. MATERIALS AND METHODS  
IV.3.1. Experimental animals  
All procedures were carried out in accordance with the Animal Research: 
Reporting In Vivo Experiments (ARRIVE) and the Canadian Council on Animal Care 
guidelines. The optic nerve axotomy model, a paradigm of acute axonal damage and 
RGC death, was carried out in adult Sprague-Dawley rats (Charles River, 180-200 g). 
The experimental glaucoma model, induced by ocular hypertension (OHT) surgery, was 
performed in retired breeder Brown Norway rats (Charles River, Canada; 300-400 g). 
Brown Norway rats were used for the experimental glaucoma model because they have a 
larger eye suitable for the OHT surgical procedure (Johnson et al., 1996; Morrison et al., 
1997). The number of animals used in each experiment (n) is indicated above the bar in 
the corresponding graph.   
IV.3.2. RGC retrograde labeling    
For quantification of neuronal survival, RGCs were retrogradely labeled with 
Fluorogold (2%, Fluorochrome, Englewood, CO) or DiI (3%, 1,1'-dioctadecyl-3,3,3’,3’-
tetramethyl-indocarbocyanine perchlorate; Molecular Probes, Junction City, OR). Tracers 
were dissolved in 0.9% NaCl containing 10% dimethyl sulfoxide (DMSO) and 0.5% 
Triton X-100. The superior colliculus was exposed bilaterally and a small piece of 
gelfoam (Pharmacia and Upjohn Inc., Mississauga, ON) soaked in tracer was applied to 
the surface. Seven days is the earliest time for detection of the entire RGC population 
after application of retrograde tracers to the rat superior colliculus (Vidal-Sanz et al., 
1988). Thus, to ensure that all RGCs were fully labeled prior to axonal injury, axotomy or 
OHT surgery were performed at 7 days after tracer application.    
IV.3.3. Optic nerve injury paradigms   
IV.3.3.1. Optic nerve axotomy  
Animals were deeply anesthetized (2% isoflurane, 0.8 liter/min) and the left optic 
nerve was carefully exposed within the dura and transected ~1 mm posterior to the globe. 
This procedure avoided injury to the ophthalmic artery and its branches. Fundus 
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examination was performed immediately after axotomy and 3-5 days later to check the 
integrity of the retinal circulation after surgery. Animals showing signs of compromised 
blood supply were excluded from the study.  
IV.3.3.2 Ocular hypertension (morrison model)  
Animals were anesthetized by intraperitoneal injection of 1 ml/kg of standard rat 
cocktail (100 mg/ml ketamine, 20 mg/ml xylazine, 10 mg/ml acepromazine). Unilateral 
elevation of intraocular pressure (IOP) was induced by a single injection of hypertonic 
saline solution (1.85 M NaCl) into an episcleral vein as previously described (Morrison et 
al., 1997), a procedure called OHT surgery. A plastic ring was applied to the ocular 
equator to confine the injection to the limbal plexus. Animals were kept in a room with 
constant low fluorescent light (40-100 lux) to stabilize circadian IOP variations (Jia et al., 
2000b; Moore et al., 1996). IOP was measured using a calibrated tonometer (TonoPen 
XL, Medtronic Solan, Jacksonville, FL) in awake animals to avoid the anesthetic-induced 
reduction of IOP (Jia et al., 2000a).   
IV.3.4. Phosphine-borane complex synthesis   
Phosphine-borane complex 1 (PB1) was synthesized according to previously 
published methods (Schlieve et al., 2006). Briefly, the intermediate bis (3-propionic acid 
methyl ester) phenylphosphine (Phosphine 1) was produced by adding potassium 
hydroxide to phenylphosphine dissolved in acetonitrile, cooling to 0ºC, and then slowly 
adding methyl acrylate, maintaining the temperature below 35ºC. The reaction product 
was heated at 50ºC for 8 h, washed and dried over MgSO4, then concentrated and 
purified by distillation as a clear liquid. Phosphine 1 was dissolved in tetrahydrofuran 
(THF) and cooled to 0ºC. Borane-THF was slowly added and allowed to react. The 
solvent was then removed under reduced pressure and the residue purified by flash 
chromatography producing PB1.     
IV.3.5. In vivo drug delivery  
PB1 (150 µM) or the mitogen activated protein (MAP) kinase kinase 1 (MEK1) 
inhibitor PD98059 (200 µM, Sigma, Oakville, ON) were dissolved in phosphate buffered 
saline (PBS) containing 0.1% DMSO (vehicle).  PB1, PD98059 or vehicle were injected 
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into the vitreous chamber of the injured eye using a Hamilton syringe fitted with a 32-
gauge glass microneedle. We selected a PB1 concentration of 150 µM administered in a 4 
µl volume, which yields an estimated final intravitreal concentration of 10 µM 
(approximate vitreous volume in rats: 60 µl), based on our previous in vitro study 
showing that this amount is an effective neuroprotective dose (Schlieve et al., 2006). The 
sclera was exposed and the tip of the needle was inserted at a 45° angle through the sclera 
and retina into the vitreous space using a posterior approach. This route of administration 
avoided injury to the iris or lens, which can promote RGC survival (Leon et al., 2000; 
Mansour-Robaey et al., 1994). The injection was performed within ~30 sec, after which 
the needle was gently removed. Some animals received two consecutive injections of 
PB1 and PD98059 or vehicle, through the same injection site, with a delay of 20 min 
between each injection. Surgical glue (Indermill, Tyco Health Care, Mansfield, MA) was 
used to seal the injection site.    
IV.3.6. Quantification of RGC soma and axons  
Quantification of RGC bodies or axons was performed in duplicate by an observer 
masked to the treatment assignments. For RGC density counts, rats were deeply 
anesthetized and perfused transcardially with 4% paraformaldehyde (PFA) and both eyes 
were immediately enucleated. Retinas were dissected and flat-mounted on a glass slide 
with the ganglion cell layer side up. RGCs were counted in three square areas at distances 
of 1, 2 and 3 mm from the optic disc in each of the four retinal quadrants (superior, 
inferior, nasal and temporal) for a total of 12 retinal areas encompassing a total area of 1 
mm2. For axon counts, animals received a transcardial injection of heparin (1000 U/kg) 
and sodium nitroprusside (10 mg/kg), followed by perfusion with 2% PFA and 2.5% 
glutaraldehyde. Optic nerves were dissected, fixed in 2% osmium tetroxide, and 
embedded in Epon resin. Semi-thin sections (0.7-µm thick) were cut on a microtome 
(Reichert, Vienna, Austria) and stained with 1% toluidine blue. RGC axons were counted 
at 1 mm from the optic nerve head in five non-overlapping areas (center, peripheral 
dorsal and peripheral ventral) encompassing a total area of 5.5 mm2 per nerve. The total 
area per optic nerve cross-section was measured using Northern Eclipse image analysis 
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software (Empix Imaging, Toronto, ON), and this value was used to estimate the total 
number of axons per optic nerve.    
IV.3.7. Western blot analysis  
Whole fresh retinas (n=4 per condition) were rapidly dissected and homogenized 
with an electric pestle (Kontes, Vineland, NJ) in ice-cold lysis buffer: 50 mM Tris (pH 
7.4), 1 mM EDTA, 150 mM NaCl, 1% NP-40, 5 mM Na fluoride, 0.25% Na 
deoxycholate and 2 mM NaVO3 supplemented with protease and phosphatase inhibitors. 
Retinal extracts (60–150 µg) were resolved on 10-15% SDS polyacrylamide gels and 
transferred to nitrocellulose membranes (Bio-Rad Life Science, Hercules, CA, USA). 
Non-specific binding was blocked by incubation in 10 mM Tris (pH 8.0), 150 mM NaCl, 
0.2% Tween 20 (TBST), and 5% bovine serum albumin (Fisher Scientific, Fair Lawn, 
NJ) for 1 h at room temperature (20ºC). Membranes were then incubated with the 
following primary antibodies: BDNF (1 µg/ml, Promega, Madison, WI), phospho-
ERK1/2 (Thr185/Tyr187, 1 µg/ml, Invitrogen-BioSource, Carlsbad, CA), ERK1/2 (1 
µg/ml, Invitrogen-BioSource), phospho-Akt (Thr308, 0.14 µg/ml, Cell Signaling, 
Danvers, MA), Akt (0.2 µg/ml, Cell Signaling), phospho-ASK1 (Thr838, 0.5 µg/ml, Cell 
Signaling), ASK1 (0.5 µg/ml, Cell Signaling), phospho-JNK (Thr183/Tyr185, 0.8 µg/ml, 
Cell Signaling), JNK (0.4 µg/ml, Cell Signaling), phospho-p38 (Thr180/Tyr182, 0.3 
µg/ml, Cell Signaling), p38 (0.2 µg/ml, Cell Signaling), or ß-actin (0.5 µg/ml, Sigma). 
Blots were washed in TBST and incubated in the following peroxidase-linked secondary 
antibodies: anti-mouse or anti-rabbit (0.5 µg/ml, GE Healthcare, Little Chalfont Bucks, 
UK) or anti-chicken (0.5 µg/ml, Promega). Blots were developed using 
chemiluminescence reagents (ECL or Plus-ECL, Perkin Elmer Life and Analytical 
Sciences, Woodbridge, ON) and exposed to autoradiographic film (X-OMAT; Eastman 
Kodak, Rochester, NY). Densitometric analysis was performed using Scion Image 
software (Scion Corporation, Frederick, MD) on scanned autoradiographic films obtained 
from a series of 3 independent western blots each carried out using retinal samples from 
distinct experimental groups. The densitometric values obtained for BDNF were 
normalized with respect to their ß-actin loading controls in the same blot to obtain the 
final ratios. The densitometric values for phosphorylated (active) proteins were 
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normalized with respect to their loading (non-phosphorylated) controls in the same blot to 
obtain the final phosphorylated/total protein ratios.   
IV.3.8. Statistical analysis   
Data analysis and statistics were carried out using GraphPad InStat software 
(GraphPad Software Inc., San Diego, CA) by performing one-way analyses of variance 
(ANOVA) followed by Bonferroni multiple comparison post-hoc testing.         
 
IV.4. RESULTS 
IV.4.1. Intraocular delivery of the phosphine-borane compound PB1 protects RGCs 
from axotomy-induced death  
PB1, an analogue of tris (2-carboxyethyl) phosphine (TCEP), was designed to 
contain a borane-protected phosphine group to prevent oxidation, thus enhancing the 
stability of the molecule (Schlieve et al., 2006). The phenyl group in PB1 is non-polar 
and increases the cell permeability of this compound. Once inside the cell, the methyl 
esters are cleaved by intracellular esterases resulting in an anionic molecule that is less 
likely to exit the cytosol (Fig.1). We previously demonstrated that PB1-mediated 
inhibition of sulfhydryl oxidation protects early postnatal, acutely axotomized RGCs in 
vitro (Schlieve et al., 2006), but the role of PB1 on the survival of adult RGCs in vivo 
was not established.   
To investigate this, we first examined PB1-induced RGC survival following 
axotomy of the optic nerve, an injury modality that leads to rapid apoptotic RGC death 
(Berkelaar et al., 1994). Eyes that received an intraocular injection of PB1 showed robust 
RGC neuroprotection compared to control eyes injected with vehicle (Fig. 2A-C). 
Previous studies, including ours, have demonstrated that virtually all RGCs survive for 4 
to 5 days after axotomy and then die rapidly: the RGC population is reduced to ~50% by 
day 7 and to ~10% by day 14 post-lesion (Berkelaar et al., 1994; Cheng et al., 2002; 
Mansour-Robaey et al., 1994). Figure 2D shows that in PB1-treated eyes, 66% of RGCs 
survived at one week after axotomy (1,434 ± 37 RGCs/mm2, mean ± S.E.M., n=6) 
compared to only 47% remaining in vehicle-treated eyes (1,011 ± 37 RGCs/mm2, n=4) 
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(ANOVA, P < 0.001). This neuroprotective effect was still substantial at 2 weeks after 
axotomy following PB1 treatment at the time of axotomy and one week later, accounting 
for 25% of RGC survival (533 ± 90 RGCs/mm2, n=4)  compared to 11% survival 
afforded by vehicle (239 ± 25 RGCs/mm2, n=4) (ANOVA, P < 0.01). These data indicate 
that the reducing agent PB1 promotes adult RGC neuroprotection following acute optic 
nerve injury. Microglia and macrophages, which may have incorporated Fluorogold after 
phagocytosis of dying retinal ganglion cells, were excluded from our analysis based on 
well-established morphological criteria (Kacza and Seeger, 1997; Thanos, 1991). 
Microglia were identified by their invariably smaller cell size, visible process 
ramifications, and lack of axons  (Figs. 2E, 2F) as previously described by us (Lebrun-
Julien et al., 2009).    
IV.4.2. PB1 protects RGC soma and axons in experimental glaucoma   
To determine if PB1 was able to promote RGC survival in a paradigm of optic 
nerve injury resembling glaucomatous pathophysiology, we tested its neuroprotective 
effect in a rat ocular hypertension (OHT) model. Gradual increase of eye pressure and 
progressive death of RGCs are observed in this model, with an excellent linear 
correlation between IOP increase and RGC loss (Chauhan et al., 2002; Johnson et al., 
1996; Morrison et al., 1997). Inner retinal atrophy, optic nerve degeneration, and optic 
nerve head remodeling in this model are similar to those seen in human glaucoma, 
therefore this model is considered a premier in vivo paradigm of this optic neuropathy. 
PB1 was injected intravitreally two weeks after OHT surgery to allow for IOP 
stabilization and RGC survival was examined at 3 or 5 weeks after OHT. Analysis of DiI-
positive RGCs in retinal whole mounts showed that PB1 led to higher neuronal densities 
in glaucomatous eyes compared to control eyes at 3 weeks after OHT (Figure 3A-C). 
Quantitative analysis of RGC neuroprotection demonstrated that 82% of RGCs survived 
in the presence of PB1 (1,484 ± 36 RGCs/mm2, mean ± S.E.M., n=6) compared to 59% 
in control eyes treated with vehicle (1,072 ± 64 RGCs/mm2, n=6) (Fig. 3D, ANOVA, p < 
0.001). The mean sustained IOP elevation in PB1- and vehicle-treated eyes was similar, 
allowing for a reliable comparison between these groups.  
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Glaucoma is characterized by the degeneration of RGC axons in the optic nerve 
followed by the progressive loss of cell bodies (Quigley, 1999; Schwartz et al., 1999), 
hence we also investigated the effect of PB1 on RGC axonal protection following ocular 
hypertensive damage. Analysis of axons in optic nerves treated with PB1 at 3 weeks after 
OHT demonstrated a higher number of RGC axons with normal morphology compared to 
vehicle-treated optic nerves, which featured extensive disarray of fascicular organization 
and degradation of myelin sheaths (Figure 4A-C). Axonal quantification in optic nerve 
cross sections showed that PB1 protected a significant number of RGC axons from 
glaucomatous damage (69% = 70,058 ± 4,547 axons, n=10) compared to vehicle-treated 
controls (55%= 55,997 ± 4,531 axons, n=6) (Fig. 4D, ANOVA, p < 0.001). Although a 
slight trend in RGC soma and axon protection was observed at 5 weeks after OHT (Table 
1), this effect was not statistically significant suggesting that the biological activity of a 
single dose of PB1 has a limited duration in vivo. Collectively, these results indicate that 
PB1 attenuates the loss of both RGC soma and axons in experimental glaucoma.   
IV.4.3. PB1-mediated RGC neuroprotection requires activation of the extracellular 
signal-regulated kinases 1/2 pathway   
Oxidative stress has been linked to the activation of stress-activated protein kinase 
(SAPK) signaling and subsequent cell death (Cross and Templeton, 2004; Sumbayev and 
Yasinska, 2005). To gain mechanistic insight into how PB1 promoted RGC 
neuroprotection in vivo, we asked whether PB1 leads to inhibition of pro-apoptotic 
pathways. We chose the axotomy model for these experiments because the onset of RGC 
death in this injury paradigm is extremely consistent, starting at 4-5 days after optic nerve 
lesion (Berkelaar et al., 1994). This predictable time-course of RGC loss allowed us to 
examine protein changes prior to neuronal death (24 hrs), which are more likely to 
influence RGC fate. Furthermore, a well-defined burst of superoxide occurs within 24 hrs 
of optic nerve axotomy (Kanamori et al., 2010).  
We first examined the activation of retinal Apoptosis Stimulating Kinase 1 
(ASK1), a SAPK and mitogen-activated protein kinase kinase kinase (MAPKKK) family 
member, which is activated by ROS and has been shown to mediate RGC death (Harada 
et al., 2006; Harada et al., 2010). ASK1 is normally bound to reduced thioredoxin, a 
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protein disulfide oxidoreductase that prevents ASK1 autophosphorylation. Oxidation of 
cysteine thiols in thioredoxin results in its dissociation from ASK1, triggering ASK1 
autophosphorylation and downstream stimulation of c-Jun NH2-terminal kinase (JNK) 
and p38 death signaling (Hatai et al., 2000; Ichijo et al., 1997; Saitoh et al., 1998). If PB1 
exerted RGC neuroprotection via the regulation of ASK1, a decrease in phosphorylated 
ASK1 (P-ASK1) following PB1 treatment would be expected. Western blot analysis 
demonstrated low but detectable levels of phosphorylated ASK1 in intact (non-injured, 
non-treated) retinas (Fig. 5A). An increase in phospho-ASK1 was observed in control, 
axotomized eyes treated with vehicle, however, PB1 failed to significantly reduce the 
levels of activated ASK1. Consistent with this, the levels of ASK1 downstream effectors 
JNK (P-JNK, Fig. 5B) or p38 (P-p38, Fig. 5C) were not affected by PB1. These results 
suggest that PB1-mediated RGC neuroprotection does not involve the ASK1 pathway.  
An alternative possibility is that PB1 results in the stimulation of pro-survival 
signals required for RGC viability after injury. To test this hypothesis, we investigated 
the levels of BDNF and its downstream effectors ERK1/2, Akt and CREB in axotomized 
retinas exposed to PB1 or vehicle. In control axotomized eyes treated with vehicle there 
was a slight, but significant, increase in BDNF compared to intact eyes (Fig. 6A), which 
is consistent with previous reports showing a ~50% increase in retinal BDNF mRNA 
after axotomy (Gao et al., 1997; Hirsch et al., 2000). Surprisingly, PB1 led to a 4-fold 
increase (200%) in BDNF protein levels after axotomy compared to intact retinas. 
Consistent with this, PB1 produced a robust activation of the BDNF effector ERK1/2 (P-
ERK1/2, Fig. 6B) while Akt and the transcription factor CREB remained unchanged (P-
Akt and P-CREB, Figs. 6C, D). Intraocular administration of PB1 at 2 weeks after OHT 
also resulted in enhanced ERK1/2 activation (Fig. 6E) suggesting that PB1 promotes 
RGC survival through activation of this pathway after acute and chronic optic nerve 
injury.  
To establish whether ERK1/2 signaling was involved in PB1-mediated survival of 
axotomized RGCs, we co-injected PB1 with PD98059, a pharmacological inhibitor of 
MEK1, the obligate upstream activator of ERK1/2 (Dudley et al., 1995). We previously 
established that the optimal dose of PD98059 to selectively inhibit retinal Erk1/2 in vivo 
without affecting other pathways, including Akt, is 200 µM (16.7 µM intravitreal 
127 
 
 
 
concentration) (Cheng et al., 2002). Figure 7 shows that co-administration of PB1 and 
PD98059 resulted in complete inhibition of the survival effect produced by PB1, 
characterized by low RGC densities similar to those found in vehicle-treated retinas, at 1 
week after optic nerve transection. Together, these findings demonstrate that the ERK1/2 
pathway is essential for PB1-mediated survival of injured adult RGCs in vivo.                      
 
IV.5. DISCUSSION   
The generation of an intracellular superoxide burst is a critical molecular event 
underlying RGC death after axonal injury (Geiger et al., 2002; Kanamori et al., 2010; 
Lieven et al., 2006; Nguyen et al., 2003; Swanson et al., 2005). Superoxide increases 
dramatically in RGCs at the single-cell level, soon after optic nerve axotomy, and 
precedes RGC apoptosis (Kanamori et al., 2010). Human glaucomatous retinas contain 
high levels of the lipid peroxidation indicator 4-hydroxy-2-nonenal (HNE), which leads 
to protein modification induced by superoxide (Tezel et al., 2010). Administration of 
pegylated superoxide dismutase-1 (SOD), which catalyzes the dismutation of superoxide 
into oxygen and hydrogen peroxide (H2O2), attenuates RGC death (Kanamori et al., 
2010; Schlieve et al., 2006) supporting the idea that interfering with superoxide 
generation might be beneficial. However, the translation of a protein-based therapy that 
requires intracellular delivery is considerably more challenging than a small molecule 
approach. In this study, we characterized the neuroprotective role and mechanism of 
action of PB1, a small reducing compound with several advantages including good cell 
permeability, the ability to form a high intracellular concentration gradient, and stability.   
Our data demonstrate that intraocular delivery of PB1 promotes RGC survival in 
vivo following traumatic optic nerve injury (axotomy) and ocular hypertension damage 
(experimental glaucoma). The finding that PB1-mediated neuroprotection was observed 
in these distinct injury paradigms, despite the fact that the RGC response to different 
types of lesion may vary widely, suggests that PB1 regulates a conserved pathway and 
underlines its translational potential to human disease. Glaucoma has been defined as an 
axogenic disease, characterized first by the degeneration of RGC axons in the optic nerve 
followed by the progressive loss of cell bodies (Schwartz et al., 1999). In the 
experimental glaucoma model, we performed quantitative analysis of the neuroprotective 
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effect of PB1 on two major RGC compartments: soma and axons. Consistent with the 
idea that the primary site of degeneration in glaucoma is at the level of the axon, we 
found that all eyes had more pronounced axonal loss than cell body loss. However, 
intraocular injection of PB1 protected a similar proportion of RGC soma and axons 
within the optic nerve at 3 weeks after OHT. The ability to protect all RGC compartments 
following hypertension damage is paramount for the preservation of neuronal function 
and vision; hence it is an important attribute of PB1. Interestingly, functional studies in 
macaque monkeys subjected to experimental glaucoma demonstrated that only subtle 
visual field defects are detected despite massive loss (>50%) of RGCs, whereas vision 
loss increases dramatically with more advanced glaucoma (Harwerth et al., 1999). 
Therefore, structural protection of a proportion of RGC soma and axons, as afforded by 
PB1, might be sufficient to preserve functional vision. The lack of significant soma or 
axon protection at 5 weeks after OHT suggests that a single dose of PB1 confers limited 
biological activity in vivo. A priority of future studies will be to devise sustained delivery 
strategies, such as PB1 coupled to nanoparticles, to achieve long-term neuroprotection.    
What are the molecular mechanisms underlying PB1-mediated RGC survival? 
Evidence from studies on cell death inhibition induced by manipulation of the 
mitochondrial electron transport chain is consistent with PB1 acting externally to the 
mitochondrial matrix (Seidler et al., 2010). Phosphines might scavenge superoxide 
directly, but our studies with both borane-protected phosphines and deprotected PB1 have 
ruled out significant superoxide scavenging (Niemuth N.J., Lieven C.J., Thompson A.F., 
Levin L.A., unpublished data). The redox system can regulate the function of proteins 
involved in cell death and survival by modifying gene expression, posttranslational 
modifications (e.g. phosphorylation) and stability. In most cases, superoxide stimulates 
stress-activated protein kinase (SAPK) signaling and cell apoptosis (Sumbayev and 
Yasinska, 2005). Therefore, we hypothesized that PB1 might promote survival through 
inhibition of pro-apoptotic pathways. ASK1, a crucial redox sensor for initiation of the 
SAPK signaling cascade, leads to JNK and p38 stimulation and subsequent cell death 
(Kyriakis and Avruch, 2001). Contrary to our expectations, PB1 did not reduce the levels 
of phosphorylated (active) ASK1, JNK or p38 in axotomized retinas. Thus, we conclude 
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that the regulation of the SAPK cell death signaling pathway is not a target for PB1-
induced neuroprotection.   
We then considered an alternative scenario involving PB1-induced modification 
of RGC survival pathways. PB1 stimulated a robust increase of retinal BDNF levels that 
was several-fold higher than that observed in control axotomized eyes. Emerging data 
supports a tight redox regulation of transcription factors that encode cell survival proteins 
(Trachootham et al., 2008). The transcriptional regulation of BDNF is complex and often 
depends on activity-driven events that involve Ca+2-responsive elements and cAMP-
responsive elements (CRE) required for promoter transactivation (Shieh et al., 1998; Tao 
et al., 1998). CREB is an important transcription factor because it regulates BDNF gene 
expression, it also responds to BDNF by stimulating the transcription of pro-survival 
molecules such as Bcl-2 (Bonni et al., 1995; Finkbeiner et al., 1997; Wilson et al., 1996). 
Moreover, CREB plays a role in the regulation of ROS detoxification (Herzig et al., 
2001; Krönke et al., 2003; Lee et al., 2009) and it is susceptible to redox regulation 
(Bedogni et al., 2003). PB1 failed to increase CREB activation, suggesting that other 
mechanisms including CREB-independent transcription, stability, subcellular 
localization, and translational events may underlie PB1-induced BDNF upregulation.  
BDNF binds to its signaling receptor TrkB, which is abundantly expressed by 
adult RGCs (Jelsma et al., 1993; Pérez and Caminos, 1995; Rickman and Brecha, 1995), 
and activates the pro-survival ERK1/2 and Akt pathways. Our data demonstrate that 
ERK1/2, but not Akt, was activated following PB1 administration. This finding is 
consistent with our previous observation that combined BDNF and TrkB upregulation 
promoted RGC survival exclusively via ERK1/2, while Akt was not involved (Cheng et 
al., 2002). It is possible that endogenous BDNF leads to differential activation of 
downstream pathways depending on the redox status of the cell. In PB1-treated retinas, 
BDNF might selectively use the ERK1/2 pathway to promote RGC neuroprotection. In 
addition, PB1 might directly activate upstream molecules that converge on ERK1/2. This 
latter possibility is supported by the fact that autophosphorylation and activation of 
tyrosine kinase receptors, such as TrkB, can occur by direct thiol modification of the 
receptor (Chen et al., 1998). Similarly, the activity of Ras, an upstream activator of 
ERK1/2, is modulated by redox regulation (Lander et al., 1996; Mallis et al., 2001). 
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Nonetheless, the complete inhibition of RGC survival exerted by PB1 in the presence of 
PD98059 strongly supports our hypothesis that ERK1/2 activity is essential for PB1-
mediated RGC neuroprotection in vivo.   
In summary, we demonstrate that PB1, a novel phosphine-borane complex, 
promotes RGC neuroprotection in vivo through activation of the ERK1/2 pathway. 
BDNF is a potent anti-apoptotic factor for RGCs, but its clinical application has been 
hampered due to pleiotropic effects leading to non-specific signaling, potential toxicity 
and low diffusion rates (Barinaga, 1994; Verrall, 1994). The identification of small 
molecule compounds that mimic some of the beneficial effects of BDNF, such as PB1, is 
of clinical interest. Our study offers the interesting and unexpected possibility that redox 
homeostasis in RGCs can converge on neurotrophin-related pathways to promote survival 
after axonal injury.  
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Figure 1. Chemical structure of bis (3-propionic acid methyl ester) phenylphosphine 
borane reducing complex 1 (PB1).  
The borane group protects the phosphine from oxidation increasing chemical stability 
during storage and before administration. The non-polarity of the phosphine-borane and 
the phenyl group contribute to the ability of PB1 to readily cross cell membranes. The 
methyl esters are cleaved by extracellular amines and/or intracellular esterases, resulting 
in an anionic molecule that is unlikely to exit the cytosol and thus forms a strong 
intracellular concentration gradient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
138 
 
 
 
Figure 2. The phosphine-borane compound PB1 protects RGCs from axotomy-
induced death.  
Retinal flat mounts show Fluorogold-labeled RGCs from non-injured, non-treated eyes 
(A, Intact) and axotomized PB1-treated (B) or vehicle-treated (C) eyes. Scale bars: 100 
µm. (D) Quantitative analysis of RGC survival following injection of PB1 (solid bars) or 
vehicle (hatched bars) at the time of axotomy (n=4-6 rats/group) (ANOVA, ***: 
P<0.001). Animals examined at two weeks received an injection at the time of axotomy 
and a week later. The density of RGCs in intact, non-injured Sprague-Dawley rat retinas 
is shown as reference (open bar, 100%, n=8). Data are expressed as RGCs/mm2 (mean ± 
S.E.M). (E, F) Microglia and macrophages (arrowheads) that may have incorporated 
Fluorogold after phagocytosis of dying retinal ganglion cells (arrows) were excluded 
from our analysis based on their distinct morphology. Scale bars: e, f = 10 μm. 
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Figure 3. PB1 protects RGC soma in experimental glaucoma.  
Retinal flat mounts show DiI-labeled RGCs from non-injured, non-treated eyes (A, 
Intact) and glaucomatous PB1-treated (B) or vehicle-treated (C) eyes. Scale bars: 100 
µm. (D) Quantitative analysis of RGC survival following injection of PB1 (solid bars) or 
vehicle (hatched bars) at three weeks after ocular hypertension surgery (OHT) (n=6 
rats/group) (ANOVA, ***: P<0.001). The density of RGCs in intact, non-injured Brown 
Norway rat retinas is shown as reference (open bar, 100%, n=6). Data are expressed as 
RGC densities (RGCs/mm2, mean ± S.E.M). 
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Figure 4. PB1 attenuates axonal loss in experimental glaucoma.  
Cross-sections of optic nerve segments from non-injured eyes (A, Intact) and 
glaucomatous eyes treated with PB1 (B) or vehicle (C) at 3 weeks after ocular 
hypertension surgery (OHT). PB1-treated eyes displayed a larger number of axonal fibers 
with normal morphology compared to vehicle-treated control eyes, which showed 
extensive axon degeneration. Scale bars: 20 µm. (D) Quantitative analysis of RGC axons 
in optic nerves after treatment with PB1 (solid bar), or vehicle (hatched bar) (n=6-10 
rats/group) (ANOVA, ***: P<0.001). The number of axons in the non-injured Brown 
Norway rat optic nerve is shown as reference (open bar, 100%, n=9). Data are expressed 
as the total number of RGC axons per optic nerve (mean ± S.E.M.). 
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Figure 5. The pro-apoptotic ASK1 signaling pathway is not regulated by PB1.  
Western blots of total retinal extracts probed with antibodies that selectively recognize 
phosphorylated (active) ASK1, JNK or p38. Protein samples were collected from non-
injured, non-treated eyes (Intact) or axotomized eyes treated with PB1 or vehicle and 
collected at 24 hrs post-lesion. (A) An injury-induced increase in phospho-ASK1 (P-
ASK1) was observed in control, axotomized eyes treated with vehicle. PB1 failed to 
significantly reduce the levels of active ASK1 after axotomy. The levels of ASK1 
downstream effectors P-JNK (B) or P-p38 (C) were not affected by PB1. The 
densitometric values are the ratio of phospho-proteins normalized to their loading (non-
phosphorylated) controls in the same blot for intact (open bars), PB1-treated (solid bars) 
or vehicle-treated (hatched bars) eyes (n=4/group) (ANOVA, ***: P<0.001). 
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Figure 6. PB1 increases retinal BDNF and activates ERK1/2.  
(A) PB1 led to a 4-fold increase in BDNF protein levels after axotomy compared to intact 
retinas. (B) Robust activation of the BDNF effector ERK1/2 was observed in PB1-treated 
axotomized eyes (P-ERK1/2), while Akt (P-Akt, C) and CREB (P-CREB, D) remained 
unchanged. The densitometric values are the ratio of phospho-proteins normalized to 
their loading (non-phosphorylated) controls in the same blot, or ß-action in the case of 
BDNF, for intact (open bars), PB1-treated (solid bars) or vehicle-treated (hatched bars) 
eyes (n=4/group) (ANOVA, ***: P<0.001, *: p < 0.05). 
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Figure 7. PB1-mediated RGC neuroprotection requires activation of ERK1/2.  
(A-C) Retinal flat mounts show that co-administration of PB1 and the MEK1 inhibitor 
PD98059, injected intravitreally at the time of optic nerve transection, resulted in 
inhibition of the survival effect produced by PB1 at 1 week after optic nerve transection. 
(D) Quantitative analysis of Fluorogold-labeled neurons in eyes treated with PB1 and 
PD98059 (gray bar) showed that RGC density at 1 week post-lesion was similar to that 
found in control retinas treated with vehicle (hatched bar) (n=4-6/group) (ANOVA, ***: 
P<0.001). Data are expressed as RGCs/mm2 (mean ± S.E.M). 
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IV.7. TABLES  
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V.1 STRUCTURAL PROTECTION IN GLAUCOMA  
V.1.1 Galantamine, an acetylcholinesterase inhibitor, protects RGCs soma against 
IOP induced cell death. 
In the first article presented in this thesis (Chapter 2), I explored the 
neuroprotective properties of galantamine in experimental glaucoma. For more than a 
decade, galantamine hydrobromide has been taken orally by Alzheimer's disease patient, 
resulting in optimum concentrations in the brain and providing significant improvements 
in their cognitive functions (Bores et al., 1996; Jann et al., 2002; Scott and Goa, 2000). 
Studies in human, dogs, mice and rats has shown that intraperitoneal, intravenous and 
oral administration of  radioactively labeled galantamine is followed by rapid absorption 
and presence of galantamine in the plasma and brain tissues of the subjects (Mannens et 
al., 2002; Sweeney et al., 1989). Our data showed that systemic administration of 
galantamine significantly improves the survival of RGC somata. Systemic treatment with 
galantamine did not reduce the IOP in glaucomatous eyes and was able to significantly 
delay RGC death in an IOP-independent model of traumatic optic nerve damage 
(axotomy).  
Unlike nicotinic or muscarinic agonists, galantamine has several advantages for 
the treatment of chronic neurodegenerative diseases like glaucoma. First, galantamine is a 
small molecule which easily crosses the blood-retinal-barrier. Second, the effect of 
galantamine is mediated by increasing the availability of ACh through inhibition of the 
AChE enzyme. Also, the allosteric potentiating properties of galantamine on nAChRs 
might enhance the sensitivity of these receptors and therefore improve the cholinergic 
signaling (Schrattenholz et al., 1996). We found that compared to other AChE inhibitors 
like donepezil, galantamine has a higher neuroprotective effect which this will translate 
into better long-term tolerability for galantamine. Unlike galantamine (a competitive 
AChE inhibitor), donepezil is a non-competitive AChE inhibitor and in the long-term can 
lead to downregulation of AChRs and development of resistance to the drug (Farlow, 
2003; Wilkinson, 1999). 
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V.1.2. Phenylphosphine borane reducing complex 1 (PB1), promotes RGC survival 
in different paradigms of optic nerve injury. 
In the third article presented here (Chapter 4), we described the neuroprotective 
properties of a small molecule free radical scavenger, PB1, in experimental glaucoma. 
The evidence gathered from glaucoma patients and experimental animals suggests that 
oxidative damage is a major contributor to the pathology of glaucoma (Izzotti et al., 
2006; Tezel, 2006). Recent studies demonstrated that production of superoxide precedes 
RGC apoptosis and its levels increase dramatically at the single-cell level (Kanamori et 
al., 2010). Therefore, neutralizing excessive intracellular superoxide could provide 
neuroprotection.  
To use a scavenging compound for therapeutic purposes, it must meet at least two 
requirements: high cellular permeability for easy delivery and high stability. PB1 is a 
phosphine based scavenger which contains a borane atom to protect the phosphine from 
oxidation and increase the chemical stability of the compound during storage and 
administration. In addition, having a non-polar phenyl group increases the ability of PB1 
to cross the cell membranes. PB1 has been designed to inhibit oxidation of sulfhydryl 
groups on critical cellular molecules. Our data demonstrate that intravitreal delivery of 
PB1 in glaucomatous eyes, significantly promotes RGC survival. PB1 was also 
neuroprotective in the traumatic optic nerve injury (axotomy) and improved survival of 
RGCs. PB1 was injected intravitreally two weeks after OHT and RGC survival was 
examined at three or five weeks after OHT. PB1 extended the survival of damaged RGCs 
for weeks after initial delivery, a fact that highlights the importance of ROS neutralizing 
early in the development of the glaucoma. 
Since labeling of RGCs with tracers like Fluorogold and DiI is one of the major 
techniques in our laboratory, we have established a protocol to identify the migratory 
phagocytic cells (that uptake the cell debris and the tracer) in order to exclude them from 
our RGC quantification. As showed in the Figure 2, E-F, Chapter 4, page 146; the 
phagocytic cells are detectable based on their intense Fluorogold content, thin and 
elongated cell body and their long processes. To reconfirm the identity of these cells, 
immunostaining with specific antibodies against the microglia and macrophage 
(isolectin-B4 and ED-1) has been used in our laboratory (Cheng et al., 2002). In general, 
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due to slower RGC death rate in glaucoma there are fewer phagocytic cells in the 
glaucomatous retinas at any given time compare to axotomy model. In the axotomy 
model, due to rapid rate and numerous concomitant RGCs death, the presence of 
phagocytic cells is more intense and demands trained eye to eliminate them from 
quantifications. However, an experienced researcher can easily distinguish phagocytic 
cells even in axotomy samples. We have recently adapted an immunostaining method for 
labeling RGCs that is based on detection of a protein called Brn3a, a transcription factor 
that is specifically expressed by RGCs; this technique allows easier and accurate 
quantification of RGCs in the retina (Nadal-Nicols et al., 2009).   
V.1.3. Protection of RGC axons in glaucoma 
One of the features of glaucomatous damage is the degenerative loss of RGC 
axons in the optic nerve. Loss of RGC axons becomes apparent as axonal bundles in the 
optic nerve develop irregularities and RGC axons become swollen and lose their myelin 
sheaths (Chauhan et al., 2002; Quigley et al., 1988). In our experimental glaucoma 
model, analysis of optic nerve cross-sections from glaucomatous eyes indicated a 
significant loss of axons at three and five weeks after induction of OHT. In the animals 
receiving daily treatment with galantamine, there was a significant increase in the number 
of healthy axons and integrity of the axonal bundles in the optic nerve. Therefore, RGC 
soma protection by galantamine is complemented by the RGC axonal protection.  
Despite mediating significant RGC soma survival, PB1 was only able to protect 
RGC axons up to three weeks after induction of OHT. The difference in the protective 
potentials of PB1 at the axonal and cell soma levels could be explained using two 
arguments. First, the promotion of RGC soma survival and axonal regeneration are 
mediated by different pathways. For instance, while AAV-mediated increase of FGF-2 
levels did not result in much RGC survival after axotomy, it significantly promoted 
regeneration of RGC axons (Sapieha et al., 2003). Conversely, Erk1/2 activation 
significantly improved RGCs survival after optic nerve injury but failed to induce RGC 
axon regeneration (Pernet et al., 2005). Galantamine, by activating different categories of 
ACh receptors, can simultaneously trigger several pathways and therefore mediate both 
RGC soma and axon protection. Since in our experiments PB1 treatment resulted in up-
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regulation of BDNF and activation of ERK1/2 pathway, it is expected that PB1 mainly 
promotes RGC soma protection. Secondly, the delivery rout might be an important factor 
affecting the capacity of PB1 and galantamine to achieve axonal protection. Galantamine 
was delivered systemically for the entire experimental period, ensuring its availability 
and facilitating access to the optic nerve via the blood circulation. PB1 however, was 
only delivered once and intravitreally, which greatly limited its availability and access to 
the optic nerve. In a view of the current limitations of PB1 treatment, future studies 
should take into consideration a time-release nanoparticle-based delivery system or eye 
drops to maximize neuroprotective effects of PB1. 
With regards to the timeline of the experiments, it might be argued that why our 
studies have not been extended beyond the 5 weeks after OHT surgery. In a previously 
published work in our laboratory, we have shown that RGC survival could be extended 
up to 7 weeks after OHT surgery (Zhou et al., 2005). However, in that case the 
neuroprotection was achieved by induction of a potent neuroprotective pathway through 
infecting the RGCs with a recombinant adeno-associated virus to transduce RGCs with 
genes encoding constitutively active MEK1. Compared to galantamine neuroprotection, 
the significant increase in the activation of Erk1/2 provides more robust protection of 
RGCs that could last for a longer period of time. I believe that galantamine represented 
significant neuroprotective ability in our experiments. However, as it is reflected in our 
functional experiments, rapid elevation of IOP and severity of the damage to the axons in 
this model, limits the prospects of the long term evaluation of galantamine 
neuroprotective profile. Therefore, to better evaluate the long-term neuroprotective 
potential of galantamine (beyond the 5 weeks), one might use an alternative glaucoma 
model like cauterization model with slower rate of IOP increase (Danias et al., 2006). 
V.1.4. Protection of retinal microvessels in glaucoma 
The findings presented in the second article of this thesis (Chapter 3) 
demonstrated that degenerative changes in glaucomatous retinas are not limited to RGCs 
but also affect retinal microvessels. Vascular atrophy and loss of microvasculature are 
characteristics of other neurodegenerative diseases like AD (Bailey et al., 2004; Weller et 
al., 2009). In AD, affected areas of the brain are marked by reduced capillary branching, 
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and loss of capillaries (Brown, 2010b; Challa et al., 2004). However, the current 
knowledge about the effect of glaucoma on the retinal microvasculature and their relation 
to RGCs death is limited. We initially detected a major capillary loss at five weeks after 
OHT; however, a more detailed analysis revealed that the loss of capillaries occurs as 
early as three days after OHT surgery. Our findings also indicated that galantamine 
administratation led to a higher density of retinal microvessels.  
Not only the vasoprotective effects of galantamine expand the therapeutic use of 
this drug, but it also opens the possibility of preventive treatment in glaucoma regarding 
vascular risk factors. The idea of a preventive strategy to minimize vascular damage is 
not new. For instance, loss of retinal capillaries is a major characteristics of diabetic 
retinopathy caused by leukocyte adhesion to the endothelium and loss of pericytes 
(Hammes et al., 2002; Joussen et al., 2001). Inhibition of leukostasis by drugs like 
captopril and losartan or application of NGF to prevent pericytes death significantly 
reduces the number of degenerating capillaries in experimental diabetes (Hammes et al., 
1995; Zhang et al., 2007b).  
Unlike RGCs that are irreversibly lost, the retinal capillaries are dynamic and 
their capacity to regenerate can provide important support for long-term neuronal 
protection. Such a strategy has been proposed for the treatment of diabetic retinas. In 
another approach, intravitreally injected endothelial precursor cells were able to migrate 
into damaged or empty basement membrane of string capillaries in the diabetic retinas, 
and repaired the injured vessels (Bhatwadekar et al., 2009; Caballero et al., 2007). Here 
we showed the retinal capillaries are indeed part of initial insult to the retina in glaucoma 
and that galantamine provides a novel, drug-based therapy for neuroprotection and 
vasoprotection in glaucoma. 
    
V.2. FUNCTIONAL PROTECTION IN GLAUCOMA 
V.2.1. Galantamine treatment results in the recovery of visual evoked potentials 
Visual information is converted to electrochemical signal by photoreceptors and 
relayed to the visual centers via RGC axons. The LGN is one of the main central targets 
of RGC axons in primates (Schiller and Malpeli, 1977). In the rodents, the majority of 
158 
 
 
 
RGC axons project to the superior colliculus (SC) and a smaller number to the dorsal 
lateral geniculate nucleus (dLGN) (Lund et al., 1976). Evidence shows that progression 
of glaucoma is often accompanied by visual deficits. Studies in primate glaucoma also 
indicate a significant reduction in light-stimulated responses in the visual cortex (Hare et 
al., 2001a). Cytochrome oxidase histochemistry also confirmed a significant reduction of 
functional inputs from RGCs to higher brain centers such as the LGN and visual cortex in 
primates with glaucoma (Crawford et al., 2001; Crawford et al., 2000).  
Pathological changes in the optic disk and damage to RGC axons are proposed to 
be the main cause of visual deficits. We found significant damage and loss of axons in 
the optic nerves at five weeks after induction of OHT. Therefore, it was not surprising 
that we failed to record any signal at the SC following flash stimulation of glaucomatous 
eyes. Galantamine treatment failed to recover the VEP signal despite the significant 
protection of RGC axons and soma. We hypothesized that sustained high IOP impairs the 
physiological function of surviving RGCs and therefore results in visual defects. To 
evaluate this hypothesis, we combined galantamine treatment with an IOP lowering 
strategy. In this protocol, the IOP in the glaucomatous eye was controlled by topical 
(corneal) application of timolol, a commonly used ß-adrenergic receptor blocker. This 
treatment resulted in partial the recovery of VEP in galantamine-treated animals. The 
recovery of VEP was not due to a neuroprotective effect of timolol because there was no 
functional recovery in the PBS treated animals and RGC survival did not significantly 
increase following timolol application. In conclusion, our functional studies highlight the 
importance of a combined therapeutic strategy for the treatment of glaucoma, one that 
incorporates both control of IOP regulation and neuroprotection of RGCs. 
With regards to an approach to have a better understanding about the health of 
RGCs at the end of experiments, two complementary methods could be used (besides 
VEP recordings). First, to use an immunostaining procedure like Brn3a, so we can 
exclusively label healthy and alive RGCs (Nadal-Nicols et al., 2009). Second, to apply 
the Fluorogold on the SC at the end of experiments instead of labeling the RGCs at the 
beginning; this method provides better information about the number of healthy RGCs 
that were able to pickup the fluorescent dye with their axonal terminals and transport it 
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back to their somata, therefore also represents the integrity of RGC connections to the 
brain centers. 
V.2.2. Galantamine improves retinal blood flow in glaucomatous eyes 
In the second article presented in this thesis (Chapter 3) we reported a significant 
recovery of retinal blood flow by galantamine. Neurovascular coupling is a well known 
activity-dependent phenomenon in the brain and retina. Stimulation of the retina by light 
flicker results in the dilation of retinal vessels leading to increase in retinal blood flow 
(Formaz et al., 1997; Ito et al., 2001; Scheiner et al., 1994).  
Insufficient retinal blood flow can affect the neuronal activity and consequently 
translate into an abnormal VEP response in glaucomatous eyes. One of the steps in our 
VEP recording protocol was first to ensure the animals have an ERGs within the normal 
range. ERG recordings provided important information about the integrity of the 
intraretinal signaling as we found significant reduction of the b-wave in a number of 
animals with high IOP. Reducing the retinal blood flow by application of Et-1 have 
shown to significantly decrease the magnitude of VEP response (Hara et al., 2005). 
Elevation of IOP can similarly affect the retinal blood flow, resulting in functional 
deficits (Chen and Budenz, 1998; Yaoeda et al., 2003). In fact one of our findings 
following the application of timolol was significant improvement of the ERGs (data not 
shown). This data indicates that survival and health of RGCs is only one of the factors 
necessary for functional recovery in glaucoma.  
The vasodilatory properties of galantamine, shown in our ex vivo experiments, is 
likely to lead the improved blood circulation in vivo. Nevertheless, the physical stress of 
high IOP in our experimental model demanded additional IOP lowering intervention for 
functional recovery. Visual deficits do not simply reflect IOP levels in glaucoma, as 
stepwise increases of IOP are better tolerated by healthy subjects than POAG patients 
(Pillunat et al., 1985). Therefore, it is likely that an underlying vasomodulatory problem 
in glaucomatous eyes plays a role in RGC death and disease progression in addition to a 
decline in normal retinal function.  
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V.3. MECHANISMS OF NEUROPROTECTION IN GLAUCOMA  
V.3.1. Acetylcholine receptors and galantamine-mediated neuronal and vascular 
protection 
Since galantamine is an allosteric potentiating ligand of nAChRs (Pereira et al., 2002; 
Samochocki et al., 2003), we initially hypothesized that its neuroprotective properties 
were mediated through nAChRs signaling. However, using both blockers of nAChRs and 
mAChRs, we found that mAChRs had a prominent role in galantamine-mediated 
neuroprotection. In our experiments with glaucoma model, the main method of drug 
delivery was daily i.p. injections of galantamine. However, intraocular application of 
galantamine was also used in the axotomy model. Intraocular injections of galantamine 
were in line with the intraocular injection of other drugs since systemic administration for 
a number of compounds (several muscarinic blockers) was not possible. Systemic 
application of muscarinic and nicotinic blockers used in our experiments had the risk of 
unwanted  side effects (like Pirenzepine) or was uneconomical; some of  them also did 
not cross the blood-retinal barrier. Scopolamine was the only muscarinic blocker capable 
of passing the blood-retinal barrier with minimum side effects and was used 
intraperitoneally along with galantamine in OHT experiments (Tang et al., 1997; Toide, 
1989; Wilson, 2001).  
Using subtype specific blockers of mAChRs, we found that M1 and M4 played a 
significant role in RGC survival, whereas galantamine-induced improvement of retinal 
blood flow and vascular protection depended on M1 and M3 subtypes. Studies on the 
retinal localization of mAChR subtypes in primate, rat and chick retinas showed that 
amacrine cells express M2 and M4 subtype, Müller cells express both M1 and M4 
subtypes and bipolar cells and horizontal cells express M3 subtype (Da Silva et al., 2008; 
Fischer et al., 1998; Yamada et al., 2003). G-protein-coupled mAChR regulate Ca2+ entry 
that is linked to several signal transduction pathways that mediate cellular survival 
(Figure V.1). On the same note, although expression of mAChRs has not been detected 
on RGCs; muscarine increases the intracellular Ca2+ in rabbit RGCs (Baldridge, 1996). 
Future studies on intracellular calcium levels after application of galantamine might 
provide a better understanding of the role of mAChRs on RGC survival.  
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Galantamine-mediated signaling through neighboring Müller glia or neurons may also 
lead to production of pro-survival factors that protect injured RGCs. For instance, 
increasing the antioxidant capacity of the retina could significantly improve RGC 
survival in a non-cell-autonomous manner. Oxidative stress has been proposed to be a 
major contributor in glaucomatous neurodegeneration. Müller cells and horizontal cells 
synthesize and release glutathione which protects the retina against oxidative damage 
(Pow and Crook, 1995). There are reports of reduction in retinal antioxidant capacity in 
experimental  glaucoma (Jann et al., 2002; Moreno et al., 2004). Muscarinic AChRs are 
involved in the activation of cellular antioxidant pathways, as shown in figure 1. 
Signaling through M1 subtype of mAChRs contributes to the regulation of Nrf2 activity 
(Espada et al., 2009). Nrf2 is a transcription factor that  controls  the expression of  genes 
containing AREs (Kensler et al., 2007). HIF-1 is another transcription factor linked to the 
cellular response in hypoxic conditions and M1 mAChR has been shown to be involved 
in HIF-1 regulation (Hirota et al., 2004). Therefore, galantamine treatment via activation 
of mAChRs on Müller and horizontal cells may increase the antioxidant capacity of the 
retina and improve RGC survival. These data support a model in which non-cell-
autonomous signaling events downstream of mAChR play a major role in galantamine-
induced RGC neuroprotection. Unlike RGCs, retinal and brain endothelial cells express 
the M1 and M3 subtypes of mAChRs (Elhusseiny et al., 1999; Sastry, 1985b), therefore, 
galantamine-mediated signaling through this receptors can directly activate pro-survival 
pathways in endothelial cells.  
Cholinergic signaling through mAChRs mediates vasodilation in the brain (Bény 
et al., 2008; Dauphin et al., 1994) and the presence of endothelial cells is necessary for 
this process (Schrattenholz et al., 1996). We similarly demonstrated that endothelial cells 
were necessary for galantamine-mediated relaxation of isolated retinal arterioles. 
Interestingly, endothelial cells are part of a non-neuronal cholinergic system due to 
expression of ChAT and possession of vesicular acetylcholine transporters (Kirkpatrick et 
al., 2001). This suggests that paracrine cholinergic signaling might contribute in 
endothelial cells vasodilatory functions. Muscarinic AChRs mediate release of Ca2+ from 
intracellular stores that triggers the production of endothelium-derived vasodilators like 
NO and prostacyclin (Fleming and Busse, 1999; Lückhoff et al., 1988). 
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FIGURE 1. 
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Figure 1. Muscarinic AChRs signaling and cell survival pathways. The M1, M3, and 
M5 mAChRs are selectively couple to the Gq/G11 type of G-proteins. Upon binding the 
ligand, these receptors undergo a conformational change exposing the binding site for the 
G-protein. The receptor then facilitates the exchange of G-protein-bound GDP for GTP 
that causes the dissociation of Gα from the Gβγ dimer. The GTP-bound Gα activates 
phospholipase C (PLC). Hydrolysis of phosphoinositol 4, 5-bisphosphate (PIP2) by PLC 
produces two intracellular messengers: 1,2-diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). Membrane bound DAG promotes the translocation of PKC from the 
cytoplasm to the membrane and its subsequent activation. PKC then activates the Ras and 
consequently MAPK survival pathway. IP3 by binding to IP3 receptors located on 
cytoplasmic calcium stores results in the opening of their Ca2+ channels and release of 
Ca2+ into the cytosol. Increase of cytoplasmic Ca2+ levels activates PKC and consequently 
through MAPK pathway or activation of transcription factors like Nrf2 promotes cell 
survival. The Gβγ remains anchored to the membrane and by facilitating the K+ influx 
result in membrane hyperpolarization. 
M2 and M4 receptors are coupled to Gi/o type of G-proteins. Upon binding the 
ligand receptor facilitates exchange of GDP for GTP on Gα resulting in dissociation of 
the heterotrimer G-protein components. Gα then interacts with adenylcyclase that 
decreases in cAMP levels.  The Gβγ activate the PI3K that promote cell survival via Akt 
or MAPK pathways. Interaction of Gβγ with calcium channel results in reduction of Ca2+ 
influx. Source of image: Mohammadali Almasieh. 
 
 
 
 
 
 
 
 
 
164 
 
 
 
Activation of M1/M3 receptors in the retina also results in the stimulation of 
nNOS activity and an increase in nNOS mRNA expression (Borda et al., 2005). 
Interestingly, in a eNOS deficient mice model,  retinal expression of nNOS was 
significantly up-regulated resulting in normal retinal vasculature development (Al 
Shabrawey et al., 2003). Therefore, galantamine-mediated signaling through neuronal 
mAChRs could activate nNOS and participate in the improvement of retinal blood flow. 
At the moment we are exploring several techniques to study the expression of 
muscarinic subtypes on RGCs and endothelial cells. Using the flow cytometry to separate 
RGCs and/or endothelial cells from retinal suspension and laser capture microdissection 
technique to separate RGCs from flat mounted retinas are currently in progress. 
Performing RT-PCR on this purified cell populations will help us to identify the specific 
muscarinic receptors expressed by these cells types. It is also important to remember 
allostric potentiating site of galantamine on nicotinic receptors is a different site from 
ligand binding site. Therefore it is not surprising if despite using nicotinic blockers, the 
allostric site still would be available for interaction with galantamine. The only way to 
study this interaction is to use an antibody called FK1, which selectively blocks the 
allosterically potentiating ligand site on nAChRs (Kihara et al., 2004). This antibody is 
not commercially available but we are in the process of a collaborative work to use this 
antibody in our future experiments. 
V.3.2. Molecular mechanisms of PB1-mediated RGC neuroprotection  
When the production of ROS overwhelms cellular antioxidant capacity, it results 
in disturbance of the redox system that in turn modifies activity of several cellular 
signaling pathways.  The redox state of key cellular proteins and enzymes controls the 
pattern of gene expression, posttranslational protein modifications and ion channels 
properties. Pro-apoptotic pathways like SAPK are activated as their redox sensor 
member, ASK1, initiates a signaling cascade that leads to JNK and p38 stimulation and 
subsequent cell death (Kyriakis and Avruch, 2001; Sumbayev and Yasinska, 2005). 
Based on the molecular characteristics of borane-protected phosphines, we expected that 
PB1, via scavenging superoxide, would block pro-apoptotic pathways. However, PB1 
treatment did not reduce the phosphorylated levels of ASK1 or p38 after axotomy.  
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Another possibility for PB1-induced RGC protection is through modification of 
survival pathways. The activity of a number of transcription factors like NF-κB, Nrf2 and 
HIF-1 is regulated by their redox state (Trachootham et al., 2008). Consequently, we 
found a significant increase of BDNF levels in the PB1-treated axotomized retinas. There 
are a number of studies suggesting that BDNF up-regulation is an early response in RGCs 
that undergo axonal injury. Retinal BDNF levels increase following both optic nerve 
axotomy (Gao et al., 1997) and experimental glaucoma (Guo et al., 2011; Rudzinski et 
al., 2004). A recent study used laser capture microdissection to produce RGC-enriched 
mRNA samples and was able to indicate a distinct increase in the BDNF mRNA levels 
early after ocular hypertension (Wang et al., 2011).  
PB1 might induce the BDNF up-regulation at the transcriptional level. The cAMP 
response element binding protein (CREB) is a transcription factor regulating BDNF gene 
expression and its activity is also subjected to redox modulation (Bedogni et al., 2003; 
Tao et al., 1998). CREB is involved in the regulation of ROS detoxification (Herzig et al., 
2001; Krönke et al., 2003; Lee et al., 2009) and in response to BDNF promotes 
transcription of pro-survival molecules such as Bcl-2 (Bonni et al., 1995; Finkbeiner et 
al., 1997; Wilson et al., 1996). CREB phosphorylation is triggered by  Ca2+ influx 
through receptors like NMDA and requires translocation of calmodulin from the 
cytoplasm to the nucleus (Deisseroth et al., 1998). NMDA receptors contain a redox 
modulatory site and oxidation or reduction state of this site modifies Ca2+  current through 
these receptors (Lei et al., 1992; Levy et al., 1990). In our experiments, PB1 treatment 
did not result in CREB activation, however, since CREB activity might be brief and the 
transcriptional control of BDNF is complex, this issue requires further study.  
The abundant expression of TrkB by RGCs translates BDNF stimulation into a 
strong pro-survival signaling through its downstream survival pathways ERK1/2 and Akt 
(Pérez and Caminos, 1995). In agreement with this hypothesis, we found significant 
increase in phospho-ERK1/2 levels in PB1 treated retinas.  PB1 treatment did not induce 
Akt activation, consistent with previous studies showing that combined BDNF and TrkB 
upregulation promoted RGC survival via ERK1/2 pathway but not Akt (Cheng et al., 
2002). Components of the ERK1/2 pathway are also regulated by their redox state. For 
instance, Ras, an upstream activator of ERK1/2 is under redox control (Lander et al., 
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1996; Mallis et al., 2001). In addition, the thiol site on the TrkB receptor itself can be 
subject of a modification that results in autophosphorylation and activation of the tyrosine 
kinase receptors (Chen et al., 1998 ).  
 
V.4. GENERAL CONCLUSIONS 
The work presented in this thesis introduces new approaches in the treatment of 
glaucoma and provides insight into novel molecular mechanisms involved in this disease. 
We characterized the neuroprotective effects of galantamine and PB1 in experimental 
glaucoma with the goals to extend RGC survival and to improve functional outcome. Our 
study revealed the potent role of galantamine in the protection of RGC somata and axons. 
Galantamine, by protecting the retinal capillaries and improving retinal blood flow, also 
targets potential vascular defects in glaucoma. We found that the neuroprotective effect 
of galantamine is mediated through activity of mAChRs. G-protein-coupled M1 and M4 
mAChR were involved in RGCs survival and axonal protection whereas vascular 
protection and blood flow improvement were mediated through M1 and M3 mAChRs. 
Galantamine has broad effect acting on other neurotransmitter systems, such as 
modulating the release of glutamate, serotonin and gamma-aminobutyric acid, thus 
expanding the possibility of RGC neuroprotection through other signaling pathways. The 
data from our functional studies suggest that an ideal therapy for glaucoma is to combine 
standard pressure controlling drugs and a neuroprotective treatment. 
Oxidative stress contributes to glaucoma pathology and an imbalance in the redox 
regulation of critical proteins might lead to RGC death. We showed that treatment with 
PB1, a phosphane-borane reducing compound, significantly promoted RGCs survival. 
Significant improvement in the survival of axotomized RGCs was also achieved with 
PB1. Survival was mediated through up-regulation of BDNF by PB1and activation of the 
pro-survival ERK1/2 pathway. Redox balance plays an important role in the regulation of 
BDNF production and ERK1/2 pathway activity; therefore our study offers the 
interesting possibility that redox homeostasis in RGCs can influence neurotrophin-related 
pathways that promote RGC survival after axonal injury. 
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ABSTRACT 
Paranodal axoglial junctions are essential for the segregation of myelinated axons 
into distinct domains and efficient conduction of action potentials. Here, we show that 
netrin-1 and deleted in colorectal cancer (DCC) are enriched at the paranode in CNS 
myelin. We then address whether netrin-1 signaling influences paranodal adhesion 
between oligodendrocytes and axons. In the absence of netrin-1 or DCC function, 
oligodendroglial paranodes initially develop and mature normally but later become 
disorganized. Lack of DCC or netrin-1 resulted in detachment of paranodal loops from 
the axonal surface and the disappearance of transverse bands. Furthermore, the domain 
organization of myelin is compromised in the absence of netrin-1 signaling: K+ channels 
inappropriately invade the paranodal region, and the normally restricted paranodal 
distribution of Caspr expands longitudinally along the axon. Our findings identify an 
essential role for netrin-1 and DCC regulating the maintenance of axoglial junctions. 
 
Key words: myelin; axoglial junction; paranode; septate-like junctions; Caspr; 
neurofascin 
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INTRODUCTION 
The functional division of myelinated axons into distinct domains is crucial for 
the establishment of saltatory conduction. Concentrated at nodes of Ranvier are high 
densities of voltage-gated sodium channels that depolarize the axonal membrane, 
generating and propagating the action potential (for review, see Poliak and Peles, 2003). 
Flanking the node are the paranodal axoglial junctions, where each layer of the myelin 
sheath terminates in a cytoplasm-filled membrane loop that tightly abuts the axon. The 
paranode separates the node from the juxtaparanodal domain, the outermost region of the 
internode (for review, see Poliak and Peles, 2003). Concentrated at the juxtaparanode are 
Shaker-type voltage-gated potassium channels, which maintain internodal resting 
potential by preventing hyperexcitation and action potential backpropagation after nodal 
Na+ influx (Wang et al., 1993; Chiu et al., 1999; Vabnick et al., 1999). The molecular 
mechanisms that regulate the formation and maintenance of paranodal junctions are not 
well understood.   
The tight association between paranodal axonal and glial membranes is thought to 
act as a barrier between the node and the juxtaparanode, isolating electrical activity at the 
node of Ranvier from the internode and preventing the lateral diffusion of axonal proteins 
among domains (Poliak and Peles, 2003). Ultrastructurally, the points of contact between 
oligodendrocyte and axolemmal membranes are characterized by the presence of 
electron-dense ridges called transverse bands (Tao-Cheng and Rosenbluth, 1983). The 
axonal protein Caspr, also called paranodin, or ncp1, is concentrated at the paranode 
during myelination (Einheber et al., 1997). Caspr forms a complex in cis with the GPI 
(glycosylphosphatidylinositol)-linked protein contactin (Rios et al., 2000), and this 
association is required for the localization of Caspr to the axonal membrane (Faivre-
Sarrailh et al., 2000). The recruitment of the Caspr–contactin complex to the paranodal 
domain is dependent on the presence of the 155 kDa isoform of neurofascin (nfc155). 
Nfc155 forms a complex with Caspr and contactin in trans, and all three are essential for 
the formation of normal paranodal axoglial junctions in both the CNS and PNS (Tait et 
al., 2000; Bhat et al., 2001; Boyle et al., 2001; Charles et al., 2002; Sherman et al., 2005; 
Bonnon et al., 2007). In the absence of either Caspr or contactin, transverse bands do not 
form, the close association between many paranodal loops and the axon is disrupted, and 
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potassium channels are mislocalized to the paranodal region (Bhat et al., 2001; Boyle et 
al., 2001). Similar phenotypes are generated by loss of either ceramide galactosyl 
transferase (CGT) or myelin and lymphocyte protein (MAL), which are required for the 
proper trafficking of nfc155 (Dupree et al., 1999; Schaeren-Wiemers et al., 2004; Schafer 
et al., 2004).   
In the adult rat spinal cord, oligodendrocytes express netrin-1 and its receptor, 
deleted in colorectal cancer (DCC) (Manitt et al., 2001, 2004). Netrins are a small family 
of ∼75 kDa proteins with homology to laminins. They are best known as secreted 
chemotropic guidance cues for migrating cells and axons. Signaling through DCC, they 
direct the reorganization of F-actin by regulating focal adhesion kinase (FAK), fyn, PI-3 
kinase, and the Rho-GTPases Cdc42 and Rac1 (Moore et al., 2007). Additionally, they 
contribute to tissue morphogenesis by regulating cell–cell and cell–matrix adhesion; 
however, this is best understood outside the CNS (for review, see Baker et al., 2006). 
Subcellular fractionation of adult rat spinal cord white matter indicated that netrin-1 is 
enriched in fractions containing noncompact myelin membranes (Manitt et al., 2001). 
These membrane preparations typically contain proteins present at points of axoglial 
contact, including the paranodal junction (Menon et al., 2003). We demonstrate that DCC 
and netrin-1 are enriched at oligodendroglial paranodes and that, in the absence of netrin-
1 or DCC function, CNS paranodes develop and mature normally, but this organization is 
subsequently lost. The essential contribution of netrin-1 and DCC to paranodal 
maintenance, but not formation, distinguishes the phenotypes reported here from those 
found previously in other mutants, and suggests that distinct mechanisms regulate the 
organization of the paranodal axoglial junction in the developing and mature CNS. In 
summary, our findings demonstrate that netrin-1 and its receptor DCC are required for 
the maintenance of paranodal axoglial contact and represent the first reported function for 
netrin-1 in the mature CNS. 
MATERIALS AND METHODS 
Animals  
Adult male Sprague Dawley rats (180–200 g) and newborn CD1 mouse pups were 
obtained from Charles River Canada. Mice heterozygous for netrin-1 or DCC function 
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were obtained from Marc Tessier-Lavigne (Genentech, San Francisco, CA) and Robert 
Weinberg (Whitehead Institute for Biomedical Research, Cambridge, MA), respectively, 
and bred into a CD-1 genetic background. All procedures with animals were performed in 
accordance with the Canadian Council on Animal Care guidelines for the use of animals 
in research. 
Antibodies 
The following primary antibodies were used in this study: mouse monoclonal 
anti-Caspr (University of California Davis NeuroMab; catalog #75-001), guinea pig 
polyclonal anti-Caspr, rabbit polyclonal anti-Caspr (gift from Dr. David Colman, McGill 
University, Montreal, Quebec, Canada) (Svenningsen et al., 2003), mouse monoclonal 
anti-DCC intracellular domain (DCCIN) (BD Biosciences Pharmingen; catalog 
#554223), rabbit polyclonal anti-Kv1.2 (Alomone Labs; catalog #APC-010), mouse 
monoclonal anti-myelin basic protein (MBP) (Millipore Bioscience Research Reagents; 
catalog #MAB382), rabbit polyclonal anti-MBP (Millipore Bioscience Research 
Reagents; catalog #AB9046), rat monoclonal anti-MBP (Millipore Bioscience Research 
Reagents; catalog #MAB386), rabbit polyclonal anti-netrin PN2 (Manitt et al., 2001), 
rabbit polyclonal anti-neurofascin NFC2 (gift from Prof. Peter Brophy, University of 
Edinburgh, Edinburgh, UK; recognizes both 155 and 186 kDa isoforms of neurofascin) 
(Tait et al., 2000), mouse monoclonal anti-neurofilament 145 kDa (NFM) (Millipore 
Bioscience Research Reagents; catalog #MAB1621), chicken polyclonal anti-NFM 
(EnCor Biotechnology; catalog #CPCA-NF-M), chicken polyclonal anti-neurofilament 
200 kDa (NFH) (EnCor; catalog #CPCA-NF-H), mouse anti-myelin proteolipid protein 
(PLP) (Millipore Bioscience Research Reagents; catalog #MAB388), mouse monoclonal 
anti-sodium channel (pan) (Na+ch) (Sigma-Aldrich; catalog #S8809). Secondary 
antibodies used were Alexa 488-conjugated donkey anti-mouse (catalog #A21202) and 
goat anti-rabbit (catalog #A11008), Alexa 546-conjugated goat anti-mouse (catalog 
#A11030) and goat anti-rabbit (catalog #A11010), Alexa 633-conjugated goat anti-
chicken (catalog #A21103) and goat anti-mouse (catalog #A21052), and Alexa 647-
conjugated donkey anti-rabbit (catalog #A21244) from Invitrogen, and rhodamine-
conjugated donkey anti-guinea pig (Jackson ImmunoResearch; catalog #706-295-148). 
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Immunocytochemistry and confocal analysis of adult rat spinal cord.   
Adult rats were anesthetized with sodium pentobarbital (Somnotol; 65 mg/kg, i.p.; 
MTC Pharmaceuticals) and perfused transcardially with PBS, followed by 4% 
paraformaldehyde (PFA) in PBS at pH 7.4. Spinal cords were then equilibrated in 30% 
sucrose in PBS for 48 h at 4°C, embedded in optimal cutting temperature compound 
(Sakura Finetek), 18 μm longitudinal and coronal cryosections cut, and processed for 
immunohistochemistry. Images were captured using a Zeiss LSM 510 confocal 
microscope. In all cases, single confocal slices were collected. 
Immunocytochemistry and confocal analysis of cerebellar slice cultures. 
Cerebellar slice cultures were prepared based on previously published methods 
(Notterpek et al., 1993). Briefly, after decapitation, brains were dissected into ice-cold 
HBSS and 250 μm sagittal slices of cerebellum and attached brainstem were cut using a 
McIlwain tissue chopper. The tissue slices were placed on Millipore Millicell-CM 
organotypic culture inserts (Thermo Fisher Scientific) in medium containing 50% MEM 
with Earle's salts, 25% Earle's balanced salt solution, 25% heat-inactivated horse serum 
(HIHS), glutamax-II supplement with penicillin–streptomycin, amphotericin B (all 
purchased from Invitrogen), and 6.5 mg/ml glucose (Sigma-Aldrich). Membranes were 
transferred into fresh medium every 2 d. Slices processed after 25 d in vitro (DIV) are 
referred to in the text as “short-term cultures,” and those processed at 7 weeks in vitro or 
later (49 DIV for netrin mutant litters processed for EM, 67 DIV for DCC mutant litters 
processed for EM, and 60 DIV for netrin-1 and DCC mutant litters processed for 
confocal analysis) are referred to as “long-term cultures.”  
Slices processed for immunolabeling were fixed while attached to membranes 
with 4% PFA in PBS for 1 h, rinsed in PBS for 10 min, and blocked with 3% HIHS, 2% 
BSA, 0.25% Triton X-100 in PBS for 2 h. Slices were then incubated in primary antibody 
36–48 h, washed once for 10 min and then thrice for 1 h, incubated in secondary antibody 
overnight, washed, and mounted.  
Confocal images were captured as described above. For analysis of sodium and 
potassium channel distribution, slices were labeled with mouse anti-Na+ch and rabbit 
anti-Kv1.2 antibodies. The plane chosen for imaging was that at which nodal Na+ch and 
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juxtaparanodal Kv1.2 immunoreactivity was closest. The distance between Na+ch and 
Kv1.2 channel expression, and the length of the Na+ch channel immunoreactivity were 
analyzed. For analysis of neurofascin localization, the distance between the outermost 
edges of the region of neurofascin immunoreactivity was measured. The plane chosen for 
imaging was that in which the node of Ranvier most evenly bisects the region of 
neurofascin immunolabeling. For analyses of Caspr immunoreactivity, the length of each 
Caspr expression domain was measured. For analyses of neurofascin and Caspr 
localization, slices were also labeled with chicken anti-NFH and mouse anti-MBP 
antibodies. Distances were measured using LSM 510 Image Browser software. 
Electron microscopy 
Slices and attached membrane were cut out from surrounding membrane and 
fixed overnight with 2.5% glutaraldehyde in 0.1 m sodium cacodylate buffer, osmicated 
with potassium ferrocyanide-reduced 1% osmium tetroxide solution for 1 h, and then 
dehydrated with successive 10 min rinses in 30, 50, 70, 80, 95, and 100% ethanol (three 
times). Tissue was then infiltrated with 1:1, 1:2, and 1:3 ethanol to Epon blends, and then 
in pure Epon, for 1 h each, and then embedded in Epon, tissue side down, in a plastic 
BEEM capsule (Structure Probe). The 70–100 nm sections were then cut onto 200 mesh 
copper grids and stained with 4% uranyl acetate for 5 min, followed by Reynolds's lead 
citrate for 3 min.  Images were observed using a transmission electron microscope at 80 
kV using a JEM-2000FX (JEOL; used for all analyses except for those of short-term 
netrin mutant cultures) or at 120 kV using a Tecnai 12 (FEI) Gatan Bioscan CCD camera. 
For each condition, at least two slices from each of two animals were analyzed. For 
analyses of compact myelin, the width of the periaxonal space at each axon was 
measured, and the periodicity of compact myelin was calculated. For analyses of 
paranodal myelin, because of technical limitations encountered during the embedding 
process, only single paranodes were analyzed at a time. Each paranode was examined for 
the presence of four “faults.” A paranode was credited with a fault if the majority of 
paranodal loops present lacked transverse bands; if neighboring paranodal glial 
membranes lacked electron density between apposed glial loops and these membranes 
were separated by two or more membrane widths (“interloop densities”); if at least one 
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paranodal loop had detached from the axonal surface by two or more membrane widths; 
or if at least one paranodal loop faced away from the axonal surface (depicted in Fig. 
5A). 
Oligodendrocyte precursor cell transplantation into retina and immunohisto-
chemical analysis in vivo. 
Oligodendrocyte precursor cells (OPCs) were purified by shake-off from a mixed 
glial culture derived from neonatal mouse cortices, as previously described (Jarjour et al., 
2003). DCC−/− mice (CD-1 genetic background) were identified behaviorally and their 
cortices were cultured separately from their wild-type and heterozygote littermates. 
Genotypes were subsequently confirmed by PCR. Isolated OPCs were concentrated to a 
density of 15,000 cells/μl in OLDEM (oligodendrocyte defined medium) as described by 
us (Jarjour et al., 2003). The OPC suspension (2 μl) was injected into the vitreous 
chamber of the left eye of wild-type 2-month-old male CD-1 mice using a 10 μl Hamilton 
syringe with a 32 gauge glass microneedle. The needle tip was inserted into the superior 
(dorsal) hemisphere of the eye, at the level of the pars plana, at a 45° angle through the 
sclera into the vitreous body as described previously (Sapieha et al., 2005). This route of 
administration avoided retinal detachment or injury to eye structures, including the lens 
and the iris. The injection was performed within 1 min to slowly deposit the OPCs onto 
the retinal fiber layer. The needle was then gently removed, and surgical glue (Indermill; 
Tyco Health Care) was used to seal the injection site. Eight weeks after the 
transplantation, animals were perfused transcardially with 4% PFA. Eyes were then 
enucleated and the retinas were removed, fixed for an additional 30 min, and flat-
mounted vitreal side up on a glass slide for examination of the ganglion cell layer. Retinal 
tissue was permeabilized in 2% Triton X-100, 0.5% DMSO in PBS for 4 d, and blocked 
for 2 h in 10% normal goat serum, 2% Triton X-100, and 0.5% DMSO in PBS. Retinas 
were then incubated in primary antibodies for 48 h and washed once for 5 min and thrice 
for 20 min. Secondary antibodies were applied for 2 h, and retinas were washed and 
mounted on slides. Images were collected and analyses performed as described for 
organotypic slices. 
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RESULTS 
Long-term, myelinating cerebellar organotypic cultures   
Netrin-1 and DCC are expressed by myelinating oligodendrocytes in the mature 
CNS (Manitt et al., 2001, 2004). To investigate possible roles of netrin-1 and DCC in 
myelination, we sought to examine CNS white matter in the absence of netrin-1 or dcc 
expression. However, mice lacking functional netrin-1 or DCC protein die within hours 
of birth (Serafini et al., 1996; Fazeli et al., 1997), weeks before the vast majority of CNS 
myelin forms in rodents. To circumvent this limitation, we established organotypic 
cerebellar slice cultures derived from either newborn [postnatal day 0 (P0)] netrin-1 or 
dcc knock-out mice and their wild-type littermates.  In the developing rat cerebellum, 
MBP-positive oligodendroglia are first observed at P2 and increase in number throughout 
the white matter by P7. Myelinated axon segments are first observed at P7, and increase 
in abundance by P12, with extensive myelination seen by P20 (Reynolds and Wilkin, 
1988). A similar time course is observed during cerebellar development in mice (Foran 
and Peterson, 1992). The time course of oligodendroglial development in cerebellar slice 
cultures derived from wild-type newborn mice was similar to that observed in vivo. 
MBP-positive oligodendrocytes were visible at 3 DIV and increased in number and 
process complexity between 3 and 7 DIV. Widespread MBP-positive myelin profiles 
were visible by 13 DIV, and myelination was extensive by 30 DIV (Fig. 1A–D). Using 
this method, we have maintained healthy myelinating cultures as long as 70 DIV. 
Myelin develops normally in DCC- and netrin-1-deficient cerebellar slice cultures   
To investigate whether netrin-1 and DCC are required for the proper organization 
of CNS myelin, cerebellar slice cultures were prepared from newborn netrin-1 and DCC 
mutant animals and their wild-type littermates and analyzed. Extensive MBP-positive 
myelin profiles were visible in long-term (>7 weeks of age) wild-type, DCC−/−, and 
netrin-1−/− cultures (Fig. 1E–H). Compact myelin ultrastructure appeared normal in both 
DCC−/− and netrin-1−/− cerebellar slices and those collected from their wild-type 
littermates (Fig. 2; supplemental Table 1, available at www.jneurosci.org as supplemental 
material). Major dense lines, intraperiod lines, and periaxonal spaces were clearly evident 
in electron micrographs of DCC−/− and netrin-1−/− myelin cross sections, with the number 
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of myelin layers routinely exceeding 10, similar to wild-type myelin. The width of the 
periaxonal space (PS) was unaffected in both DCC−/− and netrin-1−/− slices (Fig. 2). 
Myelin periodicity was unaffected in netrin-1−/− slices, although a slight increase was 
observed in DCC−/− slices (10.83 ± 0.25 nm/wrap in DCC+/+ internodes compared with 
12.04 ± 0.35 nm/wrap in DCC−/− internodes; p < 0.05). 
Netrin-1 and DCC are enriched at CNS paranodes   
The lack of any obvious abnormalities in compact myelin is consistent with our 
previous subcellular fractionation of adult CNS white matter. These findings indicated 
that netrin-1 protein is not enriched in fractions containing compact myelin membranes, 
but that it is predominantly associated with fractions that include periaxonal and 
paranodal myelin membranes (Manitt et al., 2001). To further characterize the 
distribution of netrin-1 and its receptors in CNS white matter, we performed 
immunohistochemical analyses to determine whether these proteins were enriched in 
these regions. In 30 DIV wild-type cerebellar slice cultures, netrin-1 and DCC 
immunoreactivity overlapped with the distribution of Caspr, which is concentrated at 
paranodes (Fig. 3A–L). The distributions of netrin-1 and DCC protein were then 
examined immunohistochemically in adult rat spinal cord. Netrin-1 immunoreactivity 
colocalized with Caspr at the paranode in longitudinal sections, and DCC 
immunoreactivity was found in close proximity to the paranode (Fig. 3M–X). In axonal 
cross sections, netrin-1 immunoreactivity is closely associated with, and partially 
overlaps, that of Caspr (Fig. 3D–F,P–R), consistent with an enrichment of netrin-1 in 
regions in which the oligodendroglial paranodal loops closely appose the axonal surface. 
DCC immunoreactivity surrounded the axon at the paranode, but unlike netrin-1, it 
extended beyond the area delimited by Caspr (Fig. 3J–L,V–X). This is consistent with 
DCC localization to the oligodendroglial paranodal membrane loops, but not restricted to 
the region of axoglial contact. 
Lack of DCC and netrin-1 leads to abnormalities in paranodal organization   
The enrichment of netrin-1 and DCC protein at the paranodal region, as well as 
previous reports describing roles for netrins mediating short-range cell–cell and cell–
matrix interactions (for review, see Baker et al., 2006), raises the possibility that netrin-1 
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may regulate axo-oligodendroglial interactions. To address this, paranodal regions in 
long-term cerebellar slice cultures derived from newborn netrin-1−/− and DCC−/− mice 
and their wild-type littermates were examined by transmission electron microscopy.  The 
paranodal axoglial junction is composed of sequences of cytoplasm-containing loops of 
myelin membrane that tightly associate with each other and the axonal surface. In 
electron micrographs of myelinated axons, electron-dense transverse bands mark points 
of contact between paranodal myelin loops and the axolemma (for review, see Pedraza et 
al., 2001). In electron micrographs of wild-type cerebellar slice cultures, paranodal loops 
were regularly spaced, and transverse bands were present in which each loop of glial 
membrane contacted the axon (Fig. 4A,E), consistent with the appearance of these 
structures in vivo. 
In long-term wild-type cerebellar slices, transverse bands and interloop densities 
were readily detected at the vast majority of paranodes (Fig. 4A,E). In contrast, 
paranodes in DCC−/− and netrin-1−/− slices were frequently disorganized (Fig. 4B–D,F–
H). Transverse bands were often absent and, when present, were frequently diffuse (Fig. 
4B,F, insets). Glial loops were abnormally separated from each other, resulting in a loss 
of interloop densities (Fig. 4B). Glial membranes without axonal contact were frequently 
observed (Fig. 4B,F), and everted glial loops, oriented away from the axon, were 
common (Fig. 4C,G). Occasionally, noncompact paranode-like myelin membranes were 
localized to internodal regions (Fig. 4D,H,I).   
To quantify the differences between wild-type and DCC- or netrin-1-deficient 
paranodes in long-term cultures, paranodes were scored for the presence of each of four 
faults (Fig. 5A): (1) absence of transverse bands, (2) absence of interloop densities and 
abnormal separation between glial loops, (3) detachment of paranodal loops from the 
axolemma, and (4) presence of everted loops. In both DCC (Fig. 5B)- and netrin-1 (Fig. 
5C)-deficient slices, all four faults were more frequent than in cultures obtained from 
wild-type littermates. On average, DCC−/− paranodes scored 1.78 ± 0.13 faults per 
paranode compared with 0.18 ± 0.05 for wild-type paranodes (p < 0.005), whereas netrin-
1−/− paranodes were more severely disorganized, scoring a mean of 2.43 ± 0.09 faults per 
paranode compared with 0.27 ± 0.05 for wild-type paranodes (p < 0.005) (Fig. 5D; 
supplemental Table 2, available at www.jneurosci.org as supplemental material). When 
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paranodes were binned according to the number of faults, >50% of netrin−/− paranodes 
and ∼30% of DCC−/− paranodes, were classified as “severely abnormal,” having three to 
four faults per paranode (Fig. 5E,F; supplemental Table 3, available at 
www.jneurosci.org as supplemental material). Consistent with these trends, quantification 
of the number of aberrant paranodal loops revealed a fourfold to sevenfold increase in 
everted loops and a 6- to 10-fold increase in detached loops in DCC−/− and netrin-1−/− 
compared with wild type (supplemental Table 4, available at www.jneurosci.org as 
supplemental material). 
The organization of paranodal and juxtaparanodal domains requires netrin-1 and 
DCC   
The paranodal axoglial apparatus has been described to act as a barrier, 
preventing the diffusion of potassium channels from the juxtaparanode into the paranode 
(for review, see Poliak and Peles, 2003). To investigate whether the ultrastructural 
abnormalities present in the netrin-1- or DCC-deficient slices result in a failure of the 
paranode to properly segregate nodal sodium channels (Na+ch) and juxtaparanodal 
potassium channels (Kv1.2), we measured the distance between the Na+ch and Kv1.2-
immunoreactive domains and the length of the Na+ch-immunoreactive band (Fig. 6; 
supplemental Table 5, available at www.jneurosci.org as supplemental material). In wild-
type cultures, a clear gap was visible between nodal Na+ch and juxtaparanodal Kv1.2 
immunoreactivity (Fig. 6A,B). In netrin-1−/− and DCC−/− cultures, however, Kv1.2 
immunoreactivity was often inappropriately localized to the paranode (Fig. 6C,D, 
arrowheads), and the mean distance between Na+ch and Kv1.2 immunoreactivity was 
reduced in netrin-1−/− and DCC−/− cultures relative to wild-type cultures (Fig. 6E). In 
addition, the Na+ch-immunoreactive domain was lengthened by ∼1.5-fold in netrin-1−/− 
nodes relative to netrin-1+/+ nodes (Fig. 6A,C, arrow;F), but no such increase was 
observed in DCC−/− nodes (Fig. 6B,D,F). These data indicate that the paranodal axoglial 
junction fails to appropriately constrain the localization of ion channels at nodes of 
Ranvier lacking netrin-1−/− or DCC−/−. Furthermore, as suggested by the increased 
severity of the netrin-1−/− ultrastructural phenotype, the failure of the paranodal barrier 
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appears to be more severe in the absence of netrin-1, because Na+ch localization is also 
affected. 
Localization of Caspr and neurofascin in DCC−/− and netrin-1−/− paranodes   
Nfc155 and Caspr are concentrated at paranodal oligodendroglial and neuronal 
membranes, respectively, and are essential components of a protein complex required for 
paranodal organization (Tait et al., 2000; Bhat et al., 2001; Charles et al., 2002; Sherman 
et al., 2005). In previous studies of mutant animals with disruption of paranodal 
organization, the distribution of nfc155 and Caspr is aberrantly diffuse along myelinated 
axons instead of concentrated at paranodes (Marcus et al., 2002). Using antibodies that 
recognize either neurofascin, both 155 and 186 kDa isoforms, or Caspr, we investigated 
whether loss of netrin-1 or DCC function affects the expression or localization of these 
proteins (Figs. 7, 8; supplemental Table 5, available at www.jneurosci.org as 
supplemental material). Neurofascin localization is not altered in DCC−/− (Fig. 7A–D) or 
netrin-1−/− slices (Fig. 8A–D), and the length of the neurofascin-immunoreactive domain 
is not affected in paranodal regions lacking DCC or netrin-1 (supplemental Table 5, 
available at www.jneurosci.org as supplemental material). In contrast, the region of Caspr 
immunoreactivity flanking DCC−/− and netrin-1−/− nodes of Ranvier is markedly 
lengthened relative to that observed in cultures derived from their wild-type littermates 
(supplemental Table 5, available at www.jneurosci.org as supplemental material). 
Specifically, the Caspr-immunopositive domain expands from 2.84 ± 0.14 μm in DCC+/+ 
paranodes to 4.99 ± 0.28 μm in DCC−/− paranodes (p < 0.05), and from 3.76 ± 0.16 μm to 
5.47 ± 0.29 μm in netrin-1+/+ and netrin-1−/− paranodes (p < 0.005), respectively. 
Netrin-1 and DCC are required for the maintenance of CNS paranodal junctions   
Descriptions of aberrant paranodal organization in mutant mouse strains have 
reported junctions that form normally, but later become disorganized (Marcus et al., 
2002; Schaeren-Wiemers et al., 2004; Rasband et al., 2005). To determine whether 
paranode formation occurs normally in netrin-1 and DCC mutants, we examined the 
organization of paranodal myelin in short-term (25 DIV) cerebellar slice cultures.  In 
wild-type cultures at 25 DIV, paranodal loops were regularly spaced and transverse bands 
were present, confirming that paranodal junctions had formed and matured fully by this 
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stage (Fig. 9A,F). In contrast to what we observed in long-term cultures, 25 DIV netrin-
1−/− and DCC−/− paranodes were indistinguishable from netrin+/+ and DCC+/+ paranodes 
(Fig. 9B,G), indicating that netrin-1 and DCC are not required for the development of 
paranodal axoglial contacts. Quantification of the faults observed in long-term cultures, 
revealed no significant increase in any one fault in the absence of either netrin-1 or DCC 
at 25 DIV (Fig. 9C,H; supplemental Table 2, available at www.jneurosci.org as 
supplemental material), and the mean number of faults per paranode did not significantly 
differ between netrin-1−/− or DCC−/− and wild-type cultures (Fig. 9D,I; supplemental 
Table 2, available at www.jneurosci.org as supplemental material). When the paranodes 
were binned as described above, the vast majority of both wild-type and mutant 
paranodes were classified as normal (Fig. 9E,J; supplemental Table 3, available at 
www.jneurosci.org as supplemental material). 
Consistent with the lack of an abnormal ultrastructural phenotype, sodium and 
potassium channels were appropriately segregated at wild-type and netrin-1 or DCC-null 
nodes of Ranvier in 25 DIV cultures (supplemental Fig. S1A–D, available at 
www.jneurosci.org as supplemental material). The distance separating Na+ch and Kv1.2-
immunoreactive domains was unaltered in netrin-1−/− or DCC−/− slices, and no increase in 
the length of the Na+ch-immunoreactive band was observed (supplemental Fig. S1E–H, 
supplemental Table 5, available at www.jneurosci.org as supplemental material).  
Neurofascin was present in both 25 DIV wild-type and mutant cultures, and its 
distribution was unaltered in the absence of netrin-1 or DCC (supplemental Figs. S2, 
S3A–D,I; supplemental Table 5, available at www.jneurosci.org as supplemental 
material). The distribution of Caspr at netrin-1−/− or DCC−/− paranodes in short-term 
cultures was indistinguishable from that observed in wild-type cultures (supplemental 
Figs. S2, S3E–H,J; supplemental Table 5, available at www.jneurosci.org as 
supplemental material), consistent with normal initial development of the paranodal 
region in the absence of netrin-1 or DCC.  The normal organization of paranodal axoglial 
junctions in short-term cultures and the disruption of the ultrastructure and domain 
organization in long-term cultures indicate that the defects observed in older netrin-1−/− 
and DCC−/− cultures are not a consequence of aberrant myelin formation, but of 
maintenance of the axoglial junction. 
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Disruption of paranodal domains formed by DCC−/− oligodendrocytes in vivo   
To determine whether netrin signaling is similarly required for the maintenance of 
oligodendroglial paranodal junctions in vivo, we assessed the capacity of OPCs derived 
from DCC−/− mice to myelinate retinal ganglion cell axons when transplanted into the 
eyes of wild-type mice. The axons of retinal ganglion cells are myelinated in the optic 
nerve; however, OPCs do not invade the retina during development and the proximal 
segment of the axon within the retina remains unmyelinated (Berliner, 1931). Thus, the 
intraretinal segment of the ganglion cell axons provides a unique opportunity to assess 
the capacity of OPCs transplanted into the retina to myelinate, in the absence of 
competition from endogenous OPCs (Laeng et al., 1996). OPCs were isolated from 
mixed glial cultures derived from newborn DCC−/− pups and their wild-type and 
heterozygote littermates. OPCs were then transplanted into the retina by intravitreal 
injection into the eyes of adult mice (Fig. 10A), and the retinas were isolated and 
analyzed 8 weeks later. None of the host retinas exhibited any signs of an immune 
response. Abundant MBP-immunopositive myelin segments were observed along retinal 
ganglion cell axons in eyes that received OPCs of all genotypes (Fig. 10B). Paranodal 
specializations, visualized using the paranodal marker Caspr, were readily detected in 
newly myelinated axons (Fig. 10C–H). Quantitative analysis revealed a significant 
extension of the Caspr-immunoreactive domain, characteristic of a disrupted paranode 
structure, along retinal ganglion cell axons myelinated by DCC−/− oligodendrocytes 
compared with control retinas myelinated by oligodendrocytes expressing DCC (Fig. 
10E–H). Specifically, the Caspr-immunopositive domain expanded from 2.47 ± 0.19 μm 
(n = 28) in paranodes expressing DCC to 3.14 ± 0.15 μm in DCC−/− paranodes (n = 40; p 
< 0.01). Consistent with the phenotype found in cerebellar slice cultures lacking DCC or 
netrin-1, these findings indicate that netrin signaling through DCC regulates paranodal 
organization in the mature CNS in vivo. Importantly, these findings also indicate that the 
paranodal deficiencies detected result from the loss of a cell-autonomous function of 
DCC in oligodendrocytes. 
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DISCUSSION 
Netrins function as long-range guidance cues that direct cell and axon migration, 
and also at short-range, regulating cell–cell and cell–matrix adhesion (Baker et al., 2006). 
Signaling through its receptor DCC, netrin-1 directs the reorganization of F-actin by 
regulating FAK, fyn, PI3-kinse, and the Rho-GTPases Cdc42 and Rac1 (Moore et al., 
2007). In the adult CNS, expression of netrin-1 and its receptors is widespread in 
neuronal and glial cells including oligodendrocytes (Manitt et al., 2001, 2004). Using 
subcellular fractionation of CNS white matter, we previously demonstrated an 
enrichment of netrin-1 protein in noncompact myelin membranes implicated in axoglial 
contact (Manitt et al., 2001). Here, we show that netrin-1 and DCC are enriched in the 
paranodal region both in the adult CNS in vivo and in organotypic cerebellar cultures. 
Paranodal myelin developed normally in the absence of netrin-1 or DCC function, but 
became disorganized in mature myelin. Furthermore, our transplantation studies 
demonstrate a cell-autonomous requirement for DCC signaling in oligodendrocytes in 
vivo. We conclude that netrin-1 and DCC are required for the maintenance, but not the 
development, of CNS paranodal axoglial junctions. 
The demonstration that paranodal loops form and mature normally but later 
became disordered in the absence of netrin-1 and DCC is consistent with a role for these 
proteins in the maintenance of axoglial junctions. Reports documenting CNS paranodal 
phenotypes in mice lacking CGT (Dupree et al., 1998, 1999; Marcus et al., 2002; 
Rasband et al., 2003), ceramide sulfotransferase (CST−/−) (Ishibashi et al., 2002), MAL 
(Schaeren-Wiemers et al., 2004), 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP−/−) 
(Rasband et al., 2005), or CGT–myelin-associated glycoprotein (MAG) double mutants 
(CGT−/−:MAG−/−) (Marcus et al., 2002), have described these gene products as being 
either directly or indirectly required for the maintenance of the paranodal region. In each 
case, the paranodes begin to develop normally and then become progressively disordered, 
but the age of onset and severity of disorganization of the paranodal region vary 
considerably among them. Significant differences exist, however, between previously 
reported maintenance phenotypes and those described here. Unlike in the absence of 
Caspr, contactin, neurofascin, CGT, or MAL, paranodes appear to mature completely in 
the absence of either netrin-1 or DCC. Caspr and neurofascin cluster, and well ordered 
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transverse bands appear in a manner indistinguishable from cultures derived from wild-
type cerebella. It is only after the paranodes have matured that the axoglial junction 
destabilizes. In all previous reports of paranodal maintenance phenotypes, transverse 
bands either do not form at all or develop abnormally. A second key distinction between 
the netrin-1−/− and DCC−/− phenotypes reported here and previous studies is that 
neurofascin remains localized to the paranodal region at longer time points, despite the 
ultrastructural defects and loss of domain segregation observed. 
Nfc155 present on the glial membrane is required for the recruitment of the 
axonal Caspr–contactin complex to the paranode (Sherman et al., 2005) and associates in 
trans with contactin in this complex (Bonnon et al., 2007). A plausible hypothesis is that, 
in the absence of netrin-1 or DCC, the disengagement of the oligodendroglial membrane 
from the axonal surface disrupts the interactions between nfc155 and the Caspr–contactin 
complex, freeing a proportion of these molecules to diffuse laterally along the axon and 
away from the paranode. This interpretation implies that, although the nfc155–Caspr–
contactin complex is necessary, it is not sufficient for the maintenance of paranodal 
organization. Alternatively, the absence of netrin-1 or DCC may influence the 
localization of nfc155 to the paranodal plasma membrane, resulting in decreased 
availability of nfc155 to bind the Caspr–contactin complex. In this case, netrin–DCC 
signaling would be required to maintain the integrity of the nfc155–Caspr–contactin 
complex at the paranode. A third possibility is that nfc155 and DCC may signal 
cooperatively through common downstream signaling effectors; however, because little is 
known regarding the intracellular signaling downstream of either DCC or nfc155 in 
oligodendrocytes, additional studies are necessary to elucidate the underlying 
mechanisms involved. 
Although the phenotypes observed in netrin-1−/− and DCC−/− cerebellar slice 
cultures are similar, they are not identical. Minor increases in the periodicity of compact 
myelin (Fig. 2; supplemental Table 1, available at www.jneurosci.org as supplemental 
material) are observed in DCC−/−, but not netrin-1−/−, slices. Meanwhile, the 
ultrastructural abnormalities observed in the netrin-1 mutant paranodes are more severe 
than those found in the DCC mutants, as evidenced by the significantly larger mean 
number of faults per paranode (Fig. 5D) and the greater number of paranodes scored to be 
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severely abnormal (Fig. 5, compare E, F). In addition, whereas potassium channel 
localization is aberrant in both DCC−/− and netrin-1−/− paranodes, the sodium channel 
domain is also lengthened in the absence of netrin-1 (Fig. 6, compare A, C with B, D). 
Spreading of the domain occupied by the sodium channels has been reported at CNS 
paranodes in Caspr−/− (Bhat et al., 2001) and CGT−/− (Dupree et al., 1999) mutant mice 
but not, for example, in MAL mutants (Schaeren-Wiemers et al., 2004). The increased 
severity of the netrin-1−/− phenotype suggests that netrin-1 function at the paranode may 
be mediated in part by a DCC-independent mechanism. Oligodendrocytes express UNC5 
netrin receptors in the mature CNS (Manitt et al., 2004), and it remains to be determined 
how they may additionally contribute to netrin-1 function at the paranode. 
How, then, do netrin-1 and DCC contribute to the maintenance of paranodal 
axoglial junctions? Netrin-1 is a secreted protein; however, consistent with the restricted 
distribution of netrin-1 found at paranodes, most netrin-1 in the CNS is not freely soluble 
but membrane-associated (Manitt et al., 2001). Furthermore, disrupting DCC function 
blocks cellular adherence to immobilized substrate-bound netrin-1, supporting roles for 
netrin-1 and DCC mediating cell–cell or cell–matrix adhesion (Shekarabi et al., 2005). 
These findings suggest that netrin-1 and DCC may directly contribute to adhesion 
between oligodendroglial paranodal loops and the axonal plasma membrane. Netrin-1 
binds heparin with high affinity, and heparin sulfate proteoglycans have been 
hypothesized to localize netrin-1 on cell surfaces (Serafini et al., 1994; Kappler et al., 
2000; Suzuki et al., 2006). Consistent with a potential role mediating adhesion at 
paranodes, recent findings have identified short-range roles for netrin-1 influencing tissue 
morphogenesis outside the CNS by regulating cell–cell interactions (for review, see 
Baker et al., 2006). 
In neurons, DCC influences cytoskeletal organization and axon guidance by 
regulating the src family kinase fyn and the Rho-GTPases Cdc42 and Rac1 (Shekarabi 
and Kennedy, 2002; Li et al., 2004; Meriane et al., 2004; Shekarabi et al., 2005). 
Interestingly, loss of Cdc42 or Rac1 in oligodendroctyes results in disorganization of 
both compact and noncompact myelin membranes (Thurnherr et al., 2006). Fyn is also 
required for myelination in vivo (Sperber et al., 2001) and fyn-null oligodendrocytes do 
not form myelin-like membrane sheets in vitro (Osterhout et al., 1999). A similar defect 
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in membrane sheet formation is detected when netrin-1 or DCC-null oligodendrocytes are 
allowed to mature in vitro, without neurons (S. Rajasekharan and T. E. Kennedy, 
unpublished data); however, the possibility that the regulation of Rho-GTPases and fyn 
by DCC and netrin-1 contributes to paranode maintenance remains to be investigated. 
In summary, we conclude that netrin-1 and DCC are required to maintain the 
appropriate organization of axoglial membranes at CNS paranodal junctions. Our data 
identify an essential cell-autonomous role for netrin-1 signaling through DCC during 
oligodendrocyte maturation and myelination, and support the hypothesis that DCC 
influences paranodal organization by regulating the local organization of the actin 
cytoskeleton and promoting axo-oligodendroglial adhesion. The novel phenotypes 
identified reveal a previously unknown mechanism required for axoglial adhesion and is 
the first identified function for netrin-1 and DCC in the mature CNS. 
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Figure 1.  Normal myelin formation in wild-type and netrin-1 and DCC mutant 
cerebellar organotypic cultures.  
Oligodendrocyte maturation and myelination in slices of newborn mouse cerebellum 
follows a similar time course to that in vivo and occurs normally in the absence of netrin 
and DCC. After 3 DIV, oligodendrocytes, immunolabeled with an antibody against MBP 
and visualized using Alexa 488-conjugated secondary antibodies (green), can be readily 
detected (A). They increase in number and complexity between 3 and 7 DIV (B). By 14 
DIV, many myelinated axons are visible (C), and by 30 DIV, extensive myelination is 
observed throughout the white matter (D). Abundant myelination is observed in long-
term slice cultures derived from both DCC−/− and netrin-1−/− mutant animals (F, H) and 
their wild-type littermates (E, G). Magnification: 20× objective. Scale bar, 100 μm. 
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Figure 2.  Compact myelin ultrastructure is normal in long-term netrin-1 and DCC 
mutant cerebellar slice cultures.  
Spacing between layers of the myelin sheath was analyzed by transmission electron 
microscopy in cross sections cut from cerebellar slice cultures derived from DCC−/− or 
netrin-1−/− animals (B, D, respectively) and their wild-type littermates (A, C, 
respectively). The width of the periaxonal space was unaffected in the mutant slices. 
Although the periodicity of netrin-1+/+ and netrin-1−/− myelin wraps was not significantly 
different, the absence of DCC expression resulted in a small (∼11%), but significant, 
increase in the spacing between layers of compact myelin (supplemental Table 1, 
available at www.jneurosci.org as supplemental material). Electron micrographs were 
imaged at 410,000×. Ax, Axon; PS, periaxonal space. Scale bar, 50 nm. 
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Figure 3.  Distribution of netrin-1 and DCC in myelinated cerebellar organotypic 
slice cultures and adult rat spinal cord.  
Triple-label immunohistochemical analysis of longitudinal (A–C, G–I, M–O, S–U) and 
cross-sectional (D–F, J–L, P–R, V–X) images of the paranode in mature (30 DIV) 
cerebellar slice cultures (A–L) and adult rat spinal cord (M–X). Caspr immunoreactivity 
was visualized using Alexa 546-conjugated secondary antibodies (red). PLP (C), MBP 
(I), and NFH (O, R, U, X) immunoreactivity was visualized using Alexa 633-conjugated 
secondary antibodies (blue). Netrin-1 and DCC proteins were visualized using Alexa 
488-conjugated secondary antibodies (green). Netrin-1 protein (A–F, M–R) is localized 
to the paranodal axoglial junction, where it is closely associated, and partially overlaps 
with Caspr. DCC protein (G–L, S–X) surrounds the axon at the paranode but does not 
colocalize with Caspr to the same extent as netrin-1. Magnification: A–C, G–I, M–O, S–
U, 100× objective; digital zoom, 4; D–F, J–L, P–R, V–X, 100× objective; digital zoom, 
10. Scale bars: A–C, G–I, M–O, S–U, 2 μm; D–F, J–L, P–R, V–X, 500 nm. 
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Figure 4.  Abnormal paranodal myelin in long-term DCC- and netrin-1-deficient 
organotypic slice cultures.  
The organization of both paranodal and internodal myelin was examined using 
transmission electron microscopy in long-term (A–D, 67 DIV; E–H, 49 DIV) organotypic 
slice cultures derived from newborn DCC or netrin-1 mutant mouse cerebellum (B–D, F–
H) or that of their wild-type littermates (A, E). In slices collected from wild-type animals, 
paranodal myelin was well organized, and electron-dense transverse bands between the 
axonal and oligodendrocyte membranes (A, E, black arrowheads) and interloop densities 
between paranodal loops (A, white arrowhead) were present. In contrast, in slices lacking 
DCC or netrin-1, transverse bands are frequently disordered (B, F, insets, black 
arrowheads) or absent (B, F, insets, white arrowheads), and paranodal loops were often 
disorganized. Myelin membranes were frequently separated from the axolemma (B, F, 
black arrows) and from each other (B, white arrow). Paranodal loops oriented away from 
the axon were also frequently observed in the mutants (C, G, arrows). Regions of myelin 
decompaction resembling paranodal loops were also present in mutant internodal myelin 
(D, H, I). Magnification: A–H, 68,000×; I, 25,000×. Scale bars: A–H, 200 nm; I, 500 nm; 
A, B, E, F, insets, 100 nm. 
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Figure 5.  Quantification of paranodal defects in the absence of netrin-1 or DCC.  
The integrity of paranodal myelin was analyzed in electron micrographs of transverse 
sections of long-term cerebellar slice cultures derived from DCC−/− (67 DIV) or netrin-
1−/− (49 DIV) mice and their wild-type littermates. A, Myelin paranodes were examined 
for four defects: lack of transverse bands (1), lack of interloop densities (2), separation of 
paranodal myelin loops from the axonal surface (3), and everted paranodal loops (4). 
Each observation was counted as one fault. B, C, In both netrin and DCC mutants, the 
incidence of each of the four defects was increased, as was the mean number of faults per 
paranode (D). DCC (E) and netrin-1 (F) wild-type and mutant paranodes were classified 
as normal (0 faults), mildly abnormal (1 fault), moderately abnormal (2 faults), and 
severely abnormal (3–4 faults). Notably, whereas 97% of DCC+/+ paranodes and 97% of 
netrin-1+/+ paranodes examined were classified as normal or mildly abnormal, not a 
single wild-type paranode was severely abnormal. OL, Oligodendroglial membrane; AX, 
axolemma; TB, transverse bands; ID, interloop densities. **p < 0.005. Error bars indicate 
SEM. 
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Figure 6.  Disruption of the domain organization of the node of Ranvier in long-
term netrin-1- and DCC-deficient slice cultures.  
Long-term (60 DIV) cerebellar slice cultures were double-labeled with antibodies against 
Na+ch and Kv1.2 (A–D). Kv1.2 protein was visualized using Alexa 488-conjugated 
secondary antibodies (green), and Na+ch proteins were visualized using Alexa 546-
conjugated secondary antibodies (red). In cultures lacking netrin-1 (C) or DCC (D), a 
reduced distance between Na+ channels localized within the node of Ranvier and K+ 
channels normally localized to the juxtaparanodal region was detected. This decrease was 
primarily attributable to the apparent “leaking” of K+ channels into the paranode, and 
occasionally the node itself (C, D, arrowheads; E). In netrin-1−/−, but not DCC−/− slices, 
the length of the Na+ch-positive domain was increased relative to control (C, arrow; F). 
Magnification: 100× objective; digital zoom, 4. Scale bar, 2 μm. *p < 0.05, **p < 0.005. 
Error bars indicate SEM. 
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Figure 7.  Caspr, but not neurofascin, distribution is altered in long-term DCC-
deficient cultures.  
Long-term (60 DIV) cerebellar slice cultures were triple-labeled with antibodies against 
NFH, MBP, and either nfc (A–D) or Caspr (E–H). MBP was visualized using Alexa 488-
conjugated secondary antibodies (green), NFH was visualized using Alexa 633-
conjugated secondary antibodies (blue), and nfc or Caspr were visualized using Alexa 
546-conjugated secondary antibodies (red). The length of nfc-immunoreactive bands 
were unchanged between DCC−/− and DCC+/+ nodal regions, whereas Caspr-
immunoreactive domains were lengthened at DCC−/− paranodes relative to wild-type 
slices (supplemental Table 5, available at www.jneurosci.org as supplemental material). 
Magnification: 100× objective; digital zoom, 4. Scale bar, 2 μm. 
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Figure 8.  Caspr, but not neurofascin, distribution is altered in long-term netrin-1-
deficient cultures.  
Long-term (60 DIV) cerebellar slice cultures were triple-labeled with antibodies against 
NFH, MBP, and either nfc (A–D) or Caspr (E–H). MBP was visualized using Alexa 488-
conjugated secondary antibodies (green), NFH was visualized using Alexa 633-
conjugated secondary antibodies (blue), and nfc or Caspr were visualized using Alexa 
546-conjugated secondary antibodies (red). The length of nfc-immunoreactive bands 
were unchanged between netrin-1−/− and netrin-1+/+ nodal regions, whereas Caspr-
immunoreactive domains were lengthened at netrin-1−/− paranodes relative to wild-type 
slices (supplemental Table 5, available at www.jneurosci.org as supplemental material). 
Magnification: 100× objective; digital zoom, 4. Scale bar, 2 μm. 
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Figure 9.  Normal ultrastructure of paranodal myelin in short-term netrin-1- and 
DCC-deficient cerebellar slice cultures.  
The organization of paranodal myelin was studied by transmission electron microscopy 
in short-term organotypic slice cultures derived from newborn netrin-1−/− or DCC−/− 
animals and their wild-type littermates (A, B; F, G, respectively). At this age, paranodal 
myelin was well organized in both wild-type and mutant cultures. In almost every 
paranode studied at this age, transverse bands linked the axonal and oligodendrocyte 
membranes, and paranodal loops were closely apposed to each other. Detached and 
everted loops were rarely observed in short-term cultures (C–E, H–J). Magnification: 
25,000×. Scale bars, 500 nm. Error bars indicate SEM. 
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Figure 10.  Altered paranodal Caspr distribution in retinal ganglion cell axons 
myelinated by DCC−/− oligodendrocytes in vivo.  
Injection of OPCs into the eyes of adult mice results in myelination (A). Flat-mounted 
retina (B) was double-labeled with antibodies against MBP to visualize myelin and Caspr 
to visualize paranodes (C–H). MBP was visualized using Alexa 488-conjugated 
antibodies (green). Caspr was visualized using Alexa 546-conjugated antibodies (red). 
The Caspr-immunoreactive domains were lengthened in the DCC−/− myelin group (G, H) 
compared with oligodendrocytes expressing DCC (E, F). The white arrowheads (H) 
illustrate the edges of the Caspr-immunoreactive domain measured. Magnification: B, 
10× objective; C, 100× objective; D, 100× objective; digital zoom, 2; E–H, 100× 
objective; digital zoom, 4. Scale bars: C, D, 5 μm; E–H, 2 μm. 
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APPENDIX B  
CONTRIBUTION TO THE ARTICLES 
For the article “Structural and functional neuroprotection in glaucoma: role of 
galantamine-mediated activation of muscarinic acetylcholine receptors” (Chapter 2 
in the thesis), I performed all of the experiments in this paper and Dr. Yu Zhou 
contributed in production of preliminary data. I have formulated the initial draft and 
figures of this manuscript for publication, which was then revised with assistance from 
my supervisors. 
For the article “Retinal microvasculature protection correlates with retinal ganglion 
cell survival and blood flow restoration in experimental glaucoma” (Chapter 3 in the 
thesis), I performed all the in vivo experiments. Alex Dong worked on the isolated 
arterioles and Mylène Pouliot helped me in retinal blood flow measurements. I have 
prepared the draft and figures of this manuscript, with assistance from my supervisor. 
For the article “A cell-permeable phosphine-borane complex delays retinal ganglion 
cell death after axonal injury through activation of the pro-survival extracellular 
signal-regulated kinases 1/2 pathway” (Chapter 4 in the thesis), I performed all of the 
experiments and generated all of the data presented in this paper. Christopher J. Lieven 
helped with synthesis of the PB1 compound. I have prepared the initial draft and figures 
of this manuscript for publication, which was then revised with assistance from my 
supervisors. 
For the article “Maintenance of axo-oligodendroglial paranodal junctions requires 
DCC and netrin-1” (Appendix A in the thesis), I performed the oligodendrocyte 
precursor cell transplantation into the retina of newborn mouse pups via intravitreal 
injections and also helped in perfusion of experimental animals. The result of my 
contribution is reflected in figure 10 of this article. 
 
